biobank_id,biobank_name,cluster_id,cluster_size,cluster_theme,term,cdf_ipf
23andme; ukb,23andMe; UK Biobank,0,16,Sleep Research,Aged,1.0987
23andme; ukb,23andMe; UK Biobank,0,16,Sleep Research,Middle Aged,0.9298
23andme; ukb,23andMe; UK Biobank,0,16,Sleep Research,Adult Middle Aged,0.9251
23andme; ukb,23andMe; UK Biobank,0,16,Sleep Research,Adult,0.8854
23andme; ukb,23andMe; UK Biobank,0,16,Sleep Research,Sleep,0.8313
23andme; ukb,23andMe; UK Biobank,1,21,Genomics & GWAS,Mendelian Randomization Analysis Polymorphism Single Nucleotide,0.7985
23andme; ukb,23andMe; UK Biobank,1,21,Genomics & GWAS,Mendelian Randomization Analysis,0.7143
23andme; ukb,23andMe; UK Biobank,1,21,Genomics & GWAS,Polymorphism Single Nucleotide Risk Factors,0.5402
23andme; ukb,23andMe; UK Biobank,1,21,Genomics & GWAS,Sleep Initiation And Maintenance Disorders,0.4717
23andme; ukb,23andMe; UK Biobank,1,21,Genomics & GWAS,Polymorphism Single Nucleotide,0.4475
23andme; ukb,23andMe; UK Biobank,2,21,General Research,Genetic Predisposition To Disease,0.6377
23andme; ukb,23andMe; UK Biobank,2,21,General Research,Phenotype,0.6211
23andme; ukb,23andMe; UK Biobank,2,21,General Research,Humans Genetic Predisposition To Disease,0.6002
23andme; ukb,23andMe; UK Biobank,2,21,General Research,United Kingdom,0.5844
23andme; ukb,23andMe; UK Biobank,2,21,General Research,Multifactorial Inheritance,0.5836
23andme,23andMe,0,57,General Research,Middle Aged,1.0288
23andme,23andMe,0,57,General Research,Adult,0.9887
23andme,23andMe,0,57,General Research,Male,0.9779
23andme,23andMe,0,57,General Research,Female,0.9518
23andme,23andMe,0,57,General Research,Aged,0.888
23andme,23andMe,1,35,Genomics & GWAS,Genome Wide Association Study,1.047
23andme,23andMe,1,35,Genomics & GWAS,Mendelian Randomization Analysis,0.7956
23andme,23andMe,1,35,Genomics & GWAS,Phenotype,0.7536
23andme,23andMe,1,35,Genomics & GWAS,Polymorphism Single Nucleotide Humans,0.7065
23andme,23andMe,1,35,Genomics & GWAS,Genome Wide Association Study Polymorphism Single Nucleotide,0.6851
23andme,23andMe,2,24,Nutrition & Diet,United States,1.8264
23andme,23andMe,2,24,Nutrition & Diet,United States Food And Drug Administration,1.8123
23andme,23andMe,2,24,Nutrition & Diet,Humans United States Food And Drug Administration,1.3428
23andme,23andMe,2,24,Nutrition & Diet,Marketing,1.115
23andme,23andMe,2,24,Nutrition & Diet,Genetic Testing United States,1.0303
23andme,23andMe,3,60,Genomics & GWAS,Genetic Predisposition To Disease Humans,0.4641
23andme,23andMe,3,60,Genomics & GWAS,Genome Human,0.4476
23andme,23andMe,3,60,Genomics & GWAS,Humans Polymorphism Single Nucleotide,0.407
23andme,23andMe,3,60,Genomics & GWAS,Internet,0.3964
23andme,23andMe,3,60,Genomics & GWAS,Genetic Testing,0.376
45andup,45 and Up Study,0,62,General Research,Cross Sectional Studies,0.7808
45andup,45 and Up Study,0,62,General Research,Cross Sectional Studies Humans,0.7589
45andup,45 and Up Study,0,62,General Research,New South Wales,0.7198
45andup,45 and Up Study,0,62,General Research,Age Factors,0.7065
45andup,45 and Up Study,0,62,General Research,Self Report,0.6904
45andup,45 and Up Study,1,26,Infectious Diseases,Health Services,1.2129
45andup,45 and Up Study,1,26,Infectious Diseases,Health Services Male,0.9686
45andup,45 and Up Study,1,26,Infectious Diseases,Pandemics,0.9686
45andup,45 and Up Study,1,26,Infectious Diseases,Covid 19,0.933
45andup,45 and Up Study,1,26,Infectious Diseases,Telemedicine,0.8422
45andup,45 and Up Study,2,45,General Research,Cohort Studies Humans,0.8278
45andup,45 and Up Study,2,45,General Research,Cohort Studies,0.7905
45andup,45 and Up Study,2,45,General Research,Blood Donors,0.695
45andup,45 and Up Study,2,45,General Research,Australia Blood Donors,0.6289
45andup,45 and Up Study,2,45,General Research,Female Cohort Studies,0.4736
45andup,45 and Up Study,3,71,Epidemiology & Risk Factors,Prospective Studies,1.0354
45andup,45 and Up Study,3,71,Epidemiology & Risk Factors,Incidence,0.8332
45andup,45 and Up Study,3,71,Epidemiology & Risk Factors,Proportional Hazards Models,0.8163
45andup,45 and Up Study,3,71,Epidemiology & Risk Factors,Cardiovascular Diseases,0.7948
45andup,45 and Up Study,3,71,Epidemiology & Risk Factors,Prospective Studies Middle Aged,0.7684
45andup,45 and Up Study,4,25,Neurological Disorders,Mental Health,1.8267
45andup,45 and Up Study,4,25,Neurological Disorders,Mental Health Humans,1.2134
45andup,45 and Up Study,4,25,Neurological Disorders,Humans Mental Health,0.8086
45andup,45 and Up Study,4,25,Neurological Disorders,Exercise,0.7541
45andup,45 and Up Study,4,25,Neurological Disorders,Cognitive Dysfunction,0.7364
45andup,45 and Up Study,5,56,General Research,Adult,1.0519
45andup,45 and Up Study,5,56,General Research,Australia Adult,0.9753
45andup,45 and Up Study,5,56,General Research,Residence Characteristics,0.7762
45andup,45 and Up Study,5,56,General Research,Health Behavior,0.6414
45andup,45 and Up Study,5,56,General Research,Female Humans,0.5945
45andup,45 and Up Study,6,34,Cancer & Oncology,Breast Neoplasms,1.1823
45andup,45 and Up Study,6,34,Cancer & Oncology,Lung Neoplasms,1.1078
45andup,45 and Up Study,6,34,Cancer & Oncology,Colorectal Neoplasms,0.946
45andup,45 and Up Study,6,34,Cancer & Oncology,Humans Breast Neoplasms,0.8922
45andup,45 and Up Study,6,34,Cancer & Oncology,Prostatic Neoplasms,0.7049
45andup,45 and Up Study,7,57,General Research,Aged 80 And Over Cohort Studies,0.9075
45andup,45 and Up Study,7,57,General Research,Female Aged 80 And Over,0.794
45andup,45 and Up Study,7,57,General Research,Aged 80 And Over,0.738
45andup,45 and Up Study,7,57,General Research,Surveys And Questionnaires,0.6873
45andup,45 and Up Study,7,57,General Research,Australia Middle Aged,0.6059
45andup,45 and Up Study,8,23,General Research,Humans Retrospective Studies,1.5613
45andup,45 and Up Study,8,23,General Research,Retrospective Studies,1.386
45andup,45 and Up Study,8,23,General Research,Patient Acceptance Of Health Care,1.1913
45andup,45 and Up Study,8,23,General Research,Health Expenditures,1.1219
45andup,45 and Up Study,8,23,General Research,Delivery Of Health Care,1.0929
awigen,AWI-Gen,0,18,Epidemiology & Risk Factors,Aged,0.9946
awigen,AWI-Gen,0,18,Epidemiology & Risk Factors,Aged Adult,0.8648
awigen,AWI-Gen,0,18,Epidemiology & Risk Factors,Rural Population,0.7233
awigen,AWI-Gen,0,18,Epidemiology & Risk Factors,Prevalence,0.6292
awigen,AWI-Gen,0,18,Epidemiology & Risk Factors,Aged 80 And Over,0.5865
awigen,AWI-Gen,1,30,Metabolic & Diabetes,South Africa Female,0.5189
awigen,AWI-Gen,1,30,Metabolic & Diabetes,Body Mass Index Adult,0.5189
awigen,AWI-Gen,1,30,Metabolic & Diabetes,Ghana,0.5168
awigen,AWI-Gen,1,30,Metabolic & Diabetes,Obesity,0.5083
awigen,AWI-Gen,1,30,Metabolic & Diabetes,Body Mass Index,0.4868
awigen,AWI-Gen,2,8,Genomics & GWAS,Genome Wide Association Study,1.2162
awigen,AWI-Gen,2,8,Genomics & GWAS,Black People,1.213
awigen,AWI-Gen,2,8,Genomics & GWAS,Polymorphism Single Nucleotide,1.1168
awigen,AWI-Gen,2,8,Genomics & GWAS,Black People Humans,1.0975
awigen,AWI-Gen,2,8,Genomics & GWAS,Humans Genetic Predisposition To Disease,1.0975
ahri,Africa Health Research Institute Population Cohort,0,12,General Research,South Africa Male,0.598
ahri,Africa Health Research Institute Population Cohort,0,12,General Research,Male Middle Aged,0.598
ahri,Africa Health Research Institute Population Cohort,0,12,General Research,Adolescent,0.5649
ahri,Africa Health Research Institute Population Cohort,0,12,General Research,Young Adult,0.5389
ahri,Africa Health Research Institute Population Cohort,0,12,General Research,Adolescent Humans,0.522
ahri,Africa Health Research Institute Population Cohort,1,3,Epidemiology & Risk Factors,Child Preschool Child,1.5676
ahri,Africa Health Research Institute Population Cohort,1,3,Epidemiology & Risk Factors,South Africa Patient Acceptance Of Health Care,1.5676
ahri,Africa Health Research Institute Population Cohort,1,3,Epidemiology & Risk Factors,Humans Child Preschool,1.5676
ahri,Africa Health Research Institute Population Cohort,1,3,Epidemiology & Risk Factors,Child Mortality,1.5676
ahri,Africa Health Research Institute Population Cohort,1,3,Epidemiology & Risk Factors,Child Preschool,1.2973
ahri,Africa Health Research Institute Population Cohort,2,6,General Research,Acquired Immunodeficiency Syndrome,0.973
ahri,Africa Health Research Institute Population Cohort,2,6,General Research,Cause Of Death,0.973
ahri,Africa Health Research Institute Population Cohort,2,6,General Research,South Africa Acquired Immunodeficiency Syndrome,0.973
ahri,Africa Health Research Institute Population Cohort,2,6,General Research,Acquired Immunodeficiency Syndrome Male,0.7838
ahri,Africa Health Research Institute Population Cohort,2,6,General Research,Aged 80 And Over,0.7838
aou,All of Us Research Program,0,37,General Research,Humans Adult,2.1843
aou,All of Us Research Program,0,37,General Research,Male Middle Aged,0.8301
aou,All of Us Research Program,0,37,General Research,Adult Female,0.8164
aou,All of Us Research Program,0,37,General Research,Middle Aged,0.7555
aou,All of Us Research Program,0,37,General Research,Adult,0.7365
aou,All of Us Research Program,1,120,General Research,Young Adult,1.0231
aou,All of Us Research Program,1,120,General Research,Cross Sectional Studies Adult,0.8389
aou,All of Us Research Program,1,120,General Research,Adolescent,0.833
aou,All of Us Research Program,1,120,General Research,Cross Sectional Studies,0.8248
aou,All of Us Research Program,1,120,General Research,Adult Female,0.8239
aou,All of Us Research Program,2,70,Epidemiology & Risk Factors,Female Aged,1.0861
aou,All of Us Research Program,2,70,Epidemiology & Risk Factors,Risk Factors,1.0861
aou,All of Us Research Program,2,70,Epidemiology & Risk Factors,Databases Factual,1.0163
aou,All of Us Research Program,2,70,Epidemiology & Risk Factors,Humans Databases Factual,0.946
aou,All of Us Research Program,2,70,Epidemiology & Risk Factors,Aged,0.853
aou,All of Us Research Program,3,100,General Research,Humans Population Health,1.4127
aou,All of Us Research Program,3,100,General Research,Population Health,1.3902
aou,All of Us Research Program,3,100,General Research,Case Control Studies,0.5603
aou,All of Us Research Program,3,100,General Research,Population Health Case Control Studies,0.5169
aou,All of Us Research Program,3,100,General Research,Cross Sectional Studies,0.3754
aou,All of Us Research Program,4,37,General Research,Precision Medicine,2.3541
aou,All of Us Research Program,4,37,General Research,Humans Precision Medicine,2.0766
aou,All of Us Research Program,4,37,General Research,Biomedical Research,1.055
aou,All of Us Research Program,4,37,General Research,Research,0.5105
aou,All of Us Research Program,4,37,General Research,Information Dissemination,0.4741
aou,All of Us Research Program,5,23,Infectious Diseases,Hiv Infections,3.1126
aou,All of Us Research Program,5,23,Infectious Diseases,Hiv Infections Humans,2.9587
aou,All of Us Research Program,5,23,Infectious Diseases,United States Hiv Infections,1.5765
aou,All of Us Research Program,5,23,Infectious Diseases,Anti Hiv Agents,1.0265
aou,All of Us Research Program,5,23,Infectious Diseases,Cohort Studies,0.9022
aou,All of Us Research Program,6,20,Cancer & Oncology,Animals,3.3358
aou,All of Us Research Program,6,20,Cancer & Oncology,Mice,2.4483
aou,All of Us Research Program,6,20,Cancer & Oncology,Mice Humans,1.535
aou,All of Us Research Program,6,20,Cancer & Oncology,Cell Line Tumor,0.989
aou,All of Us Research Program,6,20,Cancer & Oncology,Xenograft Model Antitumor Assays,0.989
aou,All of Us Research Program,7,121,Genomics & GWAS,Genomics,0.6705
aou,All of Us Research Program,7,121,Genomics & GWAS,Genome Wide Association Study,0.4479
aou,All of Us Research Program,7,121,Genomics & GWAS,Genetic Predisposition To Disease,0.4071
aou,All of Us Research Program,7,121,Genomics & GWAS,Polymorphism Single Nucleotide,0.3469
aou,All of Us Research Program,7,121,Genomics & GWAS,Biomedical Research,0.3428
aou,All of Us Research Program,8,34,General Research,Ethnicity Humans,2.4132
aou,All of Us Research Program,8,34,General Research,Ethnicity,2.3205
aou,All of Us Research Program,8,34,General Research,United States Ethnicity,1.7206
aou,All of Us Research Program,8,34,General Research,Racial Groups,1.4285
aou,All of Us Research Program,8,34,General Research,Minority Groups,0.926
aou; ukb,All of Us Research Program; UK Biobank,0,14,General Research,Humans United States,0.5888
aou; ukb,All of Us Research Program; UK Biobank,0,14,General Research,United States United Kingdom,0.5888
aou; ukb,All of Us Research Program; UK Biobank,0,14,General Research,United States,0.5888
aou; ukb,All of Us Research Program; UK Biobank,0,14,General Research,Female Middle Aged,0.553
aou; ukb,All of Us Research Program; UK Biobank,0,14,General Research,Aged,0.5446
aou; ukb,All of Us Research Program; UK Biobank,1,6,General Research,Phenotype,1.3739
aou; ukb,All of Us Research Program; UK Biobank,1,6,General Research,Electronic Health Records Genome Wide Association Study,1.2479
aou; ukb,All of Us Research Program; UK Biobank,1,6,General Research,Electronic Health Records,1.2219
aou; ukb,All of Us Research Program; UK Biobank,1,6,General Research,Phenomics,1.0797
aou; ukb,All of Us Research Program; UK Biobank,1,6,General Research,Humans Electronic Health Records,1.0797
aou; ukb,All of Us Research Program; UK Biobank,2,6,Genomics & GWAS,Humans Genome Wide Association Study,1.2479
aou; ukb,All of Us Research Program; UK Biobank,2,6,Genomics & GWAS,Population Health,0.8243
aou; ukb,All of Us Research Program; UK Biobank,2,6,Genomics & GWAS,Polymorphism Single Nucleotide,0.7332
aou; ukb,All of Us Research Program; UK Biobank,2,6,Genomics & GWAS,Genome Wide Association Study,0.7168
aou; ukb,All of Us Research Program; UK Biobank,2,6,Genomics & GWAS,Genetic Predisposition To Disease,0.4374
acscps3,American Cancer Society Cancer Prevention Study-3,0,10,Environmental Health,Animals,0.8794
acscps3,American Cancer Society Cancer Prevention Study-3,0,10,Environmental Health,Polysaccharides,0.7249
acscps3,American Cancer Society Cancer Prevention Study-3,0,10,Environmental Health,Environmental Monitoring,0.7249
acscps3,American Cancer Society Cancer Prevention Study-3,0,10,Environmental Health,Cryopreservation,0.7249
acscps3,American Cancer Society Cancer Prevention Study-3,0,10,Environmental Health,Mice,0.7249
acscps3,American Cancer Society Cancer Prevention Study-3,1,41,Cancer & Oncology,Diet,0.447
acscps3,American Cancer Society Cancer Prevention Study-3,1,41,Cancer & Oncology,United States,0.4354
acscps3,American Cancer Society Cancer Prevention Study-3,1,41,Cancer & Oncology,Middle Aged United States,0.4023
acscps3,American Cancer Society Cancer Prevention Study-3,1,41,Cancer & Oncology,Neoplasms,0.3987
acscps3,American Cancer Society Cancer Prevention Study-3,1,41,Cancer & Oncology,Aged 80 And Over,0.3821
acscps3,American Cancer Society Cancer Prevention Study-3,2,24,Epidemiology & Risk Factors,Prospective Studies,0.9514
acscps3,American Cancer Society Cancer Prevention Study-3,2,24,Epidemiology & Risk Factors,Time Factors,0.8395
acscps3,American Cancer Society Cancer Prevention Study-3,2,24,Epidemiology & Risk Factors,Cohort Studies,0.6294
acscps3,American Cancer Society Cancer Prevention Study-3,2,24,Epidemiology & Risk Factors,Self Report,0.6184
acscps3,American Cancer Society Cancer Prevention Study-3,2,24,Epidemiology & Risk Factors,Prospective Studies Male,0.5642
bandim,Bandim Health Project,0,33,Infectious Diseases,Hiv Infections,0.6615
bandim,Bandim Health Project,0,33,Infectious Diseases,Adult,0.5961
bandim,Bandim Health Project,0,33,Infectious Diseases,Female Adult,0.5513
bandim,Bandim Health Project,0,33,Infectious Diseases,Young Adult,0.527
bandim,Bandim Health Project,0,33,Infectious Diseases,Cohort Studies,0.5141
bandim,Bandim Health Project,1,28,General Research,Measles Vaccine,0.7453
bandim,Bandim Health Project,1,28,General Research,Humans Child,0.6772
bandim,Bandim Health Project,1,28,General Research,Measles,0.6356
bandim,Bandim Health Project,1,28,General Research,Immunization Programs,0.602
bandim,Bandim Health Project,1,28,General Research,Diphtheria Tetanus Pertussis Vaccine,0.602
bandim,Bandim Health Project,2,13,General Research,Bcg Vaccine Male,1.5396
bandim,Bandim Health Project,2,13,General Research,Bcg Vaccine,1.5393
bandim,Bandim Health Project,2,13,General Research,Humans Bcg Vaccine,1.4586
bandim,Bandim Health Project,2,13,General Research,Rural Population,1.0264
bandim,Bandim Health Project,2,13,General Research,Infant Newborn Guinea Bissau,0.9238
biovu,BioVU Vanderbilt,0,14,General Research,Humans Black Or African American,1.3395
biovu,BioVU Vanderbilt,0,14,General Research,Haplotypes,1.0119
biovu,BioVU Vanderbilt,0,14,General Research,Female Haplotypes,1.0119
biovu,BioVU Vanderbilt,0,14,General Research,Black Or African American,0.9603
biovu,BioVU Vanderbilt,0,14,General Research,Black Or African American Male,0.9568
biovu,BioVU Vanderbilt,1,19,General Research,Genetic Predisposition To Disease Female,1.0042
biovu,BioVU Vanderbilt,1,19,General Research,Multifactorial Inheritance,0.846
biovu,BioVU Vanderbilt,1,19,General Research,Genetic Predisposition To Disease,0.8395
biovu,BioVU Vanderbilt,1,19,General Research,White People,0.8071
biovu,BioVU Vanderbilt,1,19,General Research,Female White People,0.7936
biovu,BioVU Vanderbilt,2,11,General Research,Algorithms,1.7656
biovu,BioVU Vanderbilt,2,11,General Research,Algorithms Electronic Health Records,1.1777
biovu,BioVU Vanderbilt,2,11,General Research,Computational Biology,1.0123
biovu,BioVU Vanderbilt,2,11,General Research,Data Mining,0.9617
biovu,BioVU Vanderbilt,2,11,General Research,Software,0.9617
biovu,BioVU Vanderbilt,3,32,General Research,Aged Male,0.9384
biovu,BioVU Vanderbilt,3,32,General Research,Aged,0.904
biovu,BioVU Vanderbilt,3,32,General Research,Aged 80 And Over,0.8025
biovu,BioVU Vanderbilt,3,32,General Research,Humans Aged,0.7525
biovu,BioVU Vanderbilt,3,32,General Research,Middle Aged,0.6043
biovu,BioVU Vanderbilt,4,5,General Research,Animals,2.8332
biovu,BioVU Vanderbilt,4,5,General Research,Mice,2.1158
biovu,BioVU Vanderbilt,4,5,General Research,Endothelial Cells,1.5727
biovu,BioVU Vanderbilt,4,5,General Research,Disease Models Animal,1.5727
biovu,BioVU Vanderbilt,4,5,General Research,Genotyping Techniques Male,0.7864
biovu,BioVU Vanderbilt,5,21,General Research,Dna,0.8095
biovu,BioVU Vanderbilt,5,21,General Research,Phenotype,0.7758
biovu,BioVU Vanderbilt,5,21,General Research,Humans Phenotype,0.7679
biovu,BioVU Vanderbilt,5,21,General Research,Electronic Health Records Humans,0.7434
biovu,BioVU Vanderbilt,5,21,General Research,Electronic Health Records,0.6993
biovu; ukb,BioVU Vanderbilt; UK Biobank,0,10,General Research,Phenotype,0.7138
biovu; ukb,BioVU Vanderbilt; UK Biobank,0,10,General Research,United Kingdom,0.5248
biovu; ukb,BioVU Vanderbilt; UK Biobank,0,10,General Research,Humans Genome Wide Association Study,0.5248
biovu; ukb,BioVU Vanderbilt; UK Biobank,0,10,General Research,United Kingdom Phenotype,0.4885
biovu; ukb,BioVU Vanderbilt; UK Biobank,0,10,General Research,Software,0.4885
biovu; ukb,BioVU Vanderbilt; UK Biobank,1,10,Epidemiology & Risk Factors,Female Middle Aged,0.8062
biovu; ukb,BioVU Vanderbilt; UK Biobank,1,10,Epidemiology & Risk Factors,Risk Factors,0.8062
biovu; ukb,BioVU Vanderbilt; UK Biobank,1,10,Epidemiology & Risk Factors,Aged,0.763
biovu; ukb,BioVU Vanderbilt; UK Biobank,1,10,Epidemiology & Risk Factors,Humans Aged,0.763
biovu; ukb,BioVU Vanderbilt; UK Biobank,1,10,Epidemiology & Risk Factors,Middle Aged,0.7138
biovu; ukb,BioVU Vanderbilt; UK Biobank,2,3,Cardiovascular Research,Mice,2.0369
biovu; ukb,BioVU Vanderbilt; UK Biobank,2,3,Cardiovascular Research,Animals,2.0369
biovu; ukb,BioVU Vanderbilt; UK Biobank,2,3,Cardiovascular Research,Adaptor Proteins Signal Transducing,0.8141
biovu; ukb,BioVU Vanderbilt; UK Biobank,2,3,Cardiovascular Research,Adaptor Proteins Signal Transducing Genetic Predisposition To Disease,0.8141
biovu; ukb,BioVU Vanderbilt; UK Biobank,2,3,Cardiovascular Research,Cardiovascular Diseases,0.679
bbj,Biobank Japan,0,57,General Research,Humans Female,0.8054
bbj,Biobank Japan,0,57,General Research,Male Genetic Predisposition To Disease,0.7464
bbj,Biobank Japan,0,57,General Research,Female Aged,0.6845
bbj,Biobank Japan,0,57,General Research,Male,0.6133
bbj,Biobank Japan,0,57,General Research,Genome Wide Association Study Middle Aged,0.5846
bbj,Biobank Japan,1,44,Genomics & GWAS,Humans Genome Wide Association Study,0.6483
bbj,Biobank Japan,1,44,Genomics & GWAS,Genome Wide Association Study Genetic Predisposition To Disease,0.5552
bbj,Biobank Japan,1,44,Genomics & GWAS,Genotype,0.5463
bbj,Biobank Japan,1,44,Genomics & GWAS,Polymorphism Single Nucleotide,0.5056
bbj,Biobank Japan,1,44,Genomics & GWAS,Genetic Predisposition To Disease,0.4844
bbj,Biobank Japan,2,31,General Research,Biological Specimen Banks,1.4061
bbj,Biobank Japan,2,31,General Research,Aged 80 And Over,1.0856
bbj,Biobank Japan,2,31,General Research,Aged Biological Specimen Banks,1.0681
bbj,Biobank Japan,2,31,General Research,Middle Aged,0.8909
bbj,Biobank Japan,2,31,General Research,Young Adult,0.8755
bbj,Biobank Japan,3,34,Mendelian Randomization,Mendelian Randomization Analysis Humans,1.4924
bbj,Biobank Japan,3,34,Mendelian Randomization,Mendelian Randomization Analysis,1.3743
bbj,Biobank Japan,3,34,Mendelian Randomization,East Asian People,0.6181
bbj,Biobank Japan,3,34,Mendelian Randomization,Genome Wide Association Study East Asian People,0.5151
bbj,Biobank Japan,3,34,Mendelian Randomization,Diabetes Mellitus Type 2,0.5091
bbj; ukb,Biobank Japan; UK Biobank,0,29,Genomics & GWAS,Genome Wide Association Study Polymorphism Single Nucleotide,0.823
bbj; ukb,Biobank Japan; UK Biobank,0,29,Genomics & GWAS,Polymorphism Single Nucleotide Genetic Predisposition To Disease,0.6769
bbj; ukb,Biobank Japan; UK Biobank,0,29,Genomics & GWAS,Multifactorial Inheritance,0.5209
bbj; ukb,Biobank Japan; UK Biobank,0,29,Genomics & GWAS,Linkage Disequilibrium,0.4961
bbj; ukb,Biobank Japan; UK Biobank,0,29,Genomics & GWAS,Risk Factors Genome Wide Association Study,0.4294
bbj; ukb,Biobank Japan; UK Biobank,1,23,Mendelian Randomization,Mendelian Randomization Analysis,0.9016
bbj; ukb,Biobank Japan; UK Biobank,1,23,Mendelian Randomization,Mendelian Randomization Analysis Genetic Predisposition To Disease,0.889
bbj; ukb,Biobank Japan; UK Biobank,1,23,Mendelian Randomization,Female Mendelian Randomization Analysis,0.7876
bbj; ukb,Biobank Japan; UK Biobank,1,23,Mendelian Randomization,Risk Factors Female,0.6255
bbj; ukb,Biobank Japan; UK Biobank,1,23,Mendelian Randomization,Risk Factors,0.5779
bbj; ukb,Biobank Japan; UK Biobank,2,25,General Research,United Kingdom,0.8165
bbj; ukb,Biobank Japan; UK Biobank,2,25,General Research,Biological Specimen Banks,0.7246
bbj; ukb,Biobank Japan; UK Biobank,2,25,General Research,Middle Aged,0.6819
bbj; ukb,Biobank Japan; UK Biobank,2,25,General Research,Japan,0.6756
bbj; ukb,Biobank Japan; UK Biobank,2,25,General Research,Male,0.664
constances,CONSTANCES,0,20,Infectious Diseases,Covid 19,1.6804
constances,CONSTANCES,0,20,Infectious Diseases,Sars Cov 2,1.4954
constances,CONSTANCES,0,20,Infectious Diseases,Sars Cov 2 Female,1.1716
constances,CONSTANCES,0,20,Infectious Diseases,Pandemics,0.921
constances,CONSTANCES,0,20,Infectious Diseases,Humans Middle Aged,0.8788
constances,CONSTANCES,1,11,Respiratory Diseases,Exercise,1.5916
constances,CONSTANCES,1,11,Respiratory Diseases,Smoking,1.4073
constances,CONSTANCES,1,11,Respiratory Diseases,Odds Ratio,1.3594
constances,CONSTANCES,1,11,Respiratory Diseases,Exercise Logistic Models,1.144
constances,CONSTANCES,1,11,Respiratory Diseases,Smoking Middle Aged,1.144
constances,CONSTANCES,2,16,Mental Health & Psychiatry,Cognition,1.4061
constances,CONSTANCES,2,16,Mental Health & Psychiatry,Neuropsychological Tests,1.3131
constances,CONSTANCES,2,16,Mental Health & Psychiatry,Cognition Humans,1.2553
constances,CONSTANCES,2,16,Mental Health & Psychiatry,Cognition Disorders,0.9768
constances,CONSTANCES,2,16,Mental Health & Psychiatry,Humans Cognition Disorders,0.9768
constances,CONSTANCES,3,14,Cancer & Oncology,Uterine Cervical Neoplasms,1.5007
constances,CONSTANCES,3,14,Cancer & Oncology,Early Detection Of Cancer,1.5007
constances,CONSTANCES,3,14,Cancer & Oncology,Humans Body Mass Index,1.3774
constances,CONSTANCES,3,14,Cancer & Oncology,Body Mass Index,1.3269
constances,CONSTANCES,3,14,Cancer & Oncology,Breast Neoplasms,1.2506
constances,CONSTANCES,4,13,General Research,Adolescent France,1.6261
constances,CONSTANCES,4,13,General Research,Cohort Studies Adolescent,1.5512
constances,CONSTANCES,4,13,General Research,Male Young Adult,1.5122
constances,CONSTANCES,4,13,General Research,Adolescent,1.2937
constances,CONSTANCES,4,13,General Research,Young Adult,1.2212
constances,CONSTANCES,5,19,Nutrition & Diet,Substance Related Disorders,1.1058
constances,CONSTANCES,5,19,Nutrition & Diet,Cannabis,0.9215
constances,CONSTANCES,5,19,Nutrition & Diet,Female Humans,0.9183
constances,CONSTANCES,5,19,Nutrition & Diet,Humans Male,0.7255
constances,CONSTANCES,5,19,Nutrition & Diet,Alcohol Drinking,0.7047
constances,CONSTANCES,6,27,Epidemiology & Risk Factors,Occupational Exposure,1.5076
constances,CONSTANCES,6,27,Epidemiology & Risk Factors,Occupational Diseases,1.1116
constances,CONSTANCES,6,27,Epidemiology & Risk Factors,Risk Factors Occupational Exposure,1.1077
constances,CONSTANCES,6,27,Epidemiology & Risk Factors,Self Report,0.8321
constances,CONSTANCES,6,27,Epidemiology & Risk Factors,Middle Aged Male,0.7205
constances,CONSTANCES,7,31,Epidemiology & Risk Factors,Surveys And Questionnaires,0.7664
constances,CONSTANCES,7,31,Epidemiology & Risk Factors,Adult Humans,0.6928
constances,CONSTANCES,7,31,Epidemiology & Risk Factors,Prospective Studies,0.6714
constances,CONSTANCES,7,31,Epidemiology & Risk Factors,Female Adult,0.6672
constances,CONSTANCES,7,31,Epidemiology & Risk Factors,Middle Aged Prospective Studies,0.6161
constances,CONSTANCES,8,16,Cardiovascular Research,Cardiovascular Diseases,1.8757
constances,CONSTANCES,8,16,Cardiovascular Research,Humans Cardiovascular Diseases,1.6069
constances,CONSTANCES,8,16,Cardiovascular Research,Risk Factors,1.1062
constances,CONSTANCES,8,16,Cardiovascular Research,Diabetes Mellitus Type 2,0.921
constances,CONSTANCES,8,16,Cardiovascular Research,Heart Disease Risk Factors,0.921
constances,CONSTANCES,9,10,General Research,Databases Factual,2.2467
constances,CONSTANCES,9,10,General Research,Databases Factual Cohort Studies,1.7508
constances,CONSTANCES,9,10,General Research,Data Collection,1.5628
constances,CONSTANCES,9,10,General Research,Public Health Informatics,1.5628
constances,CONSTANCES,9,10,General Research,Epidemiologic Methods,1.4735
constances,CONSTANCES,10,16,Cardiovascular Research,Hypertension,1.9907
constances,CONSTANCES,10,16,Cardiovascular Research,Blood Pressure,1.7552
constances,CONSTANCES,10,16,Cardiovascular Research,Hypertension Humans,1.4954
constances,CONSTANCES,10,16,Cardiovascular Research,Humans Adult,1.0942
constances,CONSTANCES,10,16,Cardiovascular Research,Antihypertensive Agents,0.9768
constances,CONSTANCES,11,6,Environmental Health,Air Pollutants,2.6047
constances,CONSTANCES,11,6,Environmental Health,Air Pollution,2.4559
constances,CONSTANCES,11,6,Environmental Health,Particulate Matter,2.4559
constances,CONSTANCES,11,6,Environmental Health,Humans Air Pollutants,2.0973
constances,CONSTANCES,11,6,Environmental Health,Nitrogen Dioxide,2.0973
cts,California Teachers Study,0,15,General Research,Estrogen Replacement Therapy,1.7585
cts,California Teachers Study,0,15,General Research,Estrogens,1.5481
cts,California Teachers Study,0,15,General Research,Progestins,1.4951
cts,California Teachers Study,0,15,General Research,Estrogen Replacement Therapy Aged,1.3082
cts,California Teachers Study,0,15,General Research,Case Control Studies,0.7993
cts,California Teachers Study,1,15,Epidemiology & Risk Factors,Humans Prospective Studies,1.0471
cts,California Teachers Study,1,15,Epidemiology & Risk Factors,Cross Sectional Studies,0.9324
cts,California Teachers Study,1,15,Epidemiology & Risk Factors,Logistic Models,0.7832
cts,California Teachers Study,1,15,Epidemiology & Risk Factors,Prospective Studies Middle Aged,0.7753
cts,California Teachers Study,1,15,Epidemiology & Risk Factors,Prospective Studies,0.7028
cts,California Teachers Study,2,14,Environmental Health,Aged 80 And Over Aged,1.2821
cts,California Teachers Study,2,14,Environmental Health,Environmental Exposure California,1.2425
cts,California Teachers Study,2,14,Environmental Health,California Cohort Studies,1.1691
cts,California Teachers Study,2,14,Environmental Health,Young Adult Middle Aged,1.1589
cts,California Teachers Study,2,14,Environmental Health,Environmental Exposure,1.0551
cts,California Teachers Study,3,16,Epidemiology & Risk Factors,Aged 80 And Over Risk Factors,1.4091
cts,California Teachers Study,3,16,Epidemiology & Risk Factors,Humans Young Adult,1.3428
cts,California Teachers Study,3,16,Epidemiology & Risk Factors,Young Adult,1.172
cts,California Teachers Study,3,16,Epidemiology & Risk Factors,Faculty Aged,1.0229
cts,California Teachers Study,3,16,Epidemiology & Risk Factors,Proportional Hazards Models Aged 80 And Over,1.0071
cts,California Teachers Study,4,14,Cancer & Oncology,Receptors Progesterone,1.1691
cts,California Teachers Study,4,14,Cancer & Oncology,Risk Assessment,1.1589
cts,California Teachers Study,4,14,Cancer & Oncology,Receptors Estrogen,1.0012
cts,California Teachers Study,4,14,Cancer & Oncology,Risk Assessment Breast Neoplasms,0.9352
cts,California Teachers Study,4,14,Cancer & Oncology,Anti Inflammatory Agents Non Steroidal,0.9352
cts,California Teachers Study,5,7,Environmental Health,Environmental Monitoring California,2.3381
cts,California Teachers Study,5,7,Environmental Health,Environmental Monitoring,2.0978
cts,California Teachers Study,5,7,Environmental Health,Halogenated Diphenyl Ethers,1.998
cts,California Teachers Study,5,7,Environmental Health,Solid Phase Extraction,1.197
cts,California Teachers Study,5,7,Environmental Health,California Polybrominated Biphenyls,1.197
cts,California Teachers Study,6,14,Epidemiology & Risk Factors,Pregnancy,1.0277
cts,California Teachers Study,6,14,Epidemiology & Risk Factors,Prospective Studies Humans,0.8278
cts,California Teachers Study,6,14,Epidemiology & Risk Factors,Proportional Hazards Models Pregnancy,0.8109
cts,California Teachers Study,6,14,Epidemiology & Risk Factors,Prospective Studies,0.6777
cts,California Teachers Study,6,14,Epidemiology & Risk Factors,Cohort Studies Prospective Studies,0.6624
cts,California Teachers Study,7,8,Cancer & Oncology,Recreation,1.6367
cts,California Teachers Study,7,8,Cancer & Oncology,School Teachers,1.4023
cts,California Teachers Study,7,8,Cancer & Oncology,Risk,1.2901
cts,California Teachers Study,7,8,Cancer & Oncology,Female Neoplasm Invasiveness,1.1591
cts,California Teachers Study,7,8,Cancer & Oncology,Motor Activity,1.1591
cts,California Teachers Study,8,12,Cancer & Oncology,Faculty Breast Neoplasms,1.2237
cts,California Teachers Study,8,12,Cancer & Oncology,Adolescent,1.1681
cts,California Teachers Study,8,12,Cancer & Oncology,Adult Multivariate Analysis,1.1655
cts,California Teachers Study,8,12,Cancer & Oncology,Multivariate Analysis,0.979
cts,California Teachers Study,8,12,Cancer & Oncology,Cohort Studies Faculty,0.9061
cts,California Teachers Study,9,5,Epidemiology & Risk Factors,Female Sleep,1.964
cts,California Teachers Study,9,5,Epidemiology & Risk Factors,Longitudinal Studies Female,1.8546
cts,California Teachers Study,9,5,Epidemiology & Risk Factors,Sleep,1.8546
cts,California Teachers Study,9,5,Epidemiology & Risk Factors,Cohort Studies Humans,1.6759
cts,California Teachers Study,9,5,Epidemiology & Risk Factors,Humans Retrospective Studies,1.6759
cts,California Teachers Study,10,6,Nutrition & Diet,Sugar Sweetened Beverages Female,1.8921
cts,California Teachers Study,10,6,Nutrition & Diet,Sugar Sweetened Beverages,1.8921
cts,California Teachers Study,10,6,Nutrition & Diet,Diet,1.7904
cts,California Teachers Study,10,6,Nutrition & Diet,Humans Diet,1.7904
cts,California Teachers Study,10,6,Nutrition & Diet,California Sugar Sweetened Beverages,1.3966
cts,California Teachers Study,11,6,General Research,Water Pollutants Chemical,2.7278
cts,California Teachers Study,11,6,General Research,Arsenic,2.7278
cts,California Teachers Study,11,6,General Research,Drinking Water,1.8921
cts,California Teachers Study,11,6,General Research,Water Supply,1.8921
cts,California Teachers Study,11,6,General Research,Water Pollutants Chemical Female,1.8921
cpsii,Cancer Prevention Study II Nutrition Cohort,0,12,Genomics & GWAS,Polymorphism Single Nucleotide,2.7739
cpsii,Cancer Prevention Study II Nutrition Cohort,0,12,Genomics & GWAS,Genotype,2.5755
cpsii,Cancer Prevention Study II Nutrition Cohort,0,12,Genomics & GWAS,Polymorphism Single Nucleotide Humans,1.9197
cpsii,Cancer Prevention Study II Nutrition Cohort,0,12,Genomics & GWAS,Genotype Risk Factors,1.9197
cpsii,Cancer Prevention Study II Nutrition Cohort,0,12,Genomics & GWAS,Breast Neoplasms,1.4757
cpsii,Cancer Prevention Study II Nutrition Cohort,1,20,Nutrition & Diet,Colorectal Neoplasms,1.4495
cpsii,Cancer Prevention Study II Nutrition Cohort,1,20,Nutrition & Diet,Middle Aged Colorectal Neoplasms,1.1434
cpsii,Cancer Prevention Study II Nutrition Cohort,1,20,Nutrition & Diet,Dairy Products,1.0054
cpsii,Cancer Prevention Study II Nutrition Cohort,1,20,Nutrition & Diet,Calcium Dietary Humans,0.849
cpsii,Cancer Prevention Study II Nutrition Cohort,1,20,Nutrition & Diet,Calcium Dietary,0.849
cpsii,Cancer Prevention Study II Nutrition Cohort,2,29,Cancer & Oncology,Postmenopause,1.718
cpsii,Cancer Prevention Study II Nutrition Cohort,2,29,Cancer & Oncology,Breast Neoplasms,1.2213
cpsii,Cancer Prevention Study II Nutrition Cohort,2,29,Cancer & Oncology,Humans Postmenopause,1.0318
cpsii,Cancer Prevention Study II Nutrition Cohort,2,29,Cancer & Oncology,United States Postmenopause,0.8289
cpsii,Cancer Prevention Study II Nutrition Cohort,2,29,Cancer & Oncology,Cohort Studies Prospective Studies,0.7464
cpsii,Cancer Prevention Study II Nutrition Cohort,3,23,Epidemiology & Risk Factors,Follow Up Studies Humans,1.4202
cpsii,Cancer Prevention Study II Nutrition Cohort,3,23,Epidemiology & Risk Factors,Follow Up Studies,1.3566
cpsii,Cancer Prevention Study II Nutrition Cohort,3,23,Epidemiology & Risk Factors,Prognosis,1.1438
cpsii,Cancer Prevention Study II Nutrition Cohort,3,23,Epidemiology & Risk Factors,Body Mass Index,1.0134
cpsii,Cancer Prevention Study II Nutrition Cohort,3,23,Epidemiology & Risk Factors,Prospective Studies Body Mass Index,0.9107
cpsii,Cancer Prevention Study II Nutrition Cohort,4,35,Cancer & Oncology,Prostatic Neoplasms,1.2808
cpsii,Cancer Prevention Study II Nutrition Cohort,4,35,Cancer & Oncology,Male Humans,0.8254
cpsii,Cancer Prevention Study II Nutrition Cohort,4,35,Cancer & Oncology,Risk Factors Male,0.7621
cpsii,Cancer Prevention Study II Nutrition Cohort,4,35,Cancer & Oncology,Proportional Hazards Models Cohort Studies,0.7606
cpsii,Cancer Prevention Study II Nutrition Cohort,4,35,Cancer & Oncology,Cohort Studies,0.6456
cpsii,Cancer Prevention Study II Nutrition Cohort,5,27,Respiratory Diseases,Lung Neoplasms,1.6354
cpsii,Cancer Prevention Study II Nutrition Cohort,5,27,Respiratory Diseases,Smoking Lung Neoplasms,1.4822
cpsii,Cancer Prevention Study II Nutrition Cohort,5,27,Respiratory Diseases,Smoking,1.0866
cpsii,Cancer Prevention Study II Nutrition Cohort,5,27,Respiratory Diseases,Lung Neoplasms Aged,1.0488
cpsii,Cancer Prevention Study II Nutrition Cohort,5,27,Respiratory Diseases,Smoking Cessation,0.8121
cpsii,Cancer Prevention Study II Nutrition Cohort,6,17,Environmental Health,Air Pollutants,2.4641
cpsii,Cancer Prevention Study II Nutrition Cohort,6,17,Environmental Health,Air Pollution,2.2209
cpsii,Cancer Prevention Study II Nutrition Cohort,6,17,Environmental Health,Particulate Matter,1.9361
cpsii,Cancer Prevention Study II Nutrition Cohort,6,17,Environmental Health,Environmental Exposure,1.8603
cpsii,Cancer Prevention Study II Nutrition Cohort,6,17,Environmental Health,Aged Air Pollutants,1.6714
cpsii,Cancer Prevention Study II Nutrition Cohort,7,28,Epidemiology & Risk Factors,Lymphoma Non Hodgkin,1.0113
cpsii,Cancer Prevention Study II Nutrition Cohort,7,28,Epidemiology & Risk Factors,Smoking Aged,0.9412
cpsii,Cancer Prevention Study II Nutrition Cohort,7,28,Epidemiology & Risk Factors,Aged Lymphoma Non Hodgkin,0.8585
cpsii,Cancer Prevention Study II Nutrition Cohort,7,28,Epidemiology & Risk Factors,Cohort Studies Middle Aged,0.748
cpsii,Cancer Prevention Study II Nutrition Cohort,7,28,Epidemiology & Risk Factors,Lymphoma Non Hodgkin Prospective Studies,0.6856
cpsii,Cancer Prevention Study II Nutrition Cohort,8,30,Epidemiology & Risk Factors,Male United States,1.142
cpsii,Cancer Prevention Study II Nutrition Cohort,8,30,Epidemiology & Risk Factors,Aged Surveys And Questionnaires,0.9983
cpsii,Cancer Prevention Study II Nutrition Cohort,8,30,Epidemiology & Risk Factors,Confidence Intervals,0.97
cpsii,Cancer Prevention Study II Nutrition Cohort,8,30,Epidemiology & Risk Factors,Surveys And Questionnaires Prospective Studies,0.8301
cpsii,Cancer Prevention Study II Nutrition Cohort,8,30,Epidemiology & Risk Factors,Sex Factors,0.8223
cpsii,Cancer Prevention Study II Nutrition Cohort,9,28,Cancer & Oncology,Exercise,1.0886
cpsii,Cancer Prevention Study II Nutrition Cohort,9,28,Cancer & Oncology,Female Male,1.0209
cpsii,Cancer Prevention Study II Nutrition Cohort,9,28,Cancer & Oncology,Neoplasms,0.8682
cpsii,Cancer Prevention Study II Nutrition Cohort,9,28,Cancer & Oncology,Exercise Middle Aged,0.7897
cpsii,Cancer Prevention Study II Nutrition Cohort,9,28,Cancer & Oncology,Adult Neoplasms,0.7359
cpsii,Cancer Prevention Study II Nutrition Cohort,10,30,Cancer & Oncology,Female Aged 80 And Over,1.2261
cpsii,Cancer Prevention Study II Nutrition Cohort,10,30,Cancer & Oncology,Aged 80 And Over,1.0571
cpsii,Cancer Prevention Study II Nutrition Cohort,10,30,Cancer & Oncology,Humans Adult,0.9304
cpsii,Cancer Prevention Study II Nutrition Cohort,10,30,Cancer & Oncology,Pancreatic Neoplasms,0.9199
cpsii,Cancer Prevention Study II Nutrition Cohort,10,30,Cancer & Oncology,Adult Middle Aged,0.8287
cpsii; kcps,Cancer Prevention Study II Nutrition Cohort; Korean Cancer Prevention Study,0,11,Genomics & GWAS,Polymorphism Single Nucleotide,0.7363
cpsii; kcps,Cancer Prevention Study II Nutrition Cohort; Korean Cancer Prevention Study,0,11,Genomics & GWAS,Genetic Predisposition To Disease,0.6944
cpsii; kcps,Cancer Prevention Study II Nutrition Cohort; Korean Cancer Prevention Study,0,11,Genomics & GWAS,Genome Wide Association Study,0.6837
cpsii; kcps,Cancer Prevention Study II Nutrition Cohort; Korean Cancer Prevention Study,0,11,Genomics & GWAS,Polymorphism Single Nucleotide Genetic Predisposition To Disease,0.5992
cpsii; kcps,Cancer Prevention Study II Nutrition Cohort; Korean Cancer Prevention Study,0,11,Genomics & GWAS,Alcohol Drinking,0.5992
cpsii; kcps,Cancer Prevention Study II Nutrition Cohort; Korean Cancer Prevention Study,1,10,Epidemiology & Risk Factors,Prospective Studies,0.9024
cpsii; kcps,Cancer Prevention Study II Nutrition Cohort; Korean Cancer Prevention Study,1,10,Epidemiology & Risk Factors,Proportional Hazards Models,0.752
cpsii; kcps,Cancer Prevention Study II Nutrition Cohort; Korean Cancer Prevention Study,1,10,Epidemiology & Risk Factors,Risk Factors Male,0.675
cpsii; kcps,Cancer Prevention Study II Nutrition Cohort; Korean Cancer Prevention Study,1,10,Epidemiology & Risk Factors,Incidence,0.6746
cpsii; kcps,Cancer Prevention Study II Nutrition Cohort; Korean Cancer Prevention Study,1,10,Epidemiology & Risk Factors,Fasting,0.6592
cpsii; kcps,Cancer Prevention Study II Nutrition Cohort; Korean Cancer Prevention Study,2,6,General Research,Cohort Studies Aged,1.0986
cpsii; kcps,Cancer Prevention Study II Nutrition Cohort; Korean Cancer Prevention Study,2,6,General Research,Biological Specimen Banks,1.0986
cpsii; kcps,Cancer Prevention Study II Nutrition Cohort; Korean Cancer Prevention Study,2,6,General Research,Aged Middle Aged,1.0137
cpsii; kcps,Cancer Prevention Study II Nutrition Cohort; Korean Cancer Prevention Study,2,6,General Research,Female Cohort Studies,0.9548
cpsii; kcps,Cancer Prevention Study II Nutrition Cohort; Korean Cancer Prevention Study,2,6,General Research,Humans Biological Specimen Banks,0.8676
ckb,China Kadoorie Biobank,0,46,Epidemiology & Risk Factors,Male Female,1.5093
ckb,China Kadoorie Biobank,0,46,Epidemiology & Risk Factors,Female Adult,1.1894
ckb,China Kadoorie Biobank,0,46,Epidemiology & Risk Factors,Adult Humans,0.9665
ckb,China Kadoorie Biobank,0,46,Epidemiology & Risk Factors,Prospective Studies Male,0.7698
ckb,China Kadoorie Biobank,0,46,Epidemiology & Risk Factors,Smoking Middle Aged,0.7062
ckb,China Kadoorie Biobank,1,45,Epidemiology & Risk Factors,Humans Aged,1.7985
ckb,China Kadoorie Biobank,1,45,Epidemiology & Risk Factors,Adult China,1.435
ckb,China Kadoorie Biobank,1,45,Epidemiology & Risk Factors,Asian People Humans,0.9941
ckb,China Kadoorie Biobank,1,45,Epidemiology & Risk Factors,Prevalence,0.9407
ckb,China Kadoorie Biobank,1,45,Epidemiology & Risk Factors,Rural Population Male,0.8389
ckb,China Kadoorie Biobank,2,19,Multi-omics & Biomarkers,Biomarkers,1.8425
ckb,China Kadoorie Biobank,2,19,Multi-omics & Biomarkers,Case Control Studies,1.7725
ckb,China Kadoorie Biobank,2,19,Multi-omics & Biomarkers,Male Biomarkers,1.2822
ckb,China Kadoorie Biobank,2,19,Multi-omics & Biomarkers,Adult Case Control Studies,1.1922
ckb,China Kadoorie Biobank,2,19,Multi-omics & Biomarkers,Dna Methylation,0.9538
ckb,China Kadoorie Biobank,3,40,Metabolic & Diabetes,Body Mass Index,1.7152
ckb,China Kadoorie Biobank,3,40,Metabolic & Diabetes,Obesity,1.5314
ckb,China Kadoorie Biobank,3,40,Metabolic & Diabetes,Waist Circumference,1.2923
ckb,China Kadoorie Biobank,3,40,Metabolic & Diabetes,Adiposity,1.1376
ckb,China Kadoorie Biobank,3,40,Metabolic & Diabetes,Body Mass Index Adiposity,0.9093
ckb,China Kadoorie Biobank,4,48,Metabolic & Diabetes,Asian People China,1.1307
ckb,China Kadoorie Biobank,4,48,Metabolic & Diabetes,Diabetes Mellitus Type 2,1.1014
ckb,China Kadoorie Biobank,4,48,Metabolic & Diabetes,Asian People,1.099
ckb,China Kadoorie Biobank,4,48,Metabolic & Diabetes,Aged Humans,0.9128
ckb,China Kadoorie Biobank,4,48,Metabolic & Diabetes,Female Asian People,0.8681
ckb,China Kadoorie Biobank,5,18,Sleep Research,Sleep,3.1442
ckb,China Kadoorie Biobank,5,18,Sleep Research,Sleep Adult,2.5284
ckb,China Kadoorie Biobank,5,18,Sleep Research,Sleep Initiation And Maintenance Disorders,2.0305
ckb,China Kadoorie Biobank,5,18,Sleep Research,Snoring,1.3346
ckb,China Kadoorie Biobank,5,18,Sleep Research,Snoring Sleep,1.2585
ckb,China Kadoorie Biobank,6,25,Epidemiology & Risk Factors,Stroke,1.5225
ckb,China Kadoorie Biobank,6,25,Epidemiology & Risk Factors,Pregnancy,1.2122
ckb,China Kadoorie Biobank,6,25,Epidemiology & Risk Factors,Risk Factors Stroke,1.0816
ckb,China Kadoorie Biobank,6,25,Epidemiology & Risk Factors,Brain Ischemia,0.9462
ckb,China Kadoorie Biobank,6,25,Epidemiology & Risk Factors,Prospective Studies Brain Ischemia,0.9061
ckb,China Kadoorie Biobank,7,19,General Research,Menarche,2.116
ckb,China Kadoorie Biobank,7,19,General Research,Adolescent,1.6601
ckb,China Kadoorie Biobank,7,19,General Research,Menopause,1.6157
ckb,China Kadoorie Biobank,7,19,General Research,Menarche Middle Aged,1.5451
ckb,China Kadoorie Biobank,7,19,General Research,Age Factors,1.4777
ckb,China Kadoorie Biobank,8,87,Cardiovascular Research,Female Humans,0.7213
ckb,China Kadoorie Biobank,8,87,Cardiovascular Research,Adult Female,0.6643
ckb,China Kadoorie Biobank,8,87,Cardiovascular Research,China Aged,0.5518
ckb,China Kadoorie Biobank,8,87,Cardiovascular Research,Aged Risk Factors,0.509
ckb,China Kadoorie Biobank,8,87,Cardiovascular Research,Cardiovascular Diseases,0.4843
ckb,China Kadoorie Biobank,9,55,Epidemiology & Risk Factors,Incidence Male,1.582
ckb,China Kadoorie Biobank,9,55,Epidemiology & Risk Factors,Incidence,1.3389
ckb,China Kadoorie Biobank,9,55,Epidemiology & Risk Factors,Prospective Studies Incidence,1.154
ckb,China Kadoorie Biobank,9,55,Epidemiology & Risk Factors,Female Adult,0.9253
ckb,China Kadoorie Biobank,9,55,Epidemiology & Risk Factors,Proportional Hazards Models,0.7726
ckb,China Kadoorie Biobank,10,24,Environmental Health,Cooking,2.1303
ckb,China Kadoorie Biobank,10,24,Environmental Health,Air Pollution Indoor,1.7602
ckb,China Kadoorie Biobank,10,24,Environmental Health,Coal,1.4785
ckb,China Kadoorie Biobank,10,24,Environmental Health,Rural Population,1.3217
ckb,China Kadoorie Biobank,10,24,Environmental Health,Middle Aged Air Pollution Indoor,1.2232
ckb,China Kadoorie Biobank,11,38,Cancer & Oncology,China Risk Factors,1.4111
ckb,China Kadoorie Biobank,11,38,Cancer & Oncology,Risk Factors Lung Neoplasms,0.6865
ckb,China Kadoorie Biobank,11,38,Cancer & Oncology,Cohort Studies Adult,0.6409
ckb,China Kadoorie Biobank,11,38,Cancer & Oncology,Lung Neoplasms,0.5645
ckb,China Kadoorie Biobank,11,38,Cancer & Oncology,Cohort Studies,0.5213
ckb; ukb,China Kadoorie Biobank; UK Biobank,0,18,Epidemiology & Risk Factors,Male Adult,0.602
ckb; ukb,China Kadoorie Biobank; UK Biobank,0,18,Epidemiology & Risk Factors,Adult Middle Aged,0.5474
ckb; ukb,China Kadoorie Biobank; UK Biobank,0,18,Epidemiology & Risk Factors,Female Aged,0.518
ckb; ukb,China Kadoorie Biobank; UK Biobank,0,18,Epidemiology & Risk Factors,Prospective Studies,0.4828
ckb; ukb,China Kadoorie Biobank; UK Biobank,0,18,Epidemiology & Risk Factors,Risk Assessment,0.455
ckb; ukb,China Kadoorie Biobank; UK Biobank,1,9,Mendelian Randomization,Risk Factors Adult,0.9101
ckb; ukb,China Kadoorie Biobank; UK Biobank,1,9,Mendelian Randomization,Genome Wide Association Study,0.8267
ckb; ukb,China Kadoorie Biobank; UK Biobank,1,9,Mendelian Randomization,Stroke,0.8109
ckb; ukb,China Kadoorie Biobank; UK Biobank,1,9,Mendelian Randomization,Mendelian Randomization Analysis,0.8109
ckb; ukb,China Kadoorie Biobank; UK Biobank,1,9,Mendelian Randomization,Case Control Studies,0.7785
ckb; ukb,China Kadoorie Biobank; UK Biobank,2,4,General Research,Biological Specimen Banks,1.6422
ckb; ukb,China Kadoorie Biobank; UK Biobank,2,4,General Research,United Kingdom China,1.1677
ckb; ukb,China Kadoorie Biobank; UK Biobank,2,4,General Research,Uk Biobank,1.0238
ckb; ukb,China Kadoorie Biobank; UK Biobank,2,4,General Research,United Kingdom,0.7949
ckb; ukb,China Kadoorie Biobank; UK Biobank,2,4,General Research,Aged Prognosis,0.6852
peace,China PEACE Million Persons Project,0,23,Cardiovascular Research,Adult Humans,0.8763
peace,China PEACE Million Persons Project,0,23,Cardiovascular Research,Cardiovascular Diseases,0.8709
peace,China PEACE Million Persons Project,0,23,Cardiovascular Research,Hypertension,0.8398
peace,China PEACE Million Persons Project,0,23,Cardiovascular Research,Blood Pressure,0.797
peace,China PEACE Million Persons Project,0,23,Cardiovascular Research,Hypertension China,0.797
peace,China PEACE Million Persons Project,1,28,Cardiovascular Research,Percutaneous Coronary Intervention,0.7497
peace,China PEACE Million Persons Project,1,28,Cardiovascular Research,Myocardial Infarction,0.7222
peace,China PEACE Million Persons Project,1,28,Cardiovascular Research,Hospital Mortality,0.7214
peace,China PEACE Million Persons Project,1,28,Cardiovascular Research,Retrospective Studies,0.7037
peace,China PEACE Million Persons Project,1,28,Cardiovascular Research,Humans Retrospective Studies,0.6557
peace,China PEACE Million Persons Project,2,18,Cardiovascular Research,Heart Failure,1.0896
peace,China PEACE Million Persons Project,2,18,Cardiovascular Research,Hospitalization,0.8861
peace,China PEACE Million Persons Project,2,18,Cardiovascular Research,Prospective Studies Heart Failure,0.8141
peace,China PEACE Million Persons Project,2,18,Cardiovascular Research,Prospective Studies,0.7165
peace,China PEACE Million Persons Project,2,18,Cardiovascular Research,Hospitalization Middle Aged,0.6784
dnbc,Danish National Birth Cohort,0,175,Epidemiology & Risk Factors,Denmark Humans,0.5597
dnbc,Danish National Birth Cohort,0,175,Epidemiology & Risk Factors,Risk Factors,0.5209
dnbc,Danish National Birth Cohort,0,175,Epidemiology & Risk Factors,Cohort Studies Denmark,0.5117
dnbc,Danish National Birth Cohort,0,175,Epidemiology & Risk Factors,Pregnancy Risk Factors,0.4857
dnbc,Danish National Birth Cohort,0,175,Epidemiology & Risk Factors,Risk Factors Cohort Studies,0.4835
dnbc,Danish National Birth Cohort,1,122,General Research,Gestational Age,0.8029
dnbc,Danish National Birth Cohort,1,122,General Research,Denmark Adult,0.7691
dnbc,Danish National Birth Cohort,1,122,General Research,Infant Newborn,0.739
dnbc,Danish National Birth Cohort,1,122,General Research,Birth Weight,0.6854
dnbc,Danish National Birth Cohort,1,122,General Research,Cohort Studies Humans,0.6184
dnbc,Danish National Birth Cohort,2,17,General Research,Semen Analysis,3.247
dnbc,Danish National Birth Cohort,2,17,General Research,Semen Analysis Adult,2.0051
dnbc,Danish National Birth Cohort,2,17,General Research,Semen,2.0051
dnbc,Danish National Birth Cohort,2,17,General Research,Sperm Count,1.8095
dnbc,Danish National Birth Cohort,2,17,General Research,Humans Semen Analysis,1.6054
dnbc,Danish National Birth Cohort,3,31,Environmental Health,Fluorocarbons,2.7813
dnbc,Danish National Birth Cohort,3,31,Environmental Health,Environmental Pollutants,2.2327
dnbc,Danish National Birth Cohort,3,31,Environmental Health,Alkanesulfonic Acids,2.1578
dnbc,Danish National Birth Cohort,3,31,Environmental Health,Caprylates,1.6716
dnbc,Danish National Birth Cohort,3,31,Environmental Health,Alkanesulfonic Acids Adult,1.4924
dnbc,Danish National Birth Cohort,4,128,General Research,Child Male,0.8845
dnbc,Danish National Birth Cohort,4,128,General Research,Adolescent,0.8462
dnbc,Danish National Birth Cohort,4,128,General Research,Male Adolescent,0.8072
dnbc,Danish National Birth Cohort,4,128,General Research,Child,0.7645
dnbc,Danish National Birth Cohort,4,128,General Research,Humans Denmark,0.6214
dnbc,Danish National Birth Cohort,5,94,General Research,Child Preschool,1.1076
dnbc,Danish National Birth Cohort,5,94,General Research,Infant,1.0175
dnbc,Danish National Birth Cohort,5,94,General Research,Child Preschool Infant,0.797
dnbc,Danish National Birth Cohort,5,94,General Research,Pregnancy Child Preschool,0.7449
dnbc,Danish National Birth Cohort,5,94,General Research,Infant Cohort Studies,0.6656
elsa_brasil,ELSA-Brasil,0,66,Infectious Diseases,Humans Longitudinal Studies,1.4321
elsa_brasil,ELSA-Brasil,0,66,Infectious Diseases,Longitudinal Studies Adult,0.7204
elsa_brasil,ELSA-Brasil,0,66,Infectious Diseases,Cross Sectional Studies Brazil,0.5618
elsa_brasil,ELSA-Brasil,0,66,Infectious Diseases,Pandemics,0.5405
elsa_brasil,ELSA-Brasil,0,66,Infectious Diseases,Covid 19,0.5177
elsa_brasil,ELSA-Brasil,1,49,Cardiovascular Research,Thyrotropin,1.2184
elsa_brasil,ELSA-Brasil,1,49,Cardiovascular Research,Hypertension,1.072
elsa_brasil,ELSA-Brasil,1,49,Cardiovascular Research,Thyroxine,1.0072
elsa_brasil,ELSA-Brasil,1,49,Cardiovascular Research,Hypothyroidism,0.9762
elsa_brasil,ELSA-Brasil,1,49,Cardiovascular Research,Middle Aged Thyrotropin,0.9692
elsa_brasil,ELSA-Brasil,2,31,Epidemiology & Risk Factors,Leisure Activities,2.5782
elsa_brasil,ELSA-Brasil,2,31,Epidemiology & Risk Factors,Exercise,2.2626
elsa_brasil,ELSA-Brasil,2,31,Epidemiology & Risk Factors,Humans Leisure Activities,2.0942
elsa_brasil,ELSA-Brasil,2,31,Epidemiology & Risk Factors,Middle Aged Exercise,1.7635
elsa_brasil,ELSA-Brasil,2,31,Epidemiology & Risk Factors,Leisure Activities Longitudinal Studies,1.105
elsa_brasil,ELSA-Brasil,3,56,Epidemiology & Risk Factors,Humans Risk Factors,1.3031
elsa_brasil,ELSA-Brasil,3,56,Epidemiology & Risk Factors,Cardiovascular Diseases,1.0739
elsa_brasil,ELSA-Brasil,3,56,Epidemiology & Risk Factors,Longitudinal Studies Cardiovascular Diseases,1.0314
elsa_brasil,ELSA-Brasil,3,56,Epidemiology & Risk Factors,Cardiovascular Diseases Adult,1.0158
elsa_brasil,ELSA-Brasil,3,56,Epidemiology & Risk Factors,Carotid Intima Media Thickness,0.9338
elsa_brasil,ELSA-Brasil,4,26,Metabolic & Diabetes,Metabolic Syndrome,3.0291
elsa_brasil,ELSA-Brasil,4,26,Metabolic & Diabetes,Brazil Metabolic Syndrome,2.7671
elsa_brasil,ELSA-Brasil,4,26,Metabolic & Diabetes,Metabolic Syndrome Humans,2.6789
elsa_brasil,ELSA-Brasil,4,26,Metabolic & Diabetes,Insulin Resistance Adult,0.8234
elsa_brasil,ELSA-Brasil,4,26,Metabolic & Diabetes,Insulin Resistance,0.6571
elsa_brasil,ELSA-Brasil,5,30,Neurological Disorders,Cognition,2.338
elsa_brasil,ELSA-Brasil,5,30,Neurological Disorders,Middle Aged Cognition,2.2581
elsa_brasil,ELSA-Brasil,5,30,Neurological Disorders,Neuropsychological Tests,1.7204
elsa_brasil,ELSA-Brasil,5,30,Neurological Disorders,Cognitive Dysfunction,1.6349
elsa_brasil,ELSA-Brasil,5,30,Neurological Disorders,Longitudinal Studies Cognitive Dysfunction,1.3395
elsa_brasil,ELSA-Brasil,6,28,Metabolic & Diabetes,Body Mass Index,1.7353
elsa_brasil,ELSA-Brasil,6,28,Metabolic & Diabetes,Body Mass Index Longitudinal Studies,1.7084
elsa_brasil,ELSA-Brasil,6,28,Metabolic & Diabetes,Obesity,1.5786
elsa_brasil,ELSA-Brasil,6,28,Metabolic & Diabetes,Waist Circumference,1.2982
elsa_brasil,ELSA-Brasil,6,28,Metabolic & Diabetes,Obesity Male,1.041
elsa_brasil,ELSA-Brasil,7,74,Epidemiology & Risk Factors,Male Brazil,1.2395
elsa_brasil,ELSA-Brasil,7,74,Epidemiology & Risk Factors,Risk Assessment,0.7963
elsa_brasil,ELSA-Brasil,7,74,Epidemiology & Risk Factors,Aged Adult,0.7687
elsa_brasil,ELSA-Brasil,7,74,Epidemiology & Risk Factors,Logistic Models Middle Aged,0.7628
elsa_brasil,ELSA-Brasil,7,74,Epidemiology & Risk Factors,Cross Sectional Studies Risk Factors,0.7274
elsa_brasil,ELSA-Brasil,8,124,Epidemiology & Risk Factors,Socioeconomic Factors,0.6261
elsa_brasil,ELSA-Brasil,8,124,Epidemiology & Risk Factors,Female Middle Aged,0.5529
elsa_brasil,ELSA-Brasil,8,124,Epidemiology & Risk Factors,Humans Aged,0.549
elsa_brasil,ELSA-Brasil,8,124,Epidemiology & Risk Factors,Socioeconomic Factors Male,0.5452
elsa_brasil,ELSA-Brasil,8,124,Epidemiology & Risk Factors,Aged Longitudinal Studies,0.5405
elsa_brasil,ELSA-Brasil,9,33,General Research,Female Cohort Studies,1.8426
elsa_brasil,ELSA-Brasil,9,33,General Research,Cohort Studies Middle Aged,1.6671
elsa_brasil,ELSA-Brasil,9,33,General Research,Cohort Studies,1.5366
elsa_brasil,ELSA-Brasil,9,33,General Research,Pulse Wave Analysis,1.346
elsa_brasil,ELSA-Brasil,9,33,General Research,Male Pulse Wave Analysis,1.201
elsa_brasil,ELSA-Brasil,10,25,Metabolic & Diabetes,Diabetes Mellitus Type 2,2.6667
elsa_brasil,ELSA-Brasil,10,25,Metabolic & Diabetes,Humans Diabetes Mellitus Type 2,1.9757
elsa_brasil,ELSA-Brasil,10,25,Metabolic & Diabetes,Diabetes Mellitus Type 2 Longitudinal Studies,1.7226
elsa_brasil,ELSA-Brasil,10,25,Metabolic & Diabetes,Aged Diabetes Mellitus Type 2,1.2404
elsa_brasil,ELSA-Brasil,10,25,Metabolic & Diabetes,Blood Glucose,1.1036
elsa_brasil,ELSA-Brasil,11,37,Epidemiology & Risk Factors,Biomarkers,1.5269
elsa_brasil,ELSA-Brasil,11,37,Epidemiology & Risk Factors,Female Biomarkers,1.3852
elsa_brasil,ELSA-Brasil,11,37,Epidemiology & Risk Factors,Biomarkers Middle Aged,1.3823
elsa_brasil,ELSA-Brasil,11,37,Epidemiology & Risk Factors,Incidence Male,1.0462
elsa_brasil,ELSA-Brasil,11,37,Epidemiology & Risk Factors,Disease Progression,0.9873
echo,ECHO Cohort,0,25,Multi-omics & Biomarkers,Humans Female,0.8855
echo,ECHO Cohort,0,25,Multi-omics & Biomarkers,Epigenesis Genetic,0.8612
echo,ECHO Cohort,0,25,Multi-omics & Biomarkers,Dna Methylation,0.8612
echo,ECHO Cohort,0,25,Multi-omics & Biomarkers,Gestational Age,0.7674
echo,ECHO Cohort,0,25,Multi-omics & Biomarkers,Child Gestational Age,0.7176
echo,ECHO Cohort,1,21,Environmental Health,Environmental Health,1.42
echo,ECHO Cohort,1,21,Environmental Health,National Institutes Of Health U S,1.3786
echo,ECHO Cohort,1,21,Environmental Health,Environmental Health Humans,1.364
echo,ECHO Cohort,1,21,Environmental Health,Biomedical Research,1.2124
echo,ECHO Cohort,1,21,Environmental Health,United States Environmental Exposure,1.1451
echo,ECHO Cohort,2,35,General Research,Child Development,0.9046
echo,ECHO Cohort,2,35,General Research,Humans Infant,0.8855
echo,ECHO Cohort,2,35,General Research,Infant,0.8503
echo,ECHO Cohort,2,35,General Research,Pregnancy Child,0.7831
echo,ECHO Cohort,2,35,General Research,Infant Newborn,0.5954
echo,ECHO Cohort,3,20,Epidemiology & Risk Factors,Asthma,1.0729
echo,ECHO Cohort,3,20,Epidemiology & Risk Factors,Humans Child,0.9571
echo,ECHO Cohort,3,20,Epidemiology & Risk Factors,Incidence,0.897
echo,ECHO Cohort,3,20,Epidemiology & Risk Factors,Cross Sectional Studies,0.8445
echo,ECHO Cohort,3,20,Epidemiology & Risk Factors,Adolescent,0.744
echo,ECHO Cohort,4,15,Infectious Diseases,Pandemics,2.4895
echo,ECHO Cohort,4,15,Infectious Diseases,Covid 19,2.2889
echo,ECHO Cohort,4,15,Infectious Diseases,Pandemics Covid 19,1.988
echo,ECHO Cohort,4,15,Infectious Diseases,Child Pandemics,1.7892
echo,ECHO Cohort,4,15,Infectious Diseases,Humans Child,1.1485
echo,ECHO Cohort,5,15,Nutrition & Diet,Pregnancy Complications,1.3202
echo,ECHO Cohort,5,15,Nutrition & Diet,Pregnancy Outcome,1.1002
echo,ECHO Cohort,5,15,Nutrition & Diet,Dietary Supplements,1.065
echo,ECHO Cohort,5,15,Nutrition & Diet,Prenatal Care,1.065
echo,ECHO Cohort,5,15,Nutrition & Diet,Diet,0.994
echo,ECHO Cohort,6,10,General Research,Aged,1.8852
echo,ECHO Cohort,6,10,General Research,Middle Aged,1.7941
echo,ECHO Cohort,6,10,General Research,Primary Health Care,1.5974
echo,ECHO Cohort,6,10,General Research,Adult Middle Aged,1.5082
echo,ECHO Cohort,6,10,General Research,Rural Population,1.1981
echo,ECHO Cohort,7,17,Environmental Health,Environmental Pollutants,2.0723
echo,ECHO Cohort,7,17,Environmental Health,Maternal Exposure,1.5254
echo,ECHO Cohort,7,17,Environmental Health,Maternal Exposure Child Health,1.414
echo,ECHO Cohort,7,17,Environmental Health,Phthalic Acids,1.0861
echo,ECHO Cohort,7,17,Environmental Health,Child Environmental Pollutants,1.01
echo,ECHO Cohort,8,25,General Research,Infant Newborn Female,1.1863
echo,ECHO Cohort,8,25,General Research,Humans Pregnancy,1.0389
echo,ECHO Cohort,8,25,General Research,Air Pollutants,0.9241
echo,ECHO Cohort,8,25,General Research,Infant Newborn,0.8856
echo,ECHO Cohort,8,25,General Research,Premature Birth,0.8583
echo,ECHO Cohort,9,16,Environmental Health,Pregnancy Humans,2.0841
echo,ECHO Cohort,9,16,Environmental Health,Humans Female,2.0126
echo,ECHO Cohort,9,16,Environmental Health,Female Child,1.3924
echo,ECHO Cohort,9,16,Environmental Health,Child Prenatal Exposure Delayed Effects,1.0655
echo,ECHO Cohort,9,16,Environmental Health,Outcome Assessment Health Care,0.9819
echo,ECHO Cohort,10,18,General Research,Surveys And Questionnaires,1.2511
echo,ECHO Cohort,10,18,General Research,Child Health Male,0.9383
echo,ECHO Cohort,10,18,General Research,Male Child Preschool,0.8993
echo,ECHO Cohort,10,18,General Research,Adolescent,0.8267
echo,ECHO Cohort,10,18,General Research,Child Surveys And Questionnaires,0.7974
epihealth,EpiHealth,0,14,General Research,Cohort Studies Humans,0.6499
epihealth,EpiHealth,0,14,General Research,Humans Male,0.6143
epihealth,EpiHealth,0,14,General Research,Cohort Studies,0.614
epihealth,EpiHealth,0,14,General Research,Aged Cohort Studies,0.6012
epihealth,EpiHealth,0,14,General Research,Middle Aged Female,0.6012
epihealth,EpiHealth,1,24,Cardiovascular Research,Risk Factors,0.5631
epihealth,EpiHealth,1,24,Cardiovascular Research,Cardiovascular Diseases,0.5291
epihealth,EpiHealth,1,24,Cardiovascular Research,Obesity,0.5291
epihealth,EpiHealth,1,24,Cardiovascular Research,Aged Humans,0.5156
epihealth,EpiHealth,1,24,Cardiovascular Research,Biomarkers,0.5054
epihealth,EpiHealth,2,3,General Research,Blastocyst,2.615
epihealth,EpiHealth,2,3,General Research,Animals,2.615
epihealth,EpiHealth,2,3,General Research,Mice,2.0136
epihealth,EpiHealth,2,3,General Research,Pregnancy,2.0136
epihealth,EpiHealth,2,3,General Research,Age Factors,1.0068
estbb,Estonian Biobank,0,41,Genomics & GWAS,Genome Wide Association Study Genetic Loci,1.8254
estbb,Estonian Biobank,0,41,Genomics & GWAS,Genetic Loci,1.4807
estbb,Estonian Biobank,0,41,Genomics & GWAS,Humans Genome Wide Association Study,1.0542
estbb,Estonian Biobank,0,41,Genomics & GWAS,Female Polymorphism Single Nucleotide,0.8884
estbb,Estonian Biobank,0,41,Genomics & GWAS,Genetic Predisposition To Disease Female,0.8647
estbb,Estonian Biobank,1,149,General Research,Middle Aged,1.0085
estbb,Estonian Biobank,1,149,General Research,Aged,0.901
estbb,Estonian Biobank,1,149,General Research,Adult,0.8456
estbb,Estonian Biobank,1,149,General Research,Young Adult,0.7193
estbb,Estonian Biobank,1,149,General Research,Male,0.6649
estbb,Estonian Biobank,2,227,Genomics & GWAS,Humans Genome Wide Association Study,0.461
estbb,Estonian Biobank,2,227,Genomics & GWAS,Quantitative Trait Loci,0.4411
estbb,Estonian Biobank,2,227,Genomics & GWAS,Genome Wide Association Study,0.4377
estbb,Estonian Biobank,2,227,Genomics & GWAS,Polymorphism Single Nucleotide,0.434
estbb,Estonian Biobank,2,227,Genomics & GWAS,Genetic Predisposition To Disease,0.3815
estbb,Estonian Biobank,3,33,Epidemiology & Risk Factors,Biomarkers,1.9366
estbb,Estonian Biobank,3,33,Epidemiology & Risk Factors,Biomarkers Humans,1.4868
estbb,Estonian Biobank,3,33,Epidemiology & Risk Factors,Prospective Studies,0.864
estbb,Estonian Biobank,3,33,Epidemiology & Risk Factors,Mesenteric Ischemia,0.8038
estbb,Estonian Biobank,3,33,Epidemiology & Risk Factors,Male Biomarkers,0.7758
estbb,Estonian Biobank,4,49,General Research,Estonia,1.6801
estbb,Estonian Biobank,4,49,General Research,Biological Specimen Banks,1.0386
estbb,Estonian Biobank,4,49,General Research,Electronic Health Records,0.8022
estbb,Estonian Biobank,4,49,General Research,Biomedical Research,0.5413
estbb,Estonian Biobank,4,49,General Research,Estonia Female,0.5225
estbb; ukb,Estonian Biobank; UK Biobank,0,22,Cardiovascular Research,Humans Genome Wide Association Study,0.7077
estbb; ukb,Estonian Biobank; UK Biobank,0,22,Cardiovascular Research,Phenotype,0.6064
estbb; ukb,Estonian Biobank; UK Biobank,0,22,Cardiovascular Research,Phenotype Humans,0.5366
estbb; ukb,Estonian Biobank; UK Biobank,0,22,Cardiovascular Research,Bayes Theorem,0.4698
estbb; ukb,Estonian Biobank; UK Biobank,0,22,Cardiovascular Research,Coronary Artery Disease,0.4601
estbb; ukb,Estonian Biobank; UK Biobank,1,21,Genomics & GWAS,Middle Aged,0.9125
estbb; ukb,Estonian Biobank; UK Biobank,1,21,Genomics & GWAS,Aged,0.8236
estbb; ukb,Estonian Biobank; UK Biobank,1,21,Genomics & GWAS,Adult,0.7599
estbb; ukb,Estonian Biobank; UK Biobank,1,21,Genomics & GWAS,Middle Aged Polymorphism Single Nucleotide,0.7599
estbb; ukb,Estonian Biobank; UK Biobank,1,21,Genomics & GWAS,Male,0.6613
estbb; ukb,Estonian Biobank; UK Biobank,2,10,General Research,Quantitative Trait Loci,1.4171
estbb; ukb,Estonian Biobank; UK Biobank,2,10,General Research,Quantitative Trait Loci Genome Wide Association Study,1.1804
estbb; ukb,Estonian Biobank; UK Biobank,2,10,General Research,Humans Quantitative Trait Loci,1.0336
estbb; ukb,Estonian Biobank; UK Biobank,2,10,General Research,Sex Characteristics,0.6554
estbb; ukb,Estonian Biobank; UK Biobank,2,10,General Research,Gene Environment Interaction,0.5743
epic,European Prospective Investigation into Cancer and Nutrition,0,391,General Research,Middle Aged Europe,1.3041
epic,European Prospective Investigation into Cancer and Nutrition,0,391,General Research,Humans Male,1.2196
epic,European Prospective Investigation into Cancer and Nutrition,0,391,General Research,Europe Aged,1.0858
epic,European Prospective Investigation into Cancer and Nutrition,0,391,General Research,Europe,0.965
epic,European Prospective Investigation into Cancer and Nutrition,0,391,General Research,Europe Humans,0.9
epic,European Prospective Investigation into Cancer and Nutrition,1,305,Epidemiology & Risk Factors,Male Aged,1.6305
epic,European Prospective Investigation into Cancer and Nutrition,1,305,Epidemiology & Risk Factors,Middle Aged Male,1.1659
epic,European Prospective Investigation into Cancer and Nutrition,1,305,Epidemiology & Risk Factors,Aged Humans,1.0669
epic,European Prospective Investigation into Cancer and Nutrition,1,305,Epidemiology & Risk Factors,Humans Risk Factors,0.5766
epic,European Prospective Investigation into Cancer and Nutrition,1,305,Epidemiology & Risk Factors,Aged 80 And Over Female,0.5188
epic,European Prospective Investigation into Cancer and Nutrition,2,508,Epidemiology & Risk Factors,Middle Aged Aged,1.0351
epic,European Prospective Investigation into Cancer and Nutrition,2,508,Epidemiology & Risk Factors,Europe Male,0.7642
epic,European Prospective Investigation into Cancer and Nutrition,2,508,Epidemiology & Risk Factors,Risk Factors Male,0.5993
epic,European Prospective Investigation into Cancer and Nutrition,2,508,Epidemiology & Risk Factors,Adult Middle Aged,0.573
epic,European Prospective Investigation into Cancer and Nutrition,2,508,Epidemiology & Risk Factors,Surveys And Questionnaires,0.5513
epic,European Prospective Investigation into Cancer and Nutrition,3,510,Epidemiology & Risk Factors,Male Humans,0.8279
epic,European Prospective Investigation into Cancer and Nutrition,3,510,Epidemiology & Risk Factors,Humans Prospective Studies,0.4347
epic,European Prospective Investigation into Cancer and Nutrition,3,510,Epidemiology & Risk Factors,Middle Aged Male,0.4201
epic,European Prospective Investigation into Cancer and Nutrition,3,510,Epidemiology & Risk Factors,Middle Aged Risk Factors,0.4146
epic,European Prospective Investigation into Cancer and Nutrition,3,510,Epidemiology & Risk Factors,Risk Factors Humans,0.4081
epic; ukb,European Prospective Investigation into Cancer and Nutrition; UK Biobank,0,8,Epidemiology & Risk Factors,Neoplasms,1.0986
epic; ukb,European Prospective Investigation into Cancer and Nutrition; UK Biobank,0,8,Epidemiology & Risk Factors,Prospective Studies Biological Specimen Banks,0.9318
epic; ukb,European Prospective Investigation into Cancer and Nutrition; UK Biobank,0,8,Epidemiology & Risk Factors,United Kingdom Humans,0.9318
epic; ukb,European Prospective Investigation into Cancer and Nutrition; UK Biobank,0,8,Epidemiology & Risk Factors,Biological Specimen Banks,0.824
epic; ukb,European Prospective Investigation into Cancer and Nutrition; UK Biobank,0,8,Epidemiology & Risk Factors,Risk Factors Humans,0.8188
epic; ukb,European Prospective Investigation into Cancer and Nutrition; UK Biobank,1,9,Genomics & GWAS,Polymorphism Single Nucleotide,1.0917
epic; ukb,European Prospective Investigation into Cancer and Nutrition; UK Biobank,1,9,Genomics & GWAS,Humans Mendelian Randomization Analysis,0.9765
epic; ukb,European Prospective Investigation into Cancer and Nutrition; UK Biobank,1,9,Genomics & GWAS,Genome Wide Association Study Female,0.9765
epic; ukb,European Prospective Investigation into Cancer and Nutrition; UK Biobank,1,9,Genomics & GWAS,Genome Wide Association Study,0.8774
epic; ukb,European Prospective Investigation into Cancer and Nutrition; UK Biobank,1,9,Genomics & GWAS,Polymorphism Single Nucleotide Risk Factors,0.8283
epic; ukb,European Prospective Investigation into Cancer and Nutrition; UK Biobank,2,19,Epidemiology & Risk Factors,Humans Aged,0.5658
epic; ukb,European Prospective Investigation into Cancer and Nutrition; UK Biobank,2,19,Epidemiology & Risk Factors,Incidence,0.5658
epic; ukb,European Prospective Investigation into Cancer and Nutrition; UK Biobank,2,19,Epidemiology & Risk Factors,Europe,0.5541
epic; ukb,European Prospective Investigation into Cancer and Nutrition; UK Biobank,2,19,Epidemiology & Risk Factors,Middle Aged,0.5107
epic; ukb,European Prospective Investigation into Cancer and Nutrition; UK Biobank,2,19,Epidemiology & Risk Factors,Middle Aged Male,0.4719
fmc,Finnish Maternity Cohort Serum Bank,0,8,Infectious Diseases,Chlamydia Trachomatis,1.8037
fmc,Finnish Maternity Cohort Serum Bank,0,8,Infectious Diseases,Antibodies Bacterial,1.8037
fmc,Finnish Maternity Cohort Serum Bank,0,8,Infectious Diseases,Antibodies Bacterial Finland,1.6617
fmc,Finnish Maternity Cohort Serum Bank,0,8,Infectious Diseases,Chlamydia Infections,1.6617
fmc,Finnish Maternity Cohort Serum Bank,0,8,Infectious Diseases,Finland Chlamydia Trachomatis,1.4987
fmc,Finnish Maternity Cohort Serum Bank,1,40,Epidemiology & Risk Factors,Vitamin D,0.4688
fmc,Finnish Maternity Cohort Serum Bank,1,40,Epidemiology & Risk Factors,Risk Factors,0.4517
fmc,Finnish Maternity Cohort Serum Bank,1,40,Epidemiology & Risk Factors,Risk Factors Female,0.4468
fmc,Finnish Maternity Cohort Serum Bank,1,40,Epidemiology & Risk Factors,Male,0.4262
fmc,Finnish Maternity Cohort Serum Bank,1,40,Epidemiology & Risk Factors,Cohort Studies,0.3894
fmc,Finnish Maternity Cohort Serum Bank,2,7,Infectious Diseases,Papillomavirus Vaccines,1.7128
fmc,Finnish Maternity Cohort Serum Bank,2,7,Infectious Diseases,Papillomavirus Infections,1.6525
fmc,Finnish Maternity Cohort Serum Bank,2,7,Infectious Diseases,Antibodies Viral,1.3771
fmc,Finnish Maternity Cohort Serum Bank,2,7,Infectious Diseases,Papillomavirus Vaccines Humans,1.2466
fmc,Finnish Maternity Cohort Serum Bank,2,7,Infectious Diseases,Papillomaviridae Finland,1.2466
geisinger,Geisinger MyCode Community Health Initiative,0,7,Genomics & GWAS,Genome Wide Association Study,1.337
geisinger,Geisinger MyCode Community Health Initiative,0,7,Genomics & GWAS,Case Control Studies,1.3013
geisinger,Geisinger MyCode Community Health Initiative,0,7,Genomics & GWAS,Polymorphism Single Nucleotide,1.1738
geisinger,Geisinger MyCode Community Health Initiative,0,7,Genomics & GWAS,Genome Wide Association Study Case Control Studies,1.0993
geisinger,Geisinger MyCode Community Health Initiative,0,7,Genomics & GWAS,Genotype Humans,1.0993
geisinger,Geisinger MyCode Community Health Initiative,1,21,General Research,Female Humans,0.5833
geisinger,Geisinger MyCode Community Health Initiative,1,21,General Research,Phenotype,0.4822
geisinger,Geisinger MyCode Community Health Initiative,1,21,General Research,Genetic Testing,0.449
geisinger,Geisinger MyCode Community Health Initiative,1,21,General Research,Retrospective Studies,0.4338
geisinger,Geisinger MyCode Community Health Initiative,1,21,General Research,Arrhythmogenic Right Ventricular Dysplasia,0.4338
geisinger,Geisinger MyCode Community Health Initiative,2,11,General Research,Cohort Studies,1.0664
geisinger,Geisinger MyCode Community Health Initiative,2,11,General Research,Genomics,1.0081
geisinger,Geisinger MyCode Community Health Initiative,2,11,General Research,Adult Cohort Studies,0.9369
geisinger,Geisinger MyCode Community Health Initiative,2,11,General Research,Cohort Studies Humans,0.8508
geisinger,Geisinger MyCode Community Health Initiative,2,11,General Research,Female Genomics,0.8281
generations,Generations Study,0,4,Cancer & Oncology,Female Cohort Studies,2.4336
generations,Generations Study,0,4,Cancer & Oncology,Shift Work Schedule,2.2083
generations,Generations Study,0,4,Cancer & Oncology,Cohort Studies Breast Neoplasms,1.675
generations,Generations Study,0,4,Cancer & Oncology,Work Schedule Tolerance Female,1.675
generations,Generations Study,0,4,Cancer & Oncology,Work Schedule Tolerance,1.675
generations,Generations Study,1,6,Epidemiology & Risk Factors,Female Prospective Studies,2.2513
generations,Generations Study,1,6,Epidemiology & Risk Factors,Breast Risk,2.2513
generations,Generations Study,1,6,Epidemiology & Risk Factors,Risk Female,2.2513
generations,Generations Study,1,6,Epidemiology & Risk Factors,Prospective Studies United Kingdom,2.0971
generations,Generations Study,1,6,Epidemiology & Risk Factors,Breast,2.0971
generations,Generations Study,2,47,General Research,Female Adult,0.4462
generations,Generations Study,2,47,General Research,Young Adult,0.4462
generations,Generations Study,2,47,General Research,Aged,0.4456
generations,Generations Study,2,47,General Research,Adolescent,0.4325
generations,Generations Study,2,47,General Research,Male,0.4261
gel,"Genomics England / 100,000 Genomes Project",0,52,General Research,Animals,2.1551
gel,"Genomics England / 100,000 Genomes Project",0,52,General Research,Mice,1.6429
gel,"Genomics England / 100,000 Genomes Project",0,52,General Research,Humans Mice,0.9809
gel,"Genomics England / 100,000 Genomes Project",0,52,General Research,Zebrafish,0.8936
gel,"Genomics England / 100,000 Genomes Project",0,52,General Research,Animals Female,0.6888
gel,"Genomics England / 100,000 Genomes Project",1,109,General Research,Female,1.0979
gel,"Genomics England / 100,000 Genomes Project",1,109,General Research,Male,1.091
gel,"Genomics England / 100,000 Genomes Project",1,109,General Research,Adult,1.0888
gel,"Genomics England / 100,000 Genomes Project",1,109,General Research,Middle Aged,1.0677
gel,"Genomics England / 100,000 Genomes Project",1,109,General Research,Adolescent,1.0477
gel,"Genomics England / 100,000 Genomes Project",2,245,General Research,Mutation,0.3486
gel,"Genomics England / 100,000 Genomes Project",2,245,General Research,Phenotype,0.2965
gel,"Genomics England / 100,000 Genomes Project",2,245,General Research,Genome Wide Association Study,0.2876
gel,"Genomics England / 100,000 Genomes Project",2,245,General Research,Genetic Predisposition To Disease,0.262
gel,"Genomics England / 100,000 Genomes Project",2,245,General Research,Genetic Variation,0.2389
gel,"Genomics England / 100,000 Genomes Project",3,129,General Research,Genetic Testing,0.8986
gel,"Genomics England / 100,000 Genomes Project",3,129,General Research,Genomics,0.7942
gel,"Genomics England / 100,000 Genomes Project",3,129,General Research,Whole Genome Sequencing,0.6878
gel,"Genomics England / 100,000 Genomes Project",3,129,General Research,United Kingdom,0.5696
gel,"Genomics England / 100,000 Genomes Project",3,129,General Research,Whole Genome Sequencing Humans,0.5684
gel; ukb,"Genomics England / 100,000 Genomes Project; UK Biobank",0,8,General Research,Genomics,0.7798
gel; ukb,"Genomics England / 100,000 Genomes Project; UK Biobank",0,8,General Research,Genome Wide Association Study,0.7356
gel; ukb,"Genomics England / 100,000 Genomes Project; UK Biobank",0,8,General Research,Genome Wide Association Study Genetic Predisposition To Disease,0.6719
gel; ukb,"Genomics England / 100,000 Genomes Project; UK Biobank",0,8,General Research,Uk Biobank,0.6719
gel; ukb,"Genomics England / 100,000 Genomes Project; UK Biobank",0,8,General Research,Genomics United Kingdom,0.6212
gel; ukb,"Genomics England / 100,000 Genomes Project; UK Biobank",1,11,General Research,Adult,0.7841
gel; ukb,"Genomics England / 100,000 Genomes Project; UK Biobank",1,11,General Research,Middle Aged,0.7562
gel; ukb,"Genomics England / 100,000 Genomes Project; UK Biobank",1,11,General Research,Aged,0.6515
gel; ukb,"Genomics England / 100,000 Genomes Project; UK Biobank",1,11,General Research,Female,0.6301
gel; ukb,"Genomics England / 100,000 Genomes Project; UK Biobank",1,11,General Research,Male,0.6301
gel; ukb,"Genomics England / 100,000 Genomes Project; UK Biobank",2,5,General Research,Humans Uromodulin,0.994
gel; ukb,"Genomics England / 100,000 Genomes Project; UK Biobank",2,5,General Research,Humans Monophenol Monooxygenase,0.994
gel; ukb,"Genomics England / 100,000 Genomes Project; UK Biobank",2,5,General Research,Uromodulin,0.994
gel; ukb,"Genomics England / 100,000 Genomes Project; UK Biobank",2,5,General Research,Heterozygote,0.994
gel; ukb,"Genomics England / 100,000 Genomes Project; UK Biobank",2,5,General Research,Male Phenotype,0.994
nako,German National Cohort (NAKO),0,7,General Research,Turkey,1.9082
nako,German National Cohort (NAKO),0,7,General Research,Transients And Migrants,1.804
nako,German National Cohort (NAKO),0,7,General Research,Feasibility Studies Transients And Migrants,1.2159
nako,German National Cohort (NAKO),0,7,General Research,Quality Of Life Female,1.2159
nako,German National Cohort (NAKO),0,7,General Research,Quality Of Life,1.2159
nako,German National Cohort (NAKO),1,17,General Research,Young Adult Adult,1.2801
nako,German National Cohort (NAKO),1,17,General Research,Male Middle Aged,1.0176
nako,German National Cohort (NAKO),1,17,General Research,Middle Aged Aged,0.9191
nako,German National Cohort (NAKO),1,17,General Research,Aged Cohort Studies,0.7503
nako,German National Cohort (NAKO),1,17,General Research,Young Adult,0.7266
nako,German National Cohort (NAKO),2,13,General Research,Middle Aged Surveys And Questionnaires,1.5698
nako,German National Cohort (NAKO),2,13,General Research,Surveys And Questionnaires,1.4285
nako,German National Cohort (NAKO),2,13,General Research,Surveys And Questionnaires Germany,1.1036
nako,German National Cohort (NAKO),2,13,General Research,Feasibility Studies,1.066
nako,German National Cohort (NAKO),2,13,General Research,Aged Middle Aged,1.0516
nako,German National Cohort (NAKO),3,15,Physical Activity,Exercise,1.5877
nako,German National Cohort (NAKO),3,15,Physical Activity,Accelerometry,1.4013
nako,German National Cohort (NAKO),3,15,Physical Activity,Male Accelerometry,1.1131
nako,German National Cohort (NAKO),3,15,Physical Activity,Middle Aged Exercise,0.77
nako,German National Cohort (NAKO),3,15,Physical Activity,Exercise Aged,0.77
nako,German National Cohort (NAKO),4,19,General Research,Chronic Disease,1.3034
nako,German National Cohort (NAKO),4,19,General Research,Middle Aged Cohort Studies,1.1292
nako,German National Cohort (NAKO),4,19,General Research,Population Surveillance,1.1292
nako,German National Cohort (NAKO),4,19,General Research,Male Chronic Disease,0.9969
nako,German National Cohort (NAKO),4,19,General Research,Population Surveillance Adult,0.9061
nako,German National Cohort (NAKO),5,8,Epidemiology & Risk Factors,Global Burden Of Disease,2.5107
nako,German National Cohort (NAKO),5,8,Epidemiology & Risk Factors,Global Health,2.2521
nako,German National Cohort (NAKO),5,8,Epidemiology & Risk Factors,Quality Adjusted Life Years,2.152
nako,German National Cohort (NAKO),5,8,Epidemiology & Risk Factors,Global Health Risk Factors,2.0871
nako,German National Cohort (NAKO),5,8,Epidemiology & Risk Factors,Prevalence,1.7879
nako,German National Cohort (NAKO),6,24,General Research,Self Report,0.6615
nako,German National Cohort (NAKO),6,24,General Research,Cross Sectional Studies,0.5846
nako,German National Cohort (NAKO),6,24,General Research,Germany Cross Sectional Studies,0.4813
nako,German National Cohort (NAKO),6,24,General Research,Germany Self Report,0.4453
nako,German National Cohort (NAKO),6,24,General Research,Cohort Studies,0.4298
nako,German National Cohort (NAKO),7,9,Cardiovascular Research,Humans Cardiovascular Diseases,1.8552
nako,German National Cohort (NAKO),7,9,Cardiovascular Research,Cardiovascular Diseases,1.7641
nako,German National Cohort (NAKO),7,9,Cardiovascular Research,Diabetes Mellitus,1.4841
nako,German National Cohort (NAKO),7,9,Cardiovascular Research,Risk Factors,1.302
nako,German National Cohort (NAKO),7,9,Cardiovascular Research,Risk Factors Middle Aged,0.9457
nako,German National Cohort (NAKO),8,17,Neuroimaging,Magnetic Resonance Imaging,1.9202
nako,German National Cohort (NAKO),8,17,Neuroimaging,Magnetic Resonance Imaging Middle Aged,1.2365
nako,German National Cohort (NAKO),8,17,Neuroimaging,Male Magnetic Resonance Imaging,1.1142
nako,German National Cohort (NAKO),8,17,Neuroimaging,Deep Learning,0.9285
nako,German National Cohort (NAKO),8,17,Neuroimaging,Whole Body Imaging,0.9285
nako,German National Cohort (NAKO),9,6,Mental Health & Psychiatry,Cognition,2.2262
nako,German National Cohort (NAKO),9,6,Mental Health & Psychiatry,Language,1.9251
nako,German National Cohort (NAKO),9,6,Mental Health & Psychiatry,Humans Language,1.4185
nako,German National Cohort (NAKO),9,6,Mental Health & Psychiatry,Neuropsychological Tests Male,1.4185
nako,German National Cohort (NAKO),9,6,Mental Health & Psychiatry,Demography,1.4185
nako,German National Cohort (NAKO),10,6,Mental Health & Psychiatry,Pandemics Covid 19,3.157
nako,German National Cohort (NAKO),10,6,Mental Health & Psychiatry,Pandemics,3.157
nako,German National Cohort (NAKO),10,6,Mental Health & Psychiatry,Covid 19,2.8693
nako,German National Cohort (NAKO),10,6,Mental Health & Psychiatry,Covid 19 Anxiety,1.9251
nako,German National Cohort (NAKO),10,6,Mental Health & Psychiatry,Depression,1.7641
golestan,Golestan Cohort Study,0,11,Cancer & Oncology,Stomach Neoplasms,1.5315
golestan,Golestan Cohort Study,0,11,Cancer & Oncology,Esophageal Neoplasms Stomach Neoplasms,1.2245
golestan,Golestan Cohort Study,0,11,Cancer & Oncology,Esophageal Neoplasms,0.9322
golestan,Golestan Cohort Study,0,11,Cancer & Oncology,Risk Assessment Adult,0.7383
golestan,Golestan Cohort Study,0,11,Cancer & Oncology,Self Report,0.7383
golestan,Golestan Cohort Study,1,16,Cardiovascular Research,Hypertension,1.0529
golestan,Golestan Cohort Study,1,16,Cardiovascular Research,Prevalence,0.9191
golestan,Golestan Cohort Study,1,16,Cardiovascular Research,Prevalence Adult,0.8418
golestan,Golestan Cohort Study,1,16,Cardiovascular Research,Female Iran,0.7929
golestan,Golestan Cohort Study,1,16,Cardiovascular Research,Hypertension Male,0.6853
golestan,Golestan Cohort Study,2,15,Epidemiology & Risk Factors,Prospective Studies Aged,1.1886
golestan,Golestan Cohort Study,2,15,Epidemiology & Risk Factors,Cohort Studies Smoking,1.0481
golestan,Golestan Cohort Study,2,15,Epidemiology & Risk Factors,Smoking Incidence,0.8979
golestan,Golestan Cohort Study,2,15,Epidemiology & Risk Factors,Smoking,0.8755
golestan,Golestan Cohort Study,2,15,Epidemiology & Risk Factors,Pancreatic Neoplasms,0.8384
golestan,Golestan Cohort Study,3,11,Epidemiology & Risk Factors,Mortality,1.6268
golestan,Golestan Cohort Study,3,11,Epidemiology & Risk Factors,Neoplasms,1.5378
golestan,Golestan Cohort Study,3,11,Epidemiology & Risk Factors,Mortality Risk Factors,1.4292
golestan,Golestan Cohort Study,3,11,Epidemiology & Risk Factors,Cardiovascular Diseases,1.3239
golestan,Golestan Cohort Study,3,11,Epidemiology & Risk Factors,Prospective Studies Middle Aged,1.1141
golestan,Golestan Cohort Study,4,10,Cancer & Oncology,Esophageal Squamous Cell Carcinoma,1.4134
golestan,Golestan Cohort Study,4,10,Cancer & Oncology,Carcinoma Squamous Cell,1.3469
golestan,Golestan Cohort Study,4,10,Cancer & Oncology,Time Factors,1.1231
golestan,Golestan Cohort Study,4,10,Cancer & Oncology,Multivariate Analysis,1.1231
golestan,Golestan Cohort Study,4,10,Cancer & Oncology,Carcinoma Squamous Cell Aged,1.0965
golestan,Golestan Cohort Study,5,10,Multi-omics & Biomarkers,Biomarkers,1.7895
golestan,Golestan Cohort Study,5,10,Multi-omics & Biomarkers,Biomarkers Male,1.3469
golestan,Golestan Cohort Study,5,10,Multi-omics & Biomarkers,Cohort Studies Volatile Organic Compounds,1.0965
golestan,Golestan Cohort Study,5,10,Multi-omics & Biomarkers,Nitrosamines,1.0965
golestan,Golestan Cohort Study,5,10,Multi-omics & Biomarkers,Tobacco Products,1.0965
golestan,Golestan Cohort Study,6,14,Nutrition & Diet,Cause Of Death,1.2255
golestan,Golestan Cohort Study,6,14,Nutrition & Diet,Diet Male,1.0504
golestan,Golestan Cohort Study,6,14,Nutrition & Diet,Diet,0.9866
golestan,Golestan Cohort Study,6,14,Nutrition & Diet,Cohort Studies Diet,0.8983
golestan,Golestan Cohort Study,6,14,Nutrition & Diet,Cause Of Death Adult,0.8462
golestan,Golestan Cohort Study,7,18,Epidemiology & Risk Factors,Aged Middle Aged,0.8863
golestan,Golestan Cohort Study,7,18,Epidemiology & Risk Factors,Incidence,0.7813
golestan,Golestan Cohort Study,7,18,Epidemiology & Risk Factors,Cohort Studies Incidence,0.7428
golestan,Golestan Cohort Study,7,18,Epidemiology & Risk Factors,Adult Proportional Hazards Models,0.7101
golestan,Golestan Cohort Study,7,18,Epidemiology & Risk Factors,Cohort Studies Female,0.6987
golestan,Golestan Cohort Study,8,7,General Research,Analgesics Opioid,1.7967
golestan,Golestan Cohort Study,8,7,General Research,Opium,1.4006
golestan,Golestan Cohort Study,8,7,General Research,Opiate Alkaloids,1.3475
golestan,Golestan Cohort Study,8,7,General Research,Analgesics Opioid Opioid Related Disorders,1.1601
golestan,Golestan Cohort Study,8,7,General Research,Cohort Studies Opium,1.1601
golestan,Golestan Cohort Study,9,4,General Research,Aspirin,2.7412
golestan,Golestan Cohort Study,9,4,General Research,Valsartan,2.7412
golestan,Golestan Cohort Study,9,4,General Research,Iran Hydroxymethylglutaryl Coa Reductase Inhibitors,2.7412
golestan,Golestan Cohort Study,9,4,General Research,Hydroxymethylglutaryl Coa Reductase Inhibitors,2.7412
golestan,Golestan Cohort Study,9,4,General Research,Hydrochlorothiazide,2.7412
hunt,HUNT Study,0,70,Mental Health & Psychiatry,Anxiety,2.3275
hunt,HUNT Study,0,70,Mental Health & Psychiatry,Depression,2.1244
hunt,HUNT Study,0,70,Mental Health & Psychiatry,Depression Female,1.2848
hunt,HUNT Study,0,70,Mental Health & Psychiatry,Male Anxiety,0.9741
hunt,HUNT Study,0,70,Mental Health & Psychiatry,Anxiety Norway,0.9102
hunt,HUNT Study,1,137,Epidemiology & Risk Factors,Male Risk Factors,1.1703
hunt,HUNT Study,1,137,Epidemiology & Risk Factors,Risk Factors Female,1.1035
hunt,HUNT Study,1,137,Epidemiology & Risk Factors,Middle Aged Aged,0.9077
hunt,HUNT Study,1,137,Epidemiology & Risk Factors,Risk Factors,0.8667
hunt,HUNT Study,1,137,Epidemiology & Risk Factors,Female Norway,0.7896
hunt,HUNT Study,2,53,Musculoskeletal,Bone Density,1.5857
hunt,HUNT Study,2,53,Musculoskeletal,Middle Aged Adult,0.9479
hunt,HUNT Study,2,53,Musculoskeletal,Osteoporosis,0.9113
hunt,HUNT Study,2,53,Musculoskeletal,Absorptiometry Photon,0.8779
hunt,HUNT Study,2,53,Musculoskeletal,Forearm,0.8779
hunt,HUNT Study,3,90,General Research,Aged 80 And Over Adult,1.36
hunt,HUNT Study,3,90,General Research,Young Adult Female,1.2327
hunt,HUNT Study,3,90,General Research,Male Young Adult,1.1309
hunt,HUNT Study,3,90,General Research,Adult Male,1.0745
hunt,HUNT Study,3,90,General Research,Cross Sectional Studies Aged,1.0147
hunt,HUNT Study,4,107,Metabolic & Diabetes,Body Mass Index,1.8587
hunt,HUNT Study,4,107,Metabolic & Diabetes,Humans Body Mass Index,1.5855
hunt,HUNT Study,4,107,Metabolic & Diabetes,Obesity,1.4055
hunt,HUNT Study,4,107,Metabolic & Diabetes,Overweight,0.8719
hunt,HUNT Study,4,107,Metabolic & Diabetes,Female Obesity,0.8405
hunt,HUNT Study,5,140,Epidemiology & Risk Factors,Prevalence,1.1608
hunt,HUNT Study,5,140,Epidemiology & Risk Factors,Humans Prevalence,1.072
hunt,HUNT Study,5,140,Epidemiology & Risk Factors,Cross Sectional Studies,0.8965
hunt,HUNT Study,5,140,Epidemiology & Risk Factors,Aged 80 And Over,0.6269
hunt,HUNT Study,5,140,Epidemiology & Risk Factors,Age Factors,0.5937
hunt,HUNT Study,6,43,General Research,Humans Pregnancy,2.7676
hunt,HUNT Study,6,43,General Research,Pregnancy,2.7425
hunt,HUNT Study,6,43,General Research,Registries,1.2498
hunt,HUNT Study,6,43,General Research,Infant Newborn,1.2046
hunt,HUNT Study,6,43,General Research,Pre Eclampsia,1.1042
hunt,HUNT Study,7,64,Genomics & GWAS,Polymorphism Single Nucleotide,1.8205
hunt,HUNT Study,7,64,Genomics & GWAS,Genetic Predisposition To Disease,1.5745
hunt,HUNT Study,7,64,Genomics & GWAS,Genotype,1.4995
hunt,HUNT Study,7,64,Genomics & GWAS,Genome Wide Association Study,1.1137
hunt,HUNT Study,7,64,Genomics & GWAS,Polymorphism Single Nucleotide Norway,0.9955
hunt,HUNT Study,8,123,General Research,Adolescent,1.5663
hunt,HUNT Study,8,123,General Research,Adolescent Norway,1.1918
hunt,HUNT Study,8,123,General Research,Surveys And Questionnaires,0.8972
hunt,HUNT Study,8,123,General Research,Female Adolescent,0.8017
hunt,HUNT Study,8,123,General Research,Surveys And Questionnaires Adult,0.6356
hunt,HUNT Study,9,222,Epidemiology & Risk Factors,Cohort Studies,0.5611
hunt,HUNT Study,9,222,Epidemiology & Risk Factors,Biomarkers,0.5111
hunt,HUNT Study,9,222,Epidemiology & Risk Factors,Male Female,0.4981
hunt,HUNT Study,9,222,Epidemiology & Risk Factors,Prospective Studies,0.4044
hunt,HUNT Study,9,222,Epidemiology & Risk Factors,Risk Assessment,0.3943
iganga_mayuge,Iganga Mayuge HDSS,0,11,Infectious Diseases,Anti Bacterial Agents,1.0087
iganga_mayuge,Iganga Mayuge HDSS,0,11,Infectious Diseases,Carrier State,0.8881
iganga_mayuge,Iganga Mayuge HDSS,0,11,Infectious Diseases,Antimalarials,0.7446
iganga_mayuge,Iganga Mayuge HDSS,0,11,Infectious Diseases,Nasopharynx,0.7446
iganga_mayuge,Iganga Mayuge HDSS,0,11,Infectious Diseases,Child Preschool Microbial Sensitivity Tests,0.7446
iganga_mayuge,Iganga Mayuge HDSS,1,6,General Research,Uganda Caregivers,1.8493
iganga_mayuge,Iganga Mayuge HDSS,1,6,General Research,Humans Child,1.8493
iganga_mayuge,Iganga Mayuge HDSS,1,6,General Research,Caregivers,1.8493
iganga_mayuge,Iganga Mayuge HDSS,1,6,General Research,Caregivers Humans,1.6282
iganga_mayuge,Iganga Mayuge HDSS,1,6,General Research,Children With Disabilities,1.0452
iganga_mayuge,Iganga Mayuge HDSS,2,29,Epidemiology & Risk Factors,Middle Aged,0.5229
iganga_mayuge,Iganga Mayuge HDSS,2,29,Epidemiology & Risk Factors,Young Adult,0.5097
iganga_mayuge,Iganga Mayuge HDSS,2,29,Epidemiology & Risk Factors,Risk Factors,0.5063
iganga_mayuge,Iganga Mayuge HDSS,2,29,Epidemiology & Risk Factors,Adult,0.4883
iganga_mayuge,Iganga Mayuge HDSS,2,29,Epidemiology & Risk Factors,Adolescent,0.4878
jphc,JPHC Study,0,40,Epidemiology & Risk Factors,Male Humans,1.5338
jphc,JPHC Study,0,40,Epidemiology & Risk Factors,Humans Japan,0.8477
jphc,JPHC Study,0,40,Epidemiology & Risk Factors,Public Health Female,0.8434
jphc,JPHC Study,0,40,Epidemiology & Risk Factors,Female Prospective Studies,0.6661
jphc,JPHC Study,0,40,Epidemiology & Risk Factors,Public Health,0.6326
jphc,JPHC Study,1,43,Epidemiology & Risk Factors,Smoking,1.0678
jphc,JPHC Study,1,43,Epidemiology & Risk Factors,Body Mass Index,0.9131
jphc,JPHC Study,1,43,Epidemiology & Risk Factors,Risk Factors Japan,0.7656
jphc,JPHC Study,1,43,Epidemiology & Risk Factors,Middle Aged Cause Of Death,0.7216
jphc,JPHC Study,1,43,Epidemiology & Risk Factors,Body Mass Index Middle Aged,0.7205
jphc,JPHC Study,2,64,Epidemiology & Risk Factors,Cross Sectional Studies,0.6467
jphc,JPHC Study,2,64,Epidemiology & Risk Factors,Prospective Studies Aged,0.5951
jphc,JPHC Study,2,64,Epidemiology & Risk Factors,Surveys And Questionnaires Female,0.546
jphc,JPHC Study,2,64,Epidemiology & Risk Factors,Female Prospective Studies,0.5204
jphc,JPHC Study,2,64,Epidemiology & Risk Factors,Japan Humans,0.4802
jphc,JPHC Study,3,36,Cancer & Oncology,Breast Neoplasms,1.3154
jphc,JPHC Study,3,36,Cancer & Oncology,Alcohol Drinking Middle Aged,1.1608
jphc,JPHC Study,3,36,Cancer & Oncology,Female Aged,1.0885
jphc,JPHC Study,3,36,Cancer & Oncology,Alcohol Drinking,0.992
jphc,JPHC Study,3,36,Cancer & Oncology,Breast Neoplasms Female,0.8322
jphc,JPHC Study,4,58,Epidemiology & Risk Factors,Diet,1.1455
jphc,JPHC Study,4,58,Epidemiology & Risk Factors,Diet Risk Factors,0.8561
jphc,JPHC Study,4,58,Epidemiology & Risk Factors,Diet Surveys Aged,0.734
jphc,JPHC Study,4,58,Epidemiology & Risk Factors,Humans Male,0.6655
jphc,JPHC Study,4,58,Epidemiology & Risk Factors,Vegetables,0.6527
jphc,JPHC Study,5,57,Epidemiology & Risk Factors,Humans Surveys And Questionnaires,1.2599
jphc,JPHC Study,5,57,Epidemiology & Risk Factors,Japan Male,1.2564
jphc,JPHC Study,5,57,Epidemiology & Risk Factors,Risk Factors Female,1.141
jphc,JPHC Study,5,57,Epidemiology & Risk Factors,Adult Humans,1.141
jphc,JPHC Study,5,57,Epidemiology & Risk Factors,Prospective Studies Middle Aged,1.1117
jphc,JPHC Study,6,20,Nutrition & Diet,Diet Records,2.4437
jphc,JPHC Study,6,20,Nutrition & Diet,Surveys And Questionnaires Reproducibility Of Results,2.2923
jphc,JPHC Study,6,20,Nutrition & Diet,Reproducibility Of Results,2.2781
jphc,JPHC Study,6,20,Nutrition & Diet,Diet Surveys,2.1287
jphc,JPHC Study,6,20,Nutrition & Diet,Statistics Nonparametric,2.045
jphc,JPHC Study,7,40,Epidemiology & Risk Factors,Stroke,1.5228
jphc,JPHC Study,7,40,Epidemiology & Risk Factors,Female Stroke,1.5064
jphc,JPHC Study,7,40,Epidemiology & Risk Factors,Incidence Aged,1.0881
jphc,JPHC Study,7,40,Epidemiology & Risk Factors,Stroke Prospective Studies,1.0643
jphc,JPHC Study,7,40,Epidemiology & Risk Factors,Adult Risk Factors,0.8682
jphc,JPHC Study,8,43,Cardiovascular Research,Cardiovascular Diseases Humans,1.5787
jphc,JPHC Study,8,43,Cardiovascular Research,Neoplasms Female,1.4078
jphc,JPHC Study,8,43,Cardiovascular Research,Cardiovascular Diseases,1.3909
jphc,JPHC Study,8,43,Cardiovascular Research,Neoplasms,1.3158
jphc,JPHC Study,8,43,Cardiovascular Research,Humans Japan,1.0376
jphc,JPHC Study,9,22,Epidemiology & Risk Factors,Case Control Studies Humans,2.6472
jphc,JPHC Study,9,22,Epidemiology & Risk Factors,Case Control Studies,2.492
jphc,JPHC Study,9,22,Epidemiology & Risk Factors,Risk Factors Case Control Studies,1.7022
jphc,JPHC Study,9,22,Epidemiology & Risk Factors,Humans Japan,1.1357
jphc,JPHC Study,9,22,Epidemiology & Risk Factors,Logistic Models Prospective Studies,0.7737
koges,Korean Genome and Epidemiology Study,0,72,Cardiovascular Research,Obesity,1.204
koges,Korean Genome and Epidemiology Study,0,72,Cardiovascular Research,Humans Cardiovascular Diseases,1.1125
koges,Korean Genome and Epidemiology Study,0,72,Cardiovascular Research,Cardiovascular Diseases,1.0462
koges,Korean Genome and Epidemiology Study,0,72,Cardiovascular Research,Obesity Adult,1.0042
koges,Korean Genome and Epidemiology Study,0,72,Cardiovascular Research,Body Mass Index,0.9744
koges,Korean Genome and Epidemiology Study,1,35,Epidemiology & Risk Factors,Longitudinal Studies,1.1833
koges,Korean Genome and Epidemiology Study,1,35,Epidemiology & Risk Factors,Longitudinal Studies Republic Of Korea,1.0978
koges,Korean Genome and Epidemiology Study,1,35,Epidemiology & Risk Factors,Particulate Matter,0.876
koges,Korean Genome and Epidemiology Study,1,35,Epidemiology & Risk Factors,Incidence Metabolic Syndrome,0.7857
koges,Korean Genome and Epidemiology Study,1,35,Epidemiology & Risk Factors,Air Pollution,0.7773
koges,Korean Genome and Epidemiology Study,2,44,Epidemiology & Risk Factors,Female Proportional Hazards Models,1.9936
koges,Korean Genome and Epidemiology Study,2,44,Epidemiology & Risk Factors,Proportional Hazards Models Middle Aged,1.9782
koges,Korean Genome and Epidemiology Study,2,44,Epidemiology & Risk Factors,Proportional Hazards Models,1.8
koges,Korean Genome and Epidemiology Study,2,44,Epidemiology & Risk Factors,Aged Adult,1.0491
koges,Korean Genome and Epidemiology Study,2,44,Epidemiology & Risk Factors,Incidence Female,1.0288
koges,Korean Genome and Epidemiology Study,3,71,Genomics & GWAS,Polymorphism Single Nucleotide,1.7754
koges,Korean Genome and Epidemiology Study,3,71,Genomics & GWAS,Genome Wide Association Study,1.4583
koges,Korean Genome and Epidemiology Study,3,71,Genomics & GWAS,Genetic Predisposition To Disease,1.2241
koges,Korean Genome and Epidemiology Study,3,71,Genomics & GWAS,Polymorphism Single Nucleotide Middle Aged,1.1947
koges,Korean Genome and Epidemiology Study,3,71,Genomics & GWAS,Genotype,0.9939
koges,Korean Genome and Epidemiology Study,4,68,Metabolic & Diabetes,Diabetes Mellitus Type 2,1.6227
koges,Korean Genome and Epidemiology Study,4,68,Metabolic & Diabetes,Female Diabetes Mellitus Type 2,1.6027
koges,Korean Genome and Epidemiology Study,4,68,Metabolic & Diabetes,Diabetes Mellitus Type 2 Middle Aged,1.4116
koges,Korean Genome and Epidemiology Study,4,68,Metabolic & Diabetes,Insulin Resistance,0.8173
koges,Korean Genome and Epidemiology Study,4,68,Metabolic & Diabetes,Blood Glucose,0.7684
koges,Korean Genome and Epidemiology Study,5,70,Musculoskeletal,Female Middle Aged,0.7621
koges,Korean Genome and Epidemiology Study,5,70,Musculoskeletal,Muscle Skeletal,0.6599
koges,Korean Genome and Epidemiology Study,5,70,Musculoskeletal,Glomerular Filtration Rate,0.6268
koges,Korean Genome and Epidemiology Study,5,70,Musculoskeletal,Machine Learning,0.6036
koges,Korean Genome and Epidemiology Study,5,70,Musculoskeletal,Humans Machine Learning,0.6036
koges,Korean Genome and Epidemiology Study,6,33,Multi-omics & Biomarkers,Female Biomarkers,1.7994
koges,Korean Genome and Epidemiology Study,6,33,Multi-omics & Biomarkers,Biomarkers,1.533
koges,Korean Genome and Epidemiology Study,6,33,Multi-omics & Biomarkers,Biomarkers Middle Aged,1.1261
koges,Korean Genome and Epidemiology Study,6,33,Multi-omics & Biomarkers,Prognosis,0.9083
koges,Korean Genome and Epidemiology Study,6,33,Multi-omics & Biomarkers,Follow Up Studies,0.9
koges,Korean Genome and Epidemiology Study,7,43,Nutrition & Diet,Female Diet,2.154
koges,Korean Genome and Epidemiology Study,7,43,Nutrition & Diet,Diet,1.721
koges,Korean Genome and Epidemiology Study,7,43,Nutrition & Diet,Diet Proportional Hazards Models,1.5799
koges,Korean Genome and Epidemiology Study,7,43,Nutrition & Diet,Diet Middle Aged,1.1618
koges,Korean Genome and Epidemiology Study,7,43,Nutrition & Diet,Proportional Hazards Models,0.9434
koges,Korean Genome and Epidemiology Study,8,32,Cardiovascular Research,Female Hypertension,2.2191
koges,Korean Genome and Epidemiology Study,8,32,Cardiovascular Research,Hypertension Middle Aged,1.9485
koges,Korean Genome and Epidemiology Study,8,32,Cardiovascular Research,Hypertension,1.79
koges,Korean Genome and Epidemiology Study,8,32,Cardiovascular Research,Blood Pressure,1.3594
koges,Korean Genome and Epidemiology Study,8,32,Cardiovascular Research,Republic Of Korea Blood Pressure,0.9403
koges,Korean Genome and Epidemiology Study,9,91,General Research,Cross Sectional Studies,1.2279
koges,Korean Genome and Epidemiology Study,9,91,General Research,Humans Cross Sectional Studies,0.8883
koges,Korean Genome and Epidemiology Study,9,91,General Research,Female Middle Aged,0.7461
koges,Korean Genome and Epidemiology Study,9,91,General Research,Cross Sectional Studies Humans,0.7315
koges,Korean Genome and Epidemiology Study,9,91,General Research,Odds Ratio,0.6219
lifepath,LIFEPATH,0,7,Aging & Longevity,Treatment Outcome Male,0.8178
lifepath,LIFEPATH,0,7,Aging & Longevity,Aging,0.8178
lifepath,LIFEPATH,0,7,Aging & Longevity,Aortic Aneurysm Abdominal Retrospective Studies,0.8178
lifepath,LIFEPATH,0,7,Aging & Longevity,Prognosis Proportional Hazards Models,0.8178
lifepath,LIFEPATH,0,7,Aging & Longevity,Prognosis,0.8178
lifepath,LIFEPATH,1,14,General Research,Blood Vessel Prosthesis Implantation,0.9175
lifepath,LIFEPATH,1,14,General Research,Blood Vessel Prosthesis,0.9094
lifepath,LIFEPATH,1,14,General Research,Blood Vessel Prosthesis Implantation Blood Vessel Prosthesis,0.8948
lifepath,LIFEPATH,1,14,General Research,Tomography X Ray Computed,0.8434
lifepath,LIFEPATH,1,14,General Research,Stents,0.8434
lifepath,LIFEPATH,2,14,General Research,Socioeconomic Factors,0.8731
lifepath,LIFEPATH,2,14,General Research,Health Status Disparities,0.8047
lifepath,LIFEPATH,2,14,General Research,Humans Child,0.6197
lifepath,LIFEPATH,2,14,General Research,Cohort Studies,0.6197
lifepath,LIFEPATH,2,14,General Research,Child,0.556
lifegene,LifeGene,0,16,General Research,Male,0.4806
lifegene,LifeGene,0,16,General Research,Pregnancy,0.4146
lifegene,LifeGene,0,16,General Research,Adolescent Male,0.4146
lifegene,LifeGene,0,16,General Research,Male Humans,0.4146
lifegene,LifeGene,0,16,General Research,Adult Pregnancy,0.3649
lifegene,LifeGene,1,2,General Research,Premenstrual Syndrome,2.3514
lifegene,LifeGene,1,2,General Research,Adolescent Humans,2.3514
lifegene,LifeGene,1,2,General Research,Adult Middle Aged,2.3514
lifegene,LifeGene,1,2,General Research,Female Premenstrual Syndrome,2.3514
lifegene,LifeGene,1,2,General Research,Humans Young Adult,1.6582
lifegene,LifeGene,2,3,General Research,Self Report,1.9459
lifegene,LifeGene,2,3,General Research,Humans Self Report,1.9459
lifegene,LifeGene,2,3,General Research,Cohort Studies,1.6582
lifegene,LifeGene,2,3,General Research,Research Design,1.5676
lifegene,LifeGene,2,3,General Research,Quality Of Life,1.2973
mvp,Million Veteran Program,0,18,General Research,White People,1.5837
mvp,Million Veteran Program,0,18,General Research,Black Or African American,1.5255
mvp,Million Veteran Program,0,18,General Research,White People Black Or African American,1.4161
mvp,Million Veteran Program,0,18,General Research,Humans White People,1.3432
mvp,Million Veteran Program,0,18,General Research,Black Or African American United States,1.2652
mvp,Million Veteran Program,1,40,General Research,United States,0.9945
mvp,Million Veteran Program,1,40,General Research,Adult,0.9793
mvp,Million Veteran Program,1,40,General Research,Adult Female,0.9639
mvp,Million Veteran Program,1,40,General Research,Middle Aged Adult,0.9317
mvp,Million Veteran Program,1,40,General Research,Humans United States,0.8734
mvp,Million Veteran Program,2,31,Genomics & GWAS,Polymorphism Single Nucleotide Humans,1.2889
mvp,Million Veteran Program,2,31,Genomics & GWAS,Humans Genetic Predisposition To Disease,1.1704
mvp,Million Veteran Program,2,31,Genomics & GWAS,Genetic Predisposition To Disease,1.0718
mvp,Million Veteran Program,2,31,Genomics & GWAS,Polymorphism Single Nucleotide,0.9822
mvp,Million Veteran Program,2,31,Genomics & GWAS,Genome Wide Association Study Polymorphism Single Nucleotide,0.9186
mvp,Million Veteran Program,3,41,General Research,Cross Sectional Studies,0.7191
mvp,Million Veteran Program,3,41,General Research,Retrospective Studies,0.7022
mvp,Million Veteran Program,3,41,General Research,Humans Retrospective Studies,0.6409
mvp,Million Veteran Program,3,41,General Research,Veterans,0.4945
mvp,Million Veteran Program,3,41,General Research,Disease Progression,0.4441
mvp,Million Veteran Program,4,21,General Research,Black People,1.4039
mvp,Million Veteran Program,4,21,General Research,Animals,1.1693
mvp,Million Veteran Program,4,21,General Research,Mice,1.0844
mvp,Million Veteran Program,4,21,General Research,Black People Female,1.0404
mvp,Million Veteran Program,4,21,General Research,Mice Genome Wide Association Study,0.8002
mvp,Million Veteran Program,5,24,Genomics & GWAS,Mendelian Randomization Analysis,1.9073
mvp,Million Veteran Program,5,24,Genomics & GWAS,Humans Mendelian Randomization Analysis,1.907
mvp,Million Veteran Program,5,24,Genomics & GWAS,Cholesterol Hdl,0.8287
mvp,Million Veteran Program,5,24,Genomics & GWAS,Polymorphism Single Nucleotide,0.725
mvp,Million Veteran Program,5,24,Genomics & GWAS,Triglycerides,0.7002
mvp,Million Veteran Program,6,35,Genomics & GWAS,Polymorphism Single Nucleotide Risk Factors,0.9872
mvp,Million Veteran Program,6,35,Genomics & GWAS,Risk Factors,0.984
mvp,Million Veteran Program,6,35,Genomics & GWAS,Male Middle Aged,0.9637
mvp,Million Veteran Program,6,35,Genomics & GWAS,Risk Factors Humans,0.8984
mvp,Million Veteran Program,6,35,Genomics & GWAS,Genetic Predisposition To Disease,0.8438
mvp,Million Veteran Program,7,24,Epidemiology & Risk Factors,Veterans Middle Aged,1.4053
mvp,Million Veteran Program,7,24,Epidemiology & Risk Factors,Risk Factors,1.159
mvp,Million Veteran Program,7,24,Epidemiology & Risk Factors,Humans Risk Factors,1.1056
mvp,Million Veteran Program,7,24,Epidemiology & Risk Factors,Prospective Studies,0.9382
mvp,Million Veteran Program,7,24,Epidemiology & Risk Factors,Male Veterans,0.8587
mvp,Million Veteran Program,8,33,Epidemiology & Risk Factors,Electronic Health Records,0.8809
mvp,Million Veteran Program,8,33,Epidemiology & Risk Factors,Algorithms,0.6967
mvp,Million Veteran Program,8,33,Epidemiology & Risk Factors,Cohort Studies,0.615
mvp,Million Veteran Program,8,33,Epidemiology & Risk Factors,Longitudinal Studies,0.5972
mvp,Million Veteran Program,8,33,Epidemiology & Risk Factors,United States Department Of Veterans Affairs,0.584
mvp; ukb,Million Veteran Program; UK Biobank,0,11,Cardiovascular Research,Blood Pressure,1.1864
mvp; ukb,Million Veteran Program; UK Biobank,0,11,Cardiovascular Research,Humans Polymorphism Single Nucleotide,1.1035
mvp; ukb,Million Veteran Program; UK Biobank,0,11,Cardiovascular Research,Polymorphism Single Nucleotide Genome Wide Association Study,0.8512
mvp; ukb,Million Veteran Program; UK Biobank,0,11,Cardiovascular Research,Hypertension,0.8512
mvp; ukb,Million Veteran Program; UK Biobank,0,11,Cardiovascular Research,Genome Wide Association Study Hypertension,0.6412
mvp; ukb,Million Veteran Program; UK Biobank,1,35,General Research,Aged,0.6546
mvp; ukb,Million Veteran Program; UK Biobank,1,35,General Research,Middle Aged,0.6338
mvp; ukb,Million Veteran Program; UK Biobank,1,35,General Research,Female Genetic Predisposition To Disease,0.5947
mvp; ukb,Million Veteran Program; UK Biobank,1,35,General Research,Adult,0.5941
mvp; ukb,Million Veteran Program; UK Biobank,1,35,General Research,Genome Wide Association Study Female,0.5614
mvp; ukb,Million Veteran Program; UK Biobank,2,22,Genomics & GWAS,Humans Genome Wide Association Study,0.9618
mvp; ukb,Million Veteran Program; UK Biobank,2,22,Genomics & GWAS,Genome Wide Association Study Genetic Predisposition To Disease,0.8673
mvp; ukb,Million Veteran Program; UK Biobank,2,22,Genomics & GWAS,Risk Factors,0.4927
mvp; ukb,Million Veteran Program; UK Biobank,2,22,Genomics & GWAS,Cardiovascular Diseases,0.4596
mvp; ukb,Million Veteran Program; UK Biobank,2,22,Genomics & GWAS,Polymorphism Single Nucleotide Mendelian Randomization Analysis,0.4256
mws,Million Women Study,0,10,Cancer & Oncology,Aged 80 And Over,1.5604
mws,Million Women Study,0,10,Cancer & Oncology,Cell Phone,1.4105
mws,Million Women Study,0,10,Cancer & Oncology,Brain Neoplasms,1.4105
mws,Million Women Study,0,10,Cancer & Oncology,United Kingdom Aged 80 And Over,1.3213
mws,Million Women Study,0,10,Cancer & Oncology,Humans Telephone,1.1442
mws,Million Women Study,1,15,Epidemiology & Risk Factors,Cohort Studies,0.9069
mws,Million Women Study,1,15,Epidemiology & Risk Factors,Female Incidence,0.8322
mws,Million Women Study,1,15,Epidemiology & Risk Factors,Proportional Hazards Models,0.7579
mws,Million Women Study,1,15,Epidemiology & Risk Factors,Hospitalization,0.7555
mws,Million Women Study,1,15,Epidemiology & Risk Factors,England,0.7349
mws,Million Women Study,2,15,Cancer & Oncology,Humans Research Design,1.2672
mws,Million Women Study,2,15,Cancer & Oncology,Breast Neoplasms Humans,1.1575
mws,Million Women Study,2,15,Cancer & Oncology,Women S Health,1.061
mws,Million Women Study,2,15,Cancer & Oncology,Research Design,0.9987
mws,Million Women Study,2,15,Cancer & Oncology,Women S Health Female,0.9889
mws,Million Women Study,3,16,Epidemiology & Risk Factors,Female Body Mass Index,1.1697
mws,Million Women Study,3,16,Epidemiology & Risk Factors,Body Mass Index,1.1107
mws,Million Women Study,3,16,Epidemiology & Risk Factors,Body Mass Index United Kingdom,0.8816
mws,Million Women Study,3,16,Epidemiology & Risk Factors,Surveys And Questionnaires,0.7584
mws,Million Women Study,3,16,Epidemiology & Risk Factors,Risk Factors Prospective Studies,0.7337
mws,Million Women Study,4,10,General Research,Female Hormone Replacement Therapy,2.1401
mws,Million Women Study,4,10,General Research,Hormone Replacement Therapy,2.0223
mws,Million Women Study,4,10,General Research,Hormone Replacement Therapy United Kingdom,1.4105
mws,Million Women Study,4,10,General Research,Menopause,0.9711
mws,Million Women Study,4,10,General Research,Clinical Trials As Topic,0.8439
mws,Million Women Study,5,8,Cancer & Oncology,Estrogens Breast Neoplasms,2.8332
mws,Million Women Study,5,8,Cancer & Oncology,Estrogens,2.5148
mws,Million Women Study,5,8,Cancer & Oncology,Progestins,2.2251
mws,Million Women Study,5,8,Cancer & Oncology,Progestins Incidence,2.0645
mws,Million Women Study,5,8,Cancer & Oncology,Hormone Replacement Therapy Progestins,1.4303
mws,Million Women Study,6,11,Musculoskeletal,Age Factors,1.4237
mws,Million Women Study,6,11,Musculoskeletal,Adiposity,1.3485
mws,Million Women Study,6,11,Musculoskeletal,Fractures Bone Risk Factors,1.2823
mws,Million Women Study,6,11,Musculoskeletal,Age Factors Middle Aged,1.2823
mws,Million Women Study,6,11,Musculoskeletal,Middle Aged Adiposity,1.2012
mws,Million Women Study,7,4,General Research,Data Interpretation Statistical,2.6448
mws,Million Women Study,7,4,General Research,Bias,2.3407
mws,Million Women Study,7,4,General Research,Research Design Female,2.3407
mws,Million Women Study,7,4,General Research,Humans Mass Screening,2.2251
mws,Million Women Study,7,4,General Research,Patient Selection Bias,2.1098
mws,Million Women Study,8,13,Epidemiology & Risk Factors,Female United Kingdom,1.0464
mws,Million Women Study,8,13,Epidemiology & Risk Factors,Prospective Studies Female,1.0059
mws,Million Women Study,8,13,Epidemiology & Risk Factors,Humans Middle Aged,0.8812
mws,Million Women Study,8,13,Epidemiology & Risk Factors,United Kingdom,0.7709
mws,Million Women Study,8,13,Epidemiology & Risk Factors,Incidence Humans,0.7202
mws,Million Women Study,9,5,General Research,United States,2.2884
mws,Million Women Study,9,5,General Research,Europe,1.6878
mws,Million Women Study,9,5,General Research,United States Female,1.6878
mws,Million Women Study,9,5,General Research,Europe Humans,1.6878
mws,Million Women Study,9,5,General Research,Risk Assessment United States,1.6878
mws,Million Women Study,10,9,Cancer & Oncology,Colorectal Neoplasms Female,2.3075
mws,Million Women Study,10,9,Cancer & Oncology,Colorectal Neoplasms,2.3075
mws,Million Women Study,10,9,Cancer & Oncology,Early Detection Of Cancer,1.5673
mws,Million Women Study,10,9,Cancer & Oncology,Middle Aged Occult Blood,1.5673
mws,Million Women Study,10,9,Cancer & Oncology,Prospective Studies Colorectal Neoplasms,1.5673
mws,Million Women Study,11,20,Cancer & Oncology,Risk Estrogen Replacement Therapy,1.2574
mws,Million Women Study,11,20,Cancer & Oncology,Risk,1.2477
mws,Million Women Study,11,20,Cancer & Oncology,Estrogen Replacement Therapy Middle Aged,1.1502
mws,Million Women Study,11,20,Cancer & Oncology,Estrogen Replacement Therapy,0.9787
mws,Million Women Study,11,20,Cancer & Oncology,Endometrial Neoplasms,0.8497
mws; whi,Million Women Study; Women's Health Initiative,0,18,Cardiovascular Research,Risk Factors,0.752
mws; whi,Million Women Study; Women's Health Initiative,0,18,Cardiovascular Research,Cardiovascular Diseases,0.7426
mws; whi,Million Women Study; Women's Health Initiative,0,18,Cardiovascular Research,Age Factors,0.5784
mws; whi,Million Women Study; Women's Health Initiative,0,18,Cardiovascular Research,Risk Factors Female,0.5784
mws; whi,Million Women Study; Women's Health Initiative,0,18,Cardiovascular Research,Breast Neoplasms Humans,0.5493
mws; whi,Million Women Study; Women's Health Initiative,1,21,General Research,Progestins,0.6446
mws; whi,Million Women Study; Women's Health Initiative,1,21,General Research,Estrogens,0.6446
mws; whi,Million Women Study; Women's Health Initiative,1,21,General Research,Adult,0.6103
mws; whi,Million Women Study; Women's Health Initiative,1,21,General Research,Cohort Studies,0.5666
mws; whi,Million Women Study; Women's Health Initiative,1,21,General Research,Adult Middle Aged,0.5456
mws; whi,Million Women Study; Women's Health Initiative,2,15,General Research,Humans Women S Health,0.8789
mws; whi,Million Women Study; Women's Health Initiative,2,15,General Research,Women S Health,0.8185
mws; whi,Million Women Study; Women's Health Initiative,2,15,General Research,Estrogen Replacement Therapy Menopause,0.7932
mws; whi,Million Women Study; Women's Health Initiative,2,15,General Research,Health Knowledge Attitudes Practice,0.7932
mws; whi,Million Women Study; Women's Health Initiative,2,15,General Research,Women S Health Female,0.7638
mec,Multiethnic Cohort Study,0,7,Nutrition & Diet,Reproducibility Of Results Female,2.9052
mec,Multiethnic Cohort Study,0,7,Nutrition & Diet,Reproducibility Of Results,2.5695
mec,Multiethnic Cohort Study,0,7,Nutrition & Diet,Portion Size,1.8388
mec,Multiethnic Cohort Study,0,7,Nutrition & Diet,Surveys And Questionnaires Cross Sectional Studies,1.4239
mec,Multiethnic Cohort Study,0,7,Nutrition & Diet,Diet Records,1.4239
mec,Multiethnic Cohort Study,1,19,Cancer & Oncology,Middle Aged Aged,1.3375
mec,Multiethnic Cohort Study,1,19,Cancer & Oncology,Receptors Estrogen,1.3253
mec,Multiethnic Cohort Study,1,19,Cancer & Oncology,Receptors Progesterone,1.3253
mec,Multiethnic Cohort Study,1,19,Cancer & Oncology,Ethnicity Middle Aged,1.2943
mec,Multiethnic Cohort Study,1,19,Cancer & Oncology,Breast Neoplasms,1.276
mec,Multiethnic Cohort Study,2,38,General Research,United States,1.4341
mec,Multiethnic Cohort Study,2,38,General Research,United States Cohort Studies,1.3774
mec,Multiethnic Cohort Study,2,38,General Research,Female United States,0.898
mec,Multiethnic Cohort Study,2,38,General Research,Ethnicity Aged,0.6277
mec,Multiethnic Cohort Study,2,38,General Research,Medicare,0.6134
mec,Multiethnic Cohort Study,3,29,Metabolic & Diabetes,Aged Middle Aged,1.1094
mec,Multiethnic Cohort Study,3,29,Metabolic & Diabetes,Ethnicity Male,1.0381
mec,Multiethnic Cohort Study,3,29,Metabolic & Diabetes,Humans Case Control Studies,1.0054
mec,Multiethnic Cohort Study,3,29,Metabolic & Diabetes,Obesity,0.819
mec,Multiethnic Cohort Study,3,29,Metabolic & Diabetes,Case Control Studies,0.8148
mec,Multiethnic Cohort Study,4,42,General Research,White People,1.116
mec,Multiethnic Cohort Study,4,42,General Research,Aged Hawaii,1.1082
mec,Multiethnic Cohort Study,4,42,General Research,Hispanic Or Latino Humans,1.0873
mec,Multiethnic Cohort Study,4,42,General Research,Hispanic Or Latino,1.0564
mec,Multiethnic Cohort Study,4,42,General Research,Asian,1.0003
mec,Multiethnic Cohort Study,5,9,Environmental Health,Air Pollutants,3.4795
mec,Multiethnic Cohort Study,5,9,Environmental Health,Air Pollution,3.1976
mec,Multiethnic Cohort Study,5,9,Environmental Health,Particulate Matter,3.0929
mec,Multiethnic Cohort Study,5,9,Environmental Health,Environmental Exposure,2.9993
mec,Multiethnic Cohort Study,5,9,Environmental Health,Particulate Matter Air Pollution,2.9018
mec,Multiethnic Cohort Study,6,35,Respiratory Diseases,Lung Neoplasms,0.9957
mec,Multiethnic Cohort Study,6,35,Respiratory Diseases,Native Hawaiian Or Pacific Islander,0.9832
mec,Multiethnic Cohort Study,6,35,Respiratory Diseases,Smoking,0.9675
mec,Multiethnic Cohort Study,6,35,Respiratory Diseases,Hispanic Or Latino,0.9264
mec,Multiethnic Cohort Study,6,35,Respiratory Diseases,Black Or African American,0.8923
mec,Multiethnic Cohort Study,7,23,Cardiovascular Research,Adult Humans,0.9642
mec,Multiethnic Cohort Study,7,23,Cardiovascular Research,Cardiovascular Diseases,0.8839
mec,Multiethnic Cohort Study,7,23,Cardiovascular Research,Adult,0.8433
mec,Multiethnic Cohort Study,7,23,Cardiovascular Research,Female Cohort Studies,0.8072
mec,Multiethnic Cohort Study,7,23,Cardiovascular Research,Humans Cardiovascular Diseases,0.7564
mec,Multiethnic Cohort Study,8,46,Cancer & Oncology,Racial Groups,0.8288
mec,Multiethnic Cohort Study,8,46,Cancer & Oncology,Middle Aged Male,0.7877
mec,Multiethnic Cohort Study,8,46,Cancer & Oncology,Female Racial Groups,0.7722
mec,Multiethnic Cohort Study,8,46,Cancer & Oncology,Colorectal Neoplasms,0.7012
mec,Multiethnic Cohort Study,8,46,Cancer & Oncology,Male Aged,0.6313
mec,Multiethnic Cohort Study,9,19,Genomics & GWAS,Polymorphism Single Nucleotide,1.8797
mec,Multiethnic Cohort Study,9,19,Genomics & GWAS,Genetic Predisposition To Disease,1.7959
mec,Multiethnic Cohort Study,9,19,Genomics & GWAS,Haplotypes,1.7257
mec,Multiethnic Cohort Study,9,19,Genomics & GWAS,Genetic Predisposition To Disease Cohort Studies,1.5119
mec,Multiethnic Cohort Study,9,19,Genomics & GWAS,Female Genetic Predisposition To Disease,1.5119
mec,Multiethnic Cohort Study,10,10,General Research,Pregnancy,2.3233
mec,Multiethnic Cohort Study,10,10,General Research,Infant Newborn,1.7162
mec,Multiethnic Cohort Study,10,10,General Research,Adult Humans,1.6633
mec,Multiethnic Cohort Study,10,10,General Research,Adult,1.4547
mec,Multiethnic Cohort Study,10,10,General Research,Pregnancy Complications,1.3734
mec,Multiethnic Cohort Study,11,15,Cancer & Oncology,Risk Factors Postmenopause,1.554
mec,Multiethnic Cohort Study,11,15,Cancer & Oncology,Postmenopause,1.4299
mec,Multiethnic Cohort Study,11,15,Cancer & Oncology,Female Cohort Studies,1.0127
mec,Multiethnic Cohort Study,11,15,Cancer & Oncology,Estrogen Replacement Therapy,0.9156
mec,Multiethnic Cohort Study,11,15,Cancer & Oncology,Aged Breast Neoplasms,0.7917
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,0,74,Epidemiology & Risk Factors,Environmental Exposure,0.9708
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,0,74,Epidemiology & Risk Factors,Cardiovascular Diseases,0.8833
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,0,74,Epidemiology & Risk Factors,Humans Cardiovascular Diseases,0.8771
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,0,74,Epidemiology & Risk Factors,Incidence Risk Factors,0.8556
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,0,74,Epidemiology & Risk Factors,Nurses Humans,0.8414
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,1,93,Nutrition & Diet,Male,1.6796
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,1,93,Nutrition & Diet,Humans Male,1.6174
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,1,93,Nutrition & Diet,Male United States,0.9835
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,1,93,Nutrition & Diet,Aged,0.944
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,1,93,Nutrition & Diet,Diet,0.6988
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,2,108,Cancer & Oncology,Premenopause,1.6763
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,2,108,Cancer & Oncology,Humans Premenopause,1.5273
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,2,108,Cancer & Oncology,Breast Neoplasms,1.46
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,2,108,Cancer & Oncology,Adult Breast Neoplasms,0.8934
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,2,108,Cancer & Oncology,Middle Aged Female,0.8389
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,3,86,Epidemiology & Risk Factors,Female Humans,1.5797
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,3,86,Epidemiology & Risk Factors,Incidence Female,1.0024
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,3,86,Epidemiology & Risk Factors,Adult Pregnancy,0.8629
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,3,86,Epidemiology & Risk Factors,Risk Assessment,0.7286
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,3,86,Epidemiology & Risk Factors,Incidence,0.7069
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,4,115,Epidemiology & Risk Factors,Follow Up Studies,0.8334
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,4,115,Epidemiology & Risk Factors,Humans United States,0.7878
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,4,115,Epidemiology & Risk Factors,Follow Up Studies Prospective Studies,0.7861
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,4,115,Epidemiology & Risk Factors,Body Mass Index,0.7577
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,4,115,Epidemiology & Risk Factors,Adult Body Mass Index,0.7357
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,5,22,Multi-omics & Biomarkers,C Reactive Protein,3.2398
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,5,22,Multi-omics & Biomarkers,C Reactive Protein Humans,2.6798
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,5,22,Multi-omics & Biomarkers,Interleukin 6,2.5321
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,5,22,Multi-omics & Biomarkers,Biomarkers,2.2465
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,5,22,Multi-omics & Biomarkers,Inflammation,2.0504
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,6,180,General Research,Adult Female,0.4835
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,6,180,General Research,Cohort Studies Humans,0.4674
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,6,180,General Research,Cohort Studies,0.4476
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,6,180,General Research,Middle Aged,0.3984
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,6,180,General Research,Aged,0.3923
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,7,41,Cancer & Oncology,Stress Disorders Post Traumatic,2.5282
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,7,41,Cancer & Oncology,Longitudinal Studies Stress Disorders Post Traumatic,1.2542
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,7,41,Cancer & Oncology,Stress Disorders Post Traumatic Adult,1.2325
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,7,41,Cancer & Oncology,Carcinoma Ovarian Epithelial,1.0647
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,7,41,Cancer & Oncology,Ovarian Neoplasms,0.9401
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,8,79,Cardiovascular Research,Female Pregnancy,2.2419
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,8,79,Cardiovascular Research,Pregnancy,1.8395
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,8,79,Cardiovascular Research,Diabetes Gestational,1.34
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,8,79,Cardiovascular Research,Adult Female,0.668
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,8,79,Cardiovascular Research,Hypertension Pregnancy Induced,0.6292
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,9,74,General Research,Adult Adolescent,1.9231
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,9,74,General Research,Adolescent,1.8481
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,9,74,General Research,Child,1.4176
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,9,74,General Research,Female Child,1.1409
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,9,74,General Research,Adolescent Pregnancy,0.7528
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,10,33,Epidemiology & Risk Factors,Bisexuality,1.7572
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,10,33,Epidemiology & Risk Factors,Sexual Behavior,1.6799
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,10,33,Epidemiology & Risk Factors,Longitudinal Studies Adult,1.6063
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,10,33,Epidemiology & Risk Factors,Heterosexuality,1.5874
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,10,33,Epidemiology & Risk Factors,Homosexuality Female,1.5874
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,11,39,Epidemiology & Risk Factors,Endometriosis,2.4017
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,11,39,Epidemiology & Risk Factors,Endometriosis Female,2.2784
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,11,39,Epidemiology & Risk Factors,Adult Prospective Studies,1.2745
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,11,39,Epidemiology & Risk Factors,Humans Adult,1.2086
nhsii; nhs,Nurses' Health Study II; Nurses' Health Study,11,39,Epidemiology & Risk Factors,Fruit Humans,0.7991
ntr,Netherlands Twin Registry,0,10,Mental Health & Psychiatry,Mothers,0.806
ntr,Netherlands Twin Registry,0,10,Mental Health & Psychiatry,Child,0.733
ntr,Netherlands Twin Registry,0,10,Mental Health & Psychiatry,Attention Deficit And Disruptive Behavior Disorders,0.6908
ntr,Netherlands Twin Registry,0,10,Mental Health & Psychiatry,Personality Inventory,0.6908
ntr,Netherlands Twin Registry,0,10,Mental Health & Psychiatry,Psychiatric Status Rating Scales,0.6438
ntr,Netherlands Twin Registry,1,9,General Research,Male Netherlands,0.9954
ntr,Netherlands Twin Registry,1,9,General Research,Netherlands Female,0.8812
ntr,Netherlands Twin Registry,1,9,General Research,Twins Dizygotic,0.8545
ntr,Netherlands Twin Registry,1,9,General Research,Female Twins Monozygotic,0.7963
ntr,Netherlands Twin Registry,1,9,General Research,Twins Monozygotic Adult,0.7675
ntr,Netherlands Twin Registry,2,11,Physical Activity,Middle Aged,0.8756
ntr,Netherlands Twin Registry,2,11,Physical Activity,Aged,0.8144
ntr,Netherlands Twin Registry,2,11,Physical Activity,Exercise,0.8144
ntr,Netherlands Twin Registry,2,11,Physical Activity,Male Female,0.6567
ntr,Netherlands Twin Registry,2,11,Physical Activity,Female Adult,0.6515
nshds,Northern Sweden Health and Disease Study,0,35,Cancer & Oncology,Biomarkers Tumor,0.5496
nshds,Northern Sweden Health and Disease Study,0,35,Cancer & Oncology,Prognosis,0.5085
nshds,Northern Sweden Health and Disease Study,0,35,Cancer & Oncology,Colorectal Neoplasms,0.4853
nshds,Northern Sweden Health and Disease Study,0,35,Cancer & Oncology,Middle Aged Risk Factors,0.4756
nshds,Northern Sweden Health and Disease Study,0,35,Cancer & Oncology,Female Humans,0.4626
nshds,Northern Sweden Health and Disease Study,1,35,Epidemiology & Risk Factors,Prospective Studies Adult,0.6614
nshds,Northern Sweden Health and Disease Study,1,35,Epidemiology & Risk Factors,Homocysteine,0.6246
nshds,Northern Sweden Health and Disease Study,1,35,Epidemiology & Risk Factors,Folic Acid,0.6246
nshds,Northern Sweden Health and Disease Study,1,35,Epidemiology & Risk Factors,Odds Ratio,0.5736
nshds,Northern Sweden Health and Disease Study,1,35,Epidemiology & Risk Factors,Adult Humans,0.5203
nshds,Northern Sweden Health and Disease Study,2,19,Respiratory Diseases,Cohort Studies,1.2921
nshds,Northern Sweden Health and Disease Study,2,19,Respiratory Diseases,Cohort Studies Humans,1.2655
nshds,Northern Sweden Health and Disease Study,2,19,Respiratory Diseases,Adult Cohort Studies,1.0144
nshds,Northern Sweden Health and Disease Study,2,19,Respiratory Diseases,Female Adult,0.673
nshds,Northern Sweden Health and Disease Study,2,19,Respiratory Diseases,Smoking,0.5353
moba,Norwegian Mother and Child Cohort Study,0,81,Infectious Diseases,Plasmids,1.9753
moba,Norwegian Mother and Child Cohort Study,0,81,Infectious Diseases,Molecular Sequence Data,1.5846
moba,Norwegian Mother and Child Cohort Study,0,81,Infectious Diseases,Bacterial Proteins,1.5115
moba,Norwegian Mother and Child Cohort Study,0,81,Infectious Diseases,Base Sequence,1.275
moba,Norwegian Mother and Child Cohort Study,0,81,Infectious Diseases,Dna Bacterial,1.2306
moba,Norwegian Mother and Child Cohort Study,1,227,General Research,Pregnancy Norway,0.7005
moba,Norwegian Mother and Child Cohort Study,1,227,General Research,Humans Adult,0.675
moba,Norwegian Mother and Child Cohort Study,1,227,General Research,Norway Female,0.5978
moba,Norwegian Mother and Child Cohort Study,1,227,General Research,Female Humans,0.5688
moba,Norwegian Mother and Child Cohort Study,1,227,General Research,Adult,0.5474
moba,Norwegian Mother and Child Cohort Study,2,137,Epidemiology & Risk Factors,Norway Humans,0.8746
moba,Norwegian Mother and Child Cohort Study,2,137,Epidemiology & Risk Factors,Infant Newborn,0.8224
moba,Norwegian Mother and Child Cohort Study,2,137,Epidemiology & Risk Factors,Gestational Age,0.7608
moba,Norwegian Mother and Child Cohort Study,2,137,Epidemiology & Risk Factors,Prospective Studies,0.7438
moba,Norwegian Mother and Child Cohort Study,2,137,Epidemiology & Risk Factors,Gestational Age Norway,0.7235
moba,Norwegian Mother and Child Cohort Study,3,170,Epidemiology & Risk Factors,Infant,1.028
moba,Norwegian Mother and Child Cohort Study,3,170,Epidemiology & Risk Factors,Child Preschool,0.9983
moba,Norwegian Mother and Child Cohort Study,3,170,Epidemiology & Risk Factors,Male,0.7073
moba,Norwegian Mother and Child Cohort Study,3,170,Epidemiology & Risk Factors,Surveys And Questionnaires Male,0.7039
moba,Norwegian Mother and Child Cohort Study,3,170,Epidemiology & Risk Factors,Prospective Studies Child Preschool,0.5891
moba,Norwegian Mother and Child Cohort Study,4,60,General Research,Video Games,1.0039
moba,Norwegian Mother and Child Cohort Study,4,60,General Research,Behavior Addictive,0.5574
moba,Norwegian Mother and Child Cohort Study,4,60,General Research,Pteridines,0.5418
moba,Norwegian Mother and Child Cohort Study,4,60,General Research,Coenzymes,0.5418
moba,Norwegian Mother and Child Cohort Study,4,60,General Research,Molybdenum Cofactors,0.5418
moba,Norwegian Mother and Child Cohort Study,5,157,General Research,Child Humans,1.3438
moba,Norwegian Mother and Child Cohort Study,5,157,General Research,Female Child,1.2367
moba,Norwegian Mother and Child Cohort Study,5,157,General Research,Child,1.1955
moba,Norwegian Mother and Child Cohort Study,5,157,General Research,Fathers,0.8155
moba,Norwegian Mother and Child Cohort Study,5,157,General Research,Mothers,0.7592
nhs,Nurses' Health Study,0,158,Cancer & Oncology,Colorectal Neoplasms,2.21
nhs,Nurses' Health Study,0,158,Cancer & Oncology,Colorectal Neoplasms Middle Aged,1.5802
nhs,Nurses' Health Study,0,158,Cancer & Oncology,Prospective Studies Colorectal Neoplasms,1.249
nhs,Nurses' Health Study,0,158,Cancer & Oncology,Microsatellite Instability,0.7964
nhs,Nurses' Health Study,0,158,Cancer & Oncology,Mutation,0.7765
nhs,Nurses' Health Study,1,335,Epidemiology & Risk Factors,Prospective Studies Middle Aged,0.7532
nhs,Nurses' Health Study,1,335,Epidemiology & Risk Factors,Middle Aged Adult,0.6524
nhs,Nurses' Health Study,1,335,Epidemiology & Risk Factors,Male,0.5468
nhs,Nurses' Health Study,1,335,Epidemiology & Risk Factors,Follow Up Studies,0.5244
nhs,Nurses' Health Study,1,335,Epidemiology & Risk Factors,Humans Aged,0.5018
nhs,Nurses' Health Study,2,93,Cardiovascular Research,Cardiovascular Diseases Humans,2.7377
nhs,Nurses' Health Study,2,93,Cardiovascular Research,Cardiovascular Diseases,2.6042
nhs,Nurses' Health Study,2,93,Cardiovascular Research,Risk Factors Cardiovascular Diseases,1.3804
nhs,Nurses' Health Study,2,93,Cardiovascular Research,Neoplasms,1.0023
nhs,Nurses' Health Study,2,93,Cardiovascular Research,Cause Of Death Cardiovascular Diseases,0.9502
nhs,Nurses' Health Study,3,178,Cardiovascular Research,Biomarkers,1.1702
nhs,Nurses' Health Study,3,178,Cardiovascular Research,Case Control Studies,0.9679
nhs,Nurses' Health Study,3,178,Cardiovascular Research,C Reactive Protein,0.8401
nhs,Nurses' Health Study,3,178,Cardiovascular Research,Inflammation,0.7708
nhs,Nurses' Health Study,3,178,Cardiovascular Research,Coronary Disease,0.6668
nhs,Nurses' Health Study,4,102,Metabolic & Diabetes,Diabetes Mellitus Type 2 Adult,2.3746
nhs,Nurses' Health Study,4,102,Metabolic & Diabetes,Diabetes Mellitus Type 2,2.2822
nhs,Nurses' Health Study,4,102,Metabolic & Diabetes,Adult Middle Aged,1.5786
nhs,Nurses' Health Study,4,102,Metabolic & Diabetes,Prospective Studies Diabetes Mellitus Type 2,1.4572
nhs,Nurses' Health Study,4,102,Metabolic & Diabetes,United States Diabetes Mellitus Type 2,1.4171
nhs,Nurses' Health Study,5,193,Epidemiology & Risk Factors,United States Adult,1.5589
nhs,Nurses' Health Study,5,193,Epidemiology & Risk Factors,Prospective Studies Middle Aged,1.0603
nhs,Nurses' Health Study,5,193,Epidemiology & Risk Factors,Female Surveys And Questionnaires,0.8651
nhs,Nurses' Health Study,5,193,Epidemiology & Risk Factors,Proportional Hazards Models Female,0.8547
nhs,Nurses' Health Study,5,193,Epidemiology & Risk Factors,Incidence Prospective Studies,0.8441
nhs,Nurses' Health Study,6,175,Genomics & GWAS,Polymorphism Single Nucleotide,1.5109
nhs,Nurses' Health Study,6,175,Genomics & GWAS,Genetic Predisposition To Disease,1.4893
nhs,Nurses' Health Study,6,175,Genomics & GWAS,Genetic Predisposition To Disease Female,1.1935
nhs,Nurses' Health Study,6,175,Genomics & GWAS,Skin Neoplasms,1.1378
nhs,Nurses' Health Study,6,175,Genomics & GWAS,Genotype,0.9569
nhs,Nurses' Health Study,7,384,General Research,Cross Sectional Studies,0.5175
nhs,Nurses' Health Study,7,384,General Research,Nurses,0.501
nhs,Nurses' Health Study,7,384,General Research,Surveys And Questionnaires,0.3996
nhs,Nurses' Health Study,7,384,General Research,Humans Aged,0.3774
nhs,Nurses' Health Study,7,384,General Research,Pregnancy,0.3515
nhs,Nurses' Health Study,8,161,Epidemiology & Risk Factors,United States Middle Aged,2.1831
nhs,Nurses' Health Study,8,161,Epidemiology & Risk Factors,Prospective Studies United States,1.8182
nhs,Nurses' Health Study,8,161,Epidemiology & Risk Factors,United States,1.1985
nhs,Nurses' Health Study,8,161,Epidemiology & Risk Factors,Middle Aged Adult,0.7591
nhs,Nurses' Health Study,8,161,Epidemiology & Risk Factors,Nurses,0.5757
nhs,Nurses' Health Study,9,210,Cancer & Oncology,Breast Neoplasms,1.9521
nhs,Nurses' Health Study,9,210,Cancer & Oncology,Adult Breast Neoplasms,1.0769
nhs,Nurses' Health Study,9,210,Cancer & Oncology,Postmenopause,0.9326
nhs,Nurses' Health Study,9,210,Cancer & Oncology,Breast Neoplasms Female,0.8417
nhs,Nurses' Health Study,9,210,Cancer & Oncology,Receptors Estrogen,0.7217
nhs; whi,Nurses' Health Study; Women's Health Initiative,0,15,Cardiovascular Research,Estrogen Replacement Therapy,0.7507
nhs; whi,Nurses' Health Study; Women's Health Initiative,0,15,Cardiovascular Research,Estrogens,0.7277
nhs; whi,Nurses' Health Study; Women's Health Initiative,0,15,Cardiovascular Research,Cardiovascular Diseases,0.7277
nhs; whi,Nurses' Health Study; Women's Health Initiative,0,15,Cardiovascular Research,Female Cardiovascular Diseases,0.6672
nhs; whi,Nurses' Health Study; Women's Health Initiative,0,15,Cardiovascular Research,Time Factors Female,0.6672
nhs; whi,Nurses' Health Study; Women's Health Initiative,1,15,Cancer & Oncology,Women S Health,0.6756
nhs; whi,Nurses' Health Study; Women's Health Initiative,1,15,Cancer & Oncology,Breast Neoplasms,0.6064
nhs; whi,Nurses' Health Study; Women's Health Initiative,1,15,Cancer & Oncology,United States,0.555
nhs; whi,Nurses' Health Study; Women's Health Initiative,1,15,Cancer & Oncology,Risk Assessment,0.5337
nhs; whi,Nurses' Health Study; Women's Health Initiative,1,15,Cancer & Oncology,Adult,0.5233
nhs; whi,Nurses' Health Study; Women's Health Initiative,2,7,Cancer & Oncology,Female Case Control Studies,1.4296
nhs; whi,Nurses' Health Study; Women's Health Initiative,2,7,Cancer & Oncology,Pancreatic Neoplasms Male,1.4296
nhs; whi,Nurses' Health Study; Women's Health Initiative,2,7,Cancer & Oncology,Pancreatic Neoplasms,1.4296
nhs; whi,Nurses' Health Study; Women's Health Initiative,2,7,Cancer & Oncology,Case Control Studies,1.4296
nhs; whi,Nurses' Health Study; Women's Health Initiative,2,7,Cancer & Oncology,Male,1.4137
persian,PERSIAN Cohort Study,0,5,Metabolic & Diabetes,Prediabetic State,2.0747
persian,PERSIAN Cohort Study,0,5,Metabolic & Diabetes,Diabetes Mellitus Type 2 Prediabetic State,2.0747
persian,PERSIAN Cohort Study,0,5,Metabolic & Diabetes,Iran Prospective Studies,1.6604
persian,PERSIAN Cohort Study,0,5,Metabolic & Diabetes,Cholesterol,1.4982
persian,PERSIAN Cohort Study,0,5,Metabolic & Diabetes,Diabetes Mellitus Type 2,1.4156
persian,PERSIAN Cohort Study,1,19,Cardiovascular Research,Cardiovascular Diseases,1.4395
persian,PERSIAN Cohort Study,1,19,Cardiovascular Research,Cardiovascular Diseases Cohort Studies,1.3377
persian,PERSIAN Cohort Study,1,19,Cardiovascular Research,Humans Cardiovascular Diseases,0.9639
persian,PERSIAN Cohort Study,1,19,Cardiovascular Research,Risk Assessment,0.7276
persian,PERSIAN Cohort Study,1,19,Cardiovascular Research,Biomarkers,0.6426
persian,PERSIAN Cohort Study,2,10,Metabolic & Diabetes,Obesity,2.011
persian,PERSIAN Cohort Study,2,10,Metabolic & Diabetes,Obesity Cohort Studies,1.5882
persian,PERSIAN Cohort Study,2,10,Metabolic & Diabetes,Obesity Iran,1.3832
persian,PERSIAN Cohort Study,2,10,Metabolic & Diabetes,Waist Circumference Obesity,1.3832
persian,PERSIAN Cohort Study,2,10,Metabolic & Diabetes,Humans Waist Circumference,1.3832
persian,PERSIAN Cohort Study,3,10,Epidemiology & Risk Factors,Risk Factors Cross Sectional Studies,1.3832
persian,PERSIAN Cohort Study,3,10,Epidemiology & Risk Factors,Noncommunicable Diseases Female,1.221
persian,PERSIAN Cohort Study,3,10,Epidemiology & Risk Factors,Longitudinal Studies,1.1237
persian,PERSIAN Cohort Study,3,10,Epidemiology & Risk Factors,Iran Noncommunicable Diseases,1.1237
persian,PERSIAN Cohort Study,3,10,Epidemiology & Risk Factors,Noncommunicable Diseases,1.0588
persian,PERSIAN Cohort Study,4,28,Cardiovascular Research,Hypertension Humans,0.8169
persian,PERSIAN Cohort Study,4,28,Cardiovascular Research,Adult Hypertension,0.7899
persian,PERSIAN Cohort Study,4,28,Cardiovascular Research,Iran Risk Factors,0.753
persian,PERSIAN Cohort Study,4,28,Cardiovascular Research,Hypertension,0.7182
persian,PERSIAN Cohort Study,4,28,Cardiovascular Research,Risk Factors Female,0.71
persian,PERSIAN Cohort Study,5,22,General Research,Iran Female,0.9604
persian,PERSIAN Cohort Study,5,22,General Research,Male Cross Sectional Studies,0.8927
persian,PERSIAN Cohort Study,5,22,General Research,Female Male,0.8727
persian,PERSIAN Cohort Study,5,22,General Research,Cohort Studies Iran,0.7051
persian,PERSIAN Cohort Study,5,22,General Research,Cross Sectional Studies Aged,0.6217
persian,PERSIAN Cohort Study,6,3,Environmental Health,Benzophenones,3.7456
persian,PERSIAN Cohort Study,6,3,Environmental Health,Maternal Exposure,3.7456
persian,PERSIAN Cohort Study,6,3,Environmental Health,Pregnancy,3.0524
persian,PERSIAN Cohort Study,6,3,Environmental Health,Female Infant,2.7674
persian,PERSIAN Cohort Study,6,3,Environmental Health,Endocrine Disruptors,2.7674
persian,PERSIAN Cohort Study,7,10,General Research,Iran Social Class,2.3823
persian,PERSIAN Cohort Study,7,10,General Research,Social Class,2.2874
persian,PERSIAN Cohort Study,7,10,General Research,Social Class Female,2.0288
persian,PERSIAN Cohort Study,7,10,General Research,Socioeconomic Factors,1.6573
persian,PERSIAN Cohort Study,7,10,General Research,Male Socioeconomic Factors,1.0588
persian,PERSIAN Cohort Study,8,5,General Research,Age Factors,2.8983
persian,PERSIAN Cohort Study,8,5,General Research,Age Factors Iran,2.7663
persian,PERSIAN Cohort Study,8,5,General Research,Cohort Studies Age Factors,2.7663
persian,PERSIAN Cohort Study,8,5,General Research,Menopause,1.6604
persian,PERSIAN Cohort Study,8,5,General Research,Humans Cohort Studies,0.8664
persian,PERSIAN Cohort Study,9,15,Epidemiology & Risk Factors,Diet,1.5861
persian,PERSIAN Cohort Study,9,15,Epidemiology & Risk Factors,Inflammation,1.2902
persian,PERSIAN Cohort Study,9,15,Epidemiology & Risk Factors,Female Inflammation,1.0782
persian,PERSIAN Cohort Study,9,15,Epidemiology & Risk Factors,Diet Risk Factors,1.0782
persian,PERSIAN Cohort Study,9,15,Epidemiology & Risk Factors,Cohort Studies Diet,0.8821
plco,PLCO Cancer Screening Trial,0,119,Epidemiology & Risk Factors,Proportional Hazards Models,1.2297
plco,PLCO Cancer Screening Trial,0,119,Epidemiology & Risk Factors,Diet,1.0894
plco,PLCO Cancer Screening Trial,0,119,Epidemiology & Risk Factors,Prospective Studies,0.8643
plco,PLCO Cancer Screening Trial,0,119,Epidemiology & Risk Factors,Humans Diet,0.7124
plco,PLCO Cancer Screening Trial,0,119,Epidemiology & Risk Factors,Risk Factors,0.7013
plco,PLCO Cancer Screening Trial,1,67,Cancer & Oncology,Early Detection Of Cancer Prostate Specific Antigen,2.0181
plco,PLCO Cancer Screening Trial,1,67,Cancer & Oncology,Prostate Specific Antigen,1.7229
plco,PLCO Cancer Screening Trial,1,67,Cancer & Oncology,Prostate Specific Antigen Mass Screening,1.4122
plco,PLCO Cancer Screening Trial,1,67,Cancer & Oncology,Prostatic Neoplasms Humans,1.2265
plco,PLCO Cancer Screening Trial,1,67,Cancer & Oncology,Male Early Detection Of Cancer,0.9692
plco,PLCO Cancer Screening Trial,2,69,Cancer & Oncology,Adenoma,1.8182
plco,PLCO Cancer Screening Trial,2,69,Cancer & Oncology,Middle Aged Adenoma,1.5924
plco,PLCO Cancer Screening Trial,2,69,Cancer & Oncology,Sigmoidoscopy,1.2174
plco,PLCO Cancer Screening Trial,2,69,Cancer & Oncology,Female Male,1.1608
plco,PLCO Cancer Screening Trial,2,69,Cancer & Oncology,Colorectal Neoplasms,1.0937
plco,PLCO Cancer Screening Trial,3,114,Cancer & Oncology,Lung Neoplasms,0.988
plco,PLCO Cancer Screening Trial,3,114,Cancer & Oncology,Tomography X Ray Computed,0.8977
plco,PLCO Cancer Screening Trial,3,114,Cancer & Oncology,Lung Neoplasms Male,0.8253
plco,PLCO Cancer Screening Trial,3,114,Cancer & Oncology,Early Detection Of Cancer,0.7023
plco,PLCO Cancer Screening Trial,3,114,Cancer & Oncology,Early Detection Of Cancer Risk Assessment,0.6933
plco,PLCO Cancer Screening Trial,4,58,Genomics & GWAS,Polymorphism Single Nucleotide,2.4634
plco,PLCO Cancer Screening Trial,4,58,Genomics & GWAS,Genetic Predisposition To Disease,1.3704
plco,PLCO Cancer Screening Trial,4,58,Genomics & GWAS,Genome Wide Association Study,1.3047
plco,PLCO Cancer Screening Trial,4,58,Genomics & GWAS,Genotype,1.2956
plco,PLCO Cancer Screening Trial,4,58,Genomics & GWAS,Humans Genetic Predisposition To Disease,1.0992
plco,PLCO Cancer Screening Trial,5,96,Cancer & Oncology,Aged Prostate Specific Antigen,1.0327
plco,PLCO Cancer Screening Trial,5,96,Cancer & Oncology,Prostate Specific Antigen,0.982
plco,PLCO Cancer Screening Trial,5,96,Cancer & Oncology,Prostatic Neoplasms Humans,0.9199
plco,PLCO Cancer Screening Trial,5,96,Cancer & Oncology,Middle Aged Prostatic Neoplasms,0.918
plco,PLCO Cancer Screening Trial,5,96,Cancer & Oncology,Prostatic Neoplasms,0.8822
plco,PLCO Cancer Screening Trial,6,185,Epidemiology & Risk Factors,Case Control Studies,0.7954
plco,PLCO Cancer Screening Trial,6,185,Epidemiology & Risk Factors,Middle Aged Humans,0.5461
plco,PLCO Cancer Screening Trial,6,185,Epidemiology & Risk Factors,Biomarkers Tumor,0.5194
plco,PLCO Cancer Screening Trial,6,185,Epidemiology & Risk Factors,Risk Factors,0.4786
plco,PLCO Cancer Screening Trial,6,185,Epidemiology & Risk Factors,Prospective Studies,0.4754
plco,PLCO Cancer Screening Trial,7,100,Cancer & Oncology,Ovarian Neoplasms,1.4729
plco,PLCO Cancer Screening Trial,7,100,Cancer & Oncology,Colorectal Neoplasms,1.2842
plco,PLCO Cancer Screening Trial,7,100,Cancer & Oncology,Female Lung Neoplasms,1.1684
plco,PLCO Cancer Screening Trial,7,100,Cancer & Oncology,Colorectal Neoplasms Mass Screening,1.1327
plco,PLCO Cancer Screening Trial,7,100,Cancer & Oncology,Lung Neoplasms,1.0808
qbb,Qatar Biobank,0,3,General Research,Fundus Oculi,3.7297
qbb,Qatar Biobank,0,3,General Research,Fundus Oculi Humans,3.7297
qbb,Qatar Biobank,0,3,General Research,Deep Learning,3.0366
qbb,Qatar Biobank,0,3,General Research,Optic Disk,2.7568
qbb,Qatar Biobank,0,3,General Research,Humans Retina,2.7568
qbb,Qatar Biobank,1,15,Metabolic & Diabetes,Diabetes Mellitus Type 2 Humans,1.2278
qbb,Qatar Biobank,1,15,Metabolic & Diabetes,Adolescent,1.1676
qbb,Qatar Biobank,1,15,Metabolic & Diabetes,Young Adult,0.9265
qbb,Qatar Biobank,1,15,Metabolic & Diabetes,Cross Sectional Studies,0.7938
qbb,Qatar Biobank,1,15,Metabolic & Diabetes,Diabetes Mellitus Type 2,0.7638
qbb,Qatar Biobank,2,13,Metabolic & Diabetes,Diabetes Mellitus,1.3472
qbb,Qatar Biobank,2,13,Metabolic & Diabetes,Humans Diabetes Mellitus,1.2687
qbb,Qatar Biobank,2,13,Metabolic & Diabetes,Waist Hip Ratio,1.0591
qbb,Qatar Biobank,2,13,Metabolic & Diabetes,Male Waist Hip Ratio,1.0591
qbb,Qatar Biobank,2,13,Metabolic & Diabetes,Middle Aged Cross Sectional Studies,1.0573
qbb,Qatar Biobank,3,12,Metabolic & Diabetes,Insulin,1.0122
qbb,Qatar Biobank,3,12,Metabolic & Diabetes,Insulin Resistance,0.9431
qbb,Qatar Biobank,3,12,Metabolic & Diabetes,Diabetes Mellitus Male,0.9163
qbb,Qatar Biobank,3,12,Metabolic & Diabetes,Biological Specimen Banks Female,0.9163
qbb,Qatar Biobank,3,12,Metabolic & Diabetes,Case Control Studies,0.9122
qbb,Qatar Biobank,4,15,General Research,Humans Qatar,0.9179
qbb,Qatar Biobank,4,15,General Research,Biological Specimen Banks,0.7991
qbb,Qatar Biobank,4,15,General Research,Mutation,0.7459
qbb,Qatar Biobank,4,15,General Research,Evidence Based Practice,0.7459
qbb,Qatar Biobank,4,15,General Research,Humans Delivery Of Health Care,0.5514
qbb,Qatar Biobank,5,7,General Research,Pregnancy,1.8394
qbb,Qatar Biobank,5,7,General Research,Microbiota Rna Ribosomal 16S,1.5984
qbb,Qatar Biobank,5,7,General Research,Pregnancy Female,1.5984
qbb,Qatar Biobank,5,7,General Research,Rna Ribosomal 16S,1.5984
qbb,Qatar Biobank,5,7,General Research,Microbiota,1.4752
qbb,Qatar Biobank,6,17,Musculoskeletal,Bone Density,1.1869
qbb,Qatar Biobank,6,17,Musculoskeletal,Absorptiometry Photon,1.1319
qbb,Qatar Biobank,6,17,Musculoskeletal,Bone Density Absorptiometry Photon,1.0717
qbb,Qatar Biobank,6,17,Musculoskeletal,Middle Aged Qatar,0.9015
qbb,Qatar Biobank,6,17,Musculoskeletal,Adult Bone Density,0.8099
qbb,Qatar Biobank,7,8,General Research,Genome Wide Association Study,2.2774
qbb,Qatar Biobank,7,8,General Research,Genome Wide Association Study Qatar,1.721
qbb,Qatar Biobank,7,8,General Research,Genetic Predisposition To Disease,1.721
qbb,Qatar Biobank,7,8,General Research,Male Genetic Predisposition To Disease,1.721
qbb,Qatar Biobank,7,8,General Research,Multifactorial Inheritance,1.721
qbb,Qatar Biobank,8,10,Metabolic & Diabetes,Triglycerides,1.7294
qbb,Qatar Biobank,8,10,Metabolic & Diabetes,Female Triglycerides,1.3768
qbb,Qatar Biobank,8,10,Metabolic & Diabetes,Triglycerides Adult,1.3768
qbb,Qatar Biobank,8,10,Metabolic & Diabetes,Blood Glucose,1.0995
qbb,Qatar Biobank,8,10,Metabolic & Diabetes,Prevalence Cross Sectional Studies,1.0326
qbb,Qatar Biobank,9,20,Multi-omics & Biomarkers,Biomarkers,1.1552
qbb,Qatar Biobank,9,20,Multi-omics & Biomarkers,Male Biomarkers,1.0601
qbb,Qatar Biobank,9,20,Multi-omics & Biomarkers,Metabolomics,1.0524
qbb,Qatar Biobank,9,20,Multi-omics & Biomarkers,Biomarkers Middle Aged,0.8647
qbb,Qatar Biobank,9,20,Multi-omics & Biomarkers,Phenotype,0.6438
qbb,Qatar Biobank,10,5,Infectious Diseases,Covid 19,2.3059
qbb,Qatar Biobank,10,5,Infectious Diseases,Pandemics,2.2378
qbb,Qatar Biobank,10,5,Infectious Diseases,Sars Cov 2,2.0652
qbb,Qatar Biobank,10,5,Infectious Diseases,Vaccination,1.6541
qbb,Qatar Biobank,10,5,Infectious Diseases,Vaccination Covid 19 Vaccines,1.6541
simpler,SIMPLER,0,14,Musculoskeletal,Osteoporosis,1.4273
simpler,SIMPLER,0,14,Musculoskeletal,Bone Density,1.2173
simpler,SIMPLER,0,14,Musculoskeletal,Osteoporosis Fractures Bone,1.2056
simpler,SIMPLER,0,14,Musculoskeletal,Caffeine Female,1.2056
simpler,SIMPLER,0,14,Musculoskeletal,Caffeine,1.2056
simpler,SIMPLER,1,35,Cardiovascular Research,Risk,0.7904
simpler,SIMPLER,1,35,Cardiovascular Research,Sweden Diet,0.7109
simpler,SIMPLER,1,35,Cardiovascular Research,Incidence Risk,0.6817
simpler,SIMPLER,1,35,Cardiovascular Research,Humans Aged,0.649
simpler,SIMPLER,1,35,Cardiovascular Research,Stroke,0.6467
simpler,SIMPLER,2,12,Epidemiology & Risk Factors,Prospective Studies Alcohol Drinking,2.1349
simpler,SIMPLER,2,12,Epidemiology & Risk Factors,Alcohol Drinking,1.7608
simpler,SIMPLER,2,12,Epidemiology & Risk Factors,Risk Factors Surveys And Questionnaires,1.3307
simpler,SIMPLER,2,12,Epidemiology & Risk Factors,Women S Health Humans,1.1268
simpler,SIMPLER,2,12,Epidemiology & Risk Factors,Carcinoma Renal Cell,1.1268
simpler,SIMPLER,3,21,Cardiovascular Research,Neoplasms,1.7376
simpler,SIMPLER,3,21,Cardiovascular Research,Female Neoplasms,1.3434
simpler,SIMPLER,3,21,Cardiovascular Research,Cardiovascular Diseases,1.3415
simpler,SIMPLER,3,21,Cardiovascular Research,Neoplasms Middle Aged,1.0897
simpler,SIMPLER,3,21,Cardiovascular Research,Mortality,0.9438
simpler,SIMPLER,4,19,General Research,Adolescent,1.6884
simpler,SIMPLER,4,19,General Research,Adolescent Male,1.6146
simpler,SIMPLER,4,19,General Research,Young Adult,1.2044
simpler,SIMPLER,4,19,General Research,Sweden Young Adult,1.2044
simpler,SIMPLER,4,19,General Research,Adult,0.9129
simpler,SIMPLER,5,24,General Research,Vegetables,1.1127
simpler,SIMPLER,5,24,General Research,Female Male,1.0693
simpler,SIMPLER,5,24,General Research,Surveys And Questionnaires Female,0.9889
simpler,SIMPLER,5,24,General Research,Aged Proportional Hazards Models,0.9889
simpler,SIMPLER,5,24,General Research,Multivariate Analysis,0.9782
simpler,SIMPLER,6,18,Cancer & Oncology,Breast Neoplasms,2.4703
simpler,SIMPLER,6,18,Cancer & Oncology,Breast Neoplasms Middle Aged,2.0928
simpler,SIMPLER,6,18,Cancer & Oncology,Receptors Estrogen,2.0806
simpler,SIMPLER,6,18,Cancer & Oncology,Receptors Progesterone,1.8351
simpler,SIMPLER,6,18,Cancer & Oncology,Female Breast Neoplasms,1.4681
simpler,SIMPLER,7,52,Epidemiology & Risk Factors,Follow Up Studies Aged,0.8886
simpler,SIMPLER,7,52,Epidemiology & Risk Factors,Follow Up Studies,0.768
simpler,SIMPLER,7,52,Epidemiology & Risk Factors,Aged 80 And Over Risk Factors,0.7404
simpler,SIMPLER,7,52,Epidemiology & Risk Factors,Sweden Aged 80 And Over,0.7289
simpler,SIMPLER,7,52,Epidemiology & Risk Factors,Aged 80 And Over,0.7191
simpler,SIMPLER,8,19,General Research,Aged Middle Aged,1.8873
simpler,SIMPLER,8,19,General Research,Female Aged,1.6143
simpler,SIMPLER,8,19,General Research,Humans Female,1.1551
simpler,SIMPLER,8,19,General Research,Surveys And Questionnaires Humans,0.8629
simpler,SIMPLER,8,19,General Research,Health Behavior,0.8413
simpler,SIMPLER,9,19,Nutrition & Diet,Polychlorinated Biphenyls,1.3908
simpler,SIMPLER,9,19,Nutrition & Diet,Diet Risk Factors,1.3002
simpler,SIMPLER,9,19,Nutrition & Diet,Seafood,1.013
simpler,SIMPLER,9,19,Nutrition & Diet,Fishes,0.9855
simpler,SIMPLER,9,19,Nutrition & Diet,Animals,0.9805
simpler,SIMPLER,10,17,Metabolic & Diabetes,Body Mass Index,2.1741
simpler,SIMPLER,10,17,Metabolic & Diabetes,Obesity,2.0942
simpler,SIMPLER,10,17,Metabolic & Diabetes,Aged Body Mass Index,1.9571
simpler,SIMPLER,10,17,Metabolic & Diabetes,Body Mass Index Female,1.0025
simpler,SIMPLER,10,17,Metabolic & Diabetes,Middle Aged Obesity,0.9928
simpler,SIMPLER,11,22,Cardiovascular Research,Follow Up Studies Female,1.3822
simpler,SIMPLER,11,22,Cardiovascular Research,Heart Failure,1.085
simpler,SIMPLER,11,22,Cardiovascular Research,Incidence Heart Failure,1.0845
simpler,SIMPLER,11,22,Cardiovascular Research,Female Aged,0.9585
simpler,SIMPLER,11,22,Cardiovascular Research,Aged Humans,0.8749
smwhs,Shanghai Men and Women's Health Studies,0,28,Cancer & Oncology,Liver Neoplasms,0.858
smwhs,Shanghai Men and Women's Health Studies,0,28,Cancer & Oncology,Feeding Behavior Female,0.7535
smwhs,Shanghai Men and Women's Health Studies,0,28,Cancer & Oncology,Female Proportional Hazards Models,0.7535
smwhs,Shanghai Men and Women's Health Studies,0,28,Cancer & Oncology,Diet Prospective Studies,0.7058
smwhs,Shanghai Men and Women's Health Studies,0,28,Cancer & Oncology,Liver Neoplasms China,0.6919
smwhs,Shanghai Men and Women's Health Studies,1,22,Metabolic & Diabetes,Body Mass Index,1.647
smwhs,Shanghai Men and Women's Health Studies,1,22,Metabolic & Diabetes,Waist Hip Ratio,1.3001
smwhs,Shanghai Men and Women's Health Studies,1,22,Metabolic & Diabetes,Body Mass Index China,1.2375
smwhs,Shanghai Men and Women's Health Studies,1,22,Metabolic & Diabetes,Obesity,0.9976
smwhs,Shanghai Men and Women's Health Studies,1,22,Metabolic & Diabetes,Risk Factors Waist Hip Ratio,0.9899
smwhs,Shanghai Men and Women's Health Studies,2,13,Cardiovascular Research,Cardiovascular Diseases,1.8479
smwhs,Shanghai Men and Women's Health Studies,2,13,Cardiovascular Research,Adult Cardiovascular Diseases,1.791
smwhs,Shanghai Men and Women's Health Studies,2,13,Cardiovascular Research,Neoplasms,1.7555
smwhs,Shanghai Men and Women's Health Studies,2,13,Cardiovascular Research,Mortality,1.5203
smwhs,Shanghai Men and Women's Health Studies,2,13,Cardiovascular Research,Neoplasms Aged,1.2419
smwhs,Shanghai Men and Women's Health Studies,3,22,Epidemiology & Risk Factors,Risk Factors Cohort Studies,1.1223
smwhs,Shanghai Men and Women's Health Studies,3,22,Epidemiology & Risk Factors,Adult Female,0.9876
smwhs,Shanghai Men and Women's Health Studies,3,22,Epidemiology & Risk Factors,Surveys And Questionnaires Aged,0.8485
smwhs,Shanghai Men and Women's Health Studies,3,22,Epidemiology & Risk Factors,Odds Ratio,0.7693
smwhs,Shanghai Men and Women's Health Studies,3,22,Epidemiology & Risk Factors,Cohort Studies,0.6443
smwhs,Shanghai Men and Women's Health Studies,4,8,Environmental Health,Occupational Exposure,2.5218
smwhs,Shanghai Men and Women's Health Studies,4,8,Environmental Health,Benzene,1.5786
smwhs,Shanghai Men and Women's Health Studies,4,8,Environmental Health,Benzene Occupational Exposure,1.5786
smwhs,Shanghai Men and Women's Health Studies,4,8,Environmental Health,Occupational Diseases,1.4707
smwhs,Shanghai Men and Women's Health Studies,4,8,Environmental Health,Occupations,1.4707
smwhs,Shanghai Men and Women's Health Studies,5,7,Cancer & Oncology,Helicobacter Infections,3.0141
smwhs,Shanghai Men and Women's Health Studies,5,7,Cancer & Oncology,Helicobacter Infections Case Control Studies,3.0141
smwhs,Shanghai Men and Women's Health Studies,5,7,Cancer & Oncology,Helicobacter Pylori,3.0141
smwhs,Shanghai Men and Women's Health Studies,5,7,Cancer & Oncology,Stomach Neoplasms,2.5357
smwhs,Shanghai Men and Women's Health Studies,5,7,Cancer & Oncology,Humans Helicobacter Pylori,2.2411
smwhs,Shanghai Men and Women's Health Studies,6,9,Genomics & GWAS,Genetic Predisposition To Disease,2.074
smwhs,Shanghai Men and Women's Health Studies,6,9,Genomics & GWAS,Polymorphism Single Nucleotide,2.0549
smwhs,Shanghai Men and Women's Health Studies,6,9,Genomics & GWAS,Telomere,1.9536
smwhs,Shanghai Men and Women's Health Studies,6,9,Genomics & GWAS,Adult Telomere,1.4032
smwhs,Shanghai Men and Women's Health Studies,6,9,Genomics & GWAS,Genetic Predisposition To Disease Case Control Studies,1.4032
smwhs,Shanghai Men and Women's Health Studies,7,20,Physical Activity,Reproducibility Of Results,1.2444
smwhs,Shanghai Men and Women's Health Studies,7,20,Physical Activity,China Surveys And Questionnaires,0.9247
smwhs,Shanghai Men and Women's Health Studies,7,20,Physical Activity,Surveys And Questionnaires,0.8382
smwhs,Shanghai Men and Women's Health Studies,7,20,Physical Activity,Exercise,0.7254
smwhs,Shanghai Men and Women's Health Studies,7,20,Physical Activity,Surveys And Questionnaires Male,0.7033
smwhs,Shanghai Men and Women's Health Studies,8,16,Epidemiology & Risk Factors,Incidence Middle Aged,1.2108
smwhs,Shanghai Men and Women's Health Studies,8,16,Epidemiology & Risk Factors,Registries,1.0989
smwhs,Shanghai Men and Women's Health Studies,8,16,Epidemiology & Risk Factors,Risk Factors Registries,1.0989
smwhs,Shanghai Men and Women's Health Studies,8,16,Epidemiology & Risk Factors,Stomach Neoplasms Aged,0.9805
smwhs,Shanghai Men and Women's Health Studies,8,16,Epidemiology & Risk Factors,Colorectal Neoplasms Female,0.9247
smwhs,Shanghai Men and Women's Health Studies,9,19,Cancer & Oncology,Biomarkers,1.3685
smwhs,Shanghai Men and Women's Health Studies,9,19,Cancer & Oncology,Biomarkers Middle Aged,1.0618
smwhs,Shanghai Men and Women's Health Studies,9,19,Cancer & Oncology,Oxidative Stress,0.9824
smwhs,Shanghai Men and Women's Health Studies,9,19,Cancer & Oncology,F2 Isoprostanes,0.8257
smwhs,Shanghai Men and Women's Health Studies,9,19,Cancer & Oncology,Humans Lung Neoplasms,0.791
smwhs,Shanghai Men and Women's Health Studies,10,21,General Research,China Male,0.9583
smwhs,Shanghai Men and Women's Health Studies,10,21,General Research,Proportional Hazards Models China,0.9129
smwhs,Shanghai Men and Women's Health Studies,10,21,General Research,Life Style,0.8115
smwhs,Shanghai Men and Women's Health Studies,10,21,General Research,Proportional Hazards Models,0.8083
smwhs,Shanghai Men and Women's Health Studies,10,21,General Research,Health Surveys,0.8067
smwhs,Shanghai Men and Women's Health Studies,11,17,Cancer & Oncology,Lung Neoplasms Humans,0.9889
smwhs,Shanghai Men and Women's Health Studies,11,17,Cancer & Oncology,Case Control Studies Female,0.9832
smwhs,Shanghai Men and Women's Health Studies,11,17,Cancer & Oncology,Case Control Studies,0.9445
smwhs,Shanghai Men and Women's Health Studies,11,17,Cancer & Oncology,Metabolomics,0.8274
smwhs,Shanghai Men and Women's Health Studies,11,17,Cancer & Oncology,Biomarkers Tumor,0.7648
twb,Taiwan Biobank,0,50,Metabolic & Diabetes,Risk Factors Middle Aged,1.2866
twb,Taiwan Biobank,0,50,Metabolic & Diabetes,Male Risk Factors,1.1821
twb,Taiwan Biobank,0,50,Metabolic & Diabetes,Risk Factors,1.0237
twb,Taiwan Biobank,0,50,Metabolic & Diabetes,Metabolic Syndrome,0.6835
twb,Taiwan Biobank,0,50,Metabolic & Diabetes,Adult Female,0.6757
twb,Taiwan Biobank,1,67,Epidemiology & Risk Factors,Retrospective Studies,0.6958
twb,Taiwan Biobank,1,67,Epidemiology & Risk Factors,Taiwan Adult,0.6931
twb,Taiwan Biobank,1,67,Epidemiology & Risk Factors,Male Middle Aged,0.5748
twb,Taiwan Biobank,1,67,Epidemiology & Risk Factors,Adult Female,0.5515
twb,Taiwan Biobank,1,67,Epidemiology & Risk Factors,Incidence,0.5135
twb,Taiwan Biobank,2,51,Genomics & GWAS,Taiwan Female,0.9665
twb,Taiwan Biobank,2,51,Genomics & GWAS,Genotype,0.7591
twb,Taiwan Biobank,2,51,Genomics & GWAS,Phenotype,0.5993
twb,Taiwan Biobank,2,51,Genomics & GWAS,Middle Aged Polymorphism Single Nucleotide,0.5123
twb,Taiwan Biobank,2,51,Genomics & GWAS,Polymorphism Single Nucleotide,0.4983
twb,Taiwan Biobank,3,39,Metabolic & Diabetes,Female Aged,1.16
twb,Taiwan Biobank,3,39,Metabolic & Diabetes,Exercise,0.8822
twb,Taiwan Biobank,3,39,Metabolic & Diabetes,Male Cholesterol Hdl,0.8686
twb,Taiwan Biobank,3,39,Metabolic & Diabetes,Aged Male,0.8489
twb,Taiwan Biobank,3,39,Metabolic & Diabetes,Male Middle Aged,0.7524
twb,Taiwan Biobank,4,43,Genomics & GWAS,Breast Neoplasms,1.8246
twb,Taiwan Biobank,4,43,Genomics & GWAS,White People,1.1348
twb,Taiwan Biobank,4,43,Genomics & GWAS,Polymorphism Single Nucleotide Breast Neoplasms,0.9701
twb,Taiwan Biobank,4,43,Genomics & GWAS,Breast Neoplasms Asian People,0.8508
twb,Taiwan Biobank,4,43,Genomics & GWAS,Humans Genome Wide Association Study,0.8498
twb,Taiwan Biobank,5,39,Metabolic & Diabetes,Obesity,1.3861
twb,Taiwan Biobank,5,39,Metabolic & Diabetes,Body Mass Index,1.2471
twb,Taiwan Biobank,5,39,Metabolic & Diabetes,Uric Acid,0.9811
twb,Taiwan Biobank,5,39,Metabolic & Diabetes,Waist Hip Ratio,0.8913
twb,Taiwan Biobank,5,39,Metabolic & Diabetes,Obesity Adult,0.8913
twb,Taiwan Biobank,6,69,Genomics & GWAS,Genome Wide Association Study,0.876
twb,Taiwan Biobank,6,69,Genomics & GWAS,Genetic Predisposition To Disease,0.828
twb,Taiwan Biobank,6,69,Genomics & GWAS,Taiwan Genome Wide Association Study,0.6931
twb,Taiwan Biobank,6,69,Genomics & GWAS,Polymorphism Single Nucleotide,0.6658
twb,Taiwan Biobank,6,69,Genomics & GWAS,Case Control Studies,0.6257
twb,Taiwan Biobank,7,30,Environmental Health,Dna Methylation,2.0408
twb,Taiwan Biobank,7,30,Environmental Health,Dna Methylation Middle Aged,1.74
twb,Taiwan Biobank,7,30,Environmental Health,Male Dna Methylation,1.7005
twb,Taiwan Biobank,7,30,Environmental Health,Particulate Matter,1.1861
twb,Taiwan Biobank,7,30,Environmental Health,Air Pollution,1.1291
myc,The Malaysian Cohort,0,17,Genomics & GWAS,Case Control Studies,1.1973
myc,The Malaysian Cohort,0,17,Genomics & GWAS,Diabetes Mellitus Type 2,1.0001
myc,The Malaysian Cohort,0,17,Genomics & GWAS,Polymorphism Single Nucleotide,0.9565
myc,The Malaysian Cohort,0,17,Genomics & GWAS,Genetic Predisposition To Disease,0.9447
myc,The Malaysian Cohort,0,17,Genomics & GWAS,Middle Aged Case Control Studies,0.7633
myc,The Malaysian Cohort,1,23,General Research,Adult Malaysia,0.6982
myc,The Malaysian Cohort,1,23,General Research,Retrospective Studies,0.6295
myc,The Malaysian Cohort,1,23,General Research,Cohort Studies,0.5927
myc,The Malaysian Cohort,1,23,General Research,Malaysia Aged,0.5789
myc,The Malaysian Cohort,1,23,General Research,Cohort Studies Adult,0.5544
myc,The Malaysian Cohort,2,27,Cardiovascular Research,Cardiovascular Diseases,0.5362
myc,The Malaysian Cohort,2,27,Cardiovascular Research,Cardiovascular Diseases Humans,0.4806
myc,The Malaysian Cohort,2,27,Cardiovascular Research,Aged 80 And Over,0.4723
myc,The Malaysian Cohort,2,27,Cardiovascular Research,Aged Middle Aged,0.4639
myc,The Malaysian Cohort,2,27,Cardiovascular Research,Risk Factors,0.4537
tommo,Tohoku Medical Megabank,0,28,General Research,Pregnancy,1.0895
tommo,Tohoku Medical Megabank,0,28,General Research,Humans Cohort Studies,1.0688
tommo,Tohoku Medical Megabank,0,28,General Research,Japan Pregnancy,0.9815
tommo,Tohoku Medical Megabank,0,28,General Research,Pregnant People,0.9548
tommo,Tohoku Medical Megabank,0,28,General Research,Pregnant People Female,0.8788
tommo,Tohoku Medical Megabank,1,41,General Research,Child Preschool,1.1991
tommo,Tohoku Medical Megabank,1,41,General Research,Humans Child Preschool,1.0791
tommo,Tohoku Medical Megabank,1,41,General Research,Infant,1.0327
tommo,Tohoku Medical Megabank,1,41,General Research,Infant Newborn,0.9784
tommo,Tohoku Medical Megabank,1,41,General Research,Infant Newborn Cohort Studies,0.8758
tommo,Tohoku Medical Megabank,2,40,General Research,Asian People,0.8977
tommo,Tohoku Medical Megabank,2,40,General Research,Genomics,0.8126
tommo,Tohoku Medical Megabank,2,40,General Research,Genome Human,0.692
tommo,Tohoku Medical Megabank,2,40,General Research,Genome Wide Association Study,0.6832
tommo,Tohoku Medical Megabank,2,40,General Research,Databases Genetic,0.6387
tommo,Tohoku Medical Megabank,3,61,General Research,Middle Aged,0.9544
tommo,Tohoku Medical Megabank,3,61,General Research,Aged,0.8884
tommo,Tohoku Medical Megabank,3,61,General Research,Female Aged,0.7884
tommo,Tohoku Medical Megabank,3,61,General Research,Adult,0.6886
tommo,Tohoku Medical Megabank,3,61,General Research,Male Adult,0.6796
tommo,Tohoku Medical Megabank,4,25,General Research,Earthquakes,1.6936
tommo,Tohoku Medical Megabank,4,25,General Research,Humans Earthquakes,1.265
tommo,Tohoku Medical Megabank,4,25,General Research,Japan Biological Specimen Banks,0.9316
tommo,Tohoku Medical Megabank,4,25,General Research,Biological Specimen Banks,0.9316
tommo,Tohoku Medical Megabank,4,25,General Research,Disasters,0.8612
ukb,UK Biobank,0,592,Neuroimaging,Brain,2.3035
ukb,UK Biobank,0,592,Neuroimaging,Magnetic Resonance Imaging,2.0102
ukb,UK Biobank,0,592,Neuroimaging,Brain Magnetic Resonance Imaging,1.303
ukb,UK Biobank,0,592,Neuroimaging,White Matter,1.0286
ukb,UK Biobank,0,592,Neuroimaging,Neuroimaging,1.018
ukb,UK Biobank,1,605,Genomics & GWAS,Phenotype,1.6754
ukb,UK Biobank,1,605,Genomics & GWAS,Models Genetic,1.3222
ukb,UK Biobank,1,605,Genomics & GWAS,Models Genetic Humans,1.0507
ukb,UK Biobank,1,605,Genomics & GWAS,Phenotype Genome Wide Association Study,1.0048
ukb,UK Biobank,1,605,Genomics & GWAS,Polymorphism Single Nucleotide,0.946
ukb,UK Biobank,2,2132,Epidemiology & Risk Factors,Female Humans,0.4499
ukb,UK Biobank,2,2132,Epidemiology & Risk Factors,Risk Factors,0.398
ukb,UK Biobank,2,2132,Epidemiology & Risk Factors,Prospective Studies,0.3503
ukb,UK Biobank,2,2132,Epidemiology & Risk Factors,Male Aged,0.3411
ukb,UK Biobank,2,2132,Epidemiology & Risk Factors,Diabetes Mellitus Type 2,0.3366
ukb,UK Biobank,3,922,Genomics & GWAS,Humans Genetic Predisposition To Disease,1.9085
ukb,UK Biobank,3,922,Genomics & GWAS,Genetic Predisposition To Disease,1.6822
ukb,UK Biobank,3,922,Genomics & GWAS,Genome Wide Association Study Humans,1.0425
ukb,UK Biobank,3,922,Genomics & GWAS,Polymorphism Single Nucleotide,0.9388
ukb,UK Biobank,3,922,Genomics & GWAS,Genome Wide Association Study,0.9251
ukb,UK Biobank,4,652,Epidemiology & Risk Factors,Biological Specimen Banks Humans,2.0832
ukb,UK Biobank,4,652,Epidemiology & Risk Factors,Biological Specimen Banks,1.2847
ukb,UK Biobank,4,652,Epidemiology & Risk Factors,Humans United Kingdom,1.0548
ukb,UK Biobank,4,652,Epidemiology & Risk Factors,United Kingdom,0.7262
ukb,UK Biobank,4,652,Epidemiology & Risk Factors,Risk Factors Biological Specimen Banks,0.5466
ukb,UK Biobank,5,279,Environmental Health,Air Pollution,3.3878
ukb,UK Biobank,5,279,Environmental Health,Air Pollutants,3.3174
ukb,UK Biobank,5,279,Environmental Health,Environmental Exposure,3.1722
ukb,UK Biobank,5,279,Environmental Health,Particulate Matter,3.1563
ukb,UK Biobank,5,279,Environmental Health,Air Pollutants Environmental Exposure,1.9207
ukb,UK Biobank,6,229,Infectious Diseases,Covid 19,3.646
ukb,UK Biobank,6,229,Infectious Diseases,Sars Cov 2,3.214
ukb,UK Biobank,6,229,Infectious Diseases,Humans Sars Cov 2,2.1357
ukb,UK Biobank,6,229,Infectious Diseases,Covid 19 Biological Specimen Banks,1.9199
ukb,UK Biobank,6,229,Infectious Diseases,Sars Cov 2 United Kingdom,1.6336
ukb,UK Biobank,7,724,General Research,Uk Biobank Humans,2.3575
ukb,UK Biobank,7,724,General Research,Uk Biobank,2.1366
ukb,UK Biobank,7,724,General Research,Biological Specimen Banks Uk Biobank,1.5155
ukb,UK Biobank,7,724,General Research,Biological Specimen Banks,1.1462
ukb,UK Biobank,7,724,General Research,Humans United Kingdom,0.6897
ukb,UK Biobank,8,250,General Research,Animals,3.6326
ukb,UK Biobank,8,250,General Research,Animals Humans,2.9688
ukb,UK Biobank,8,250,General Research,Mice,2.4144
ukb,UK Biobank,8,250,General Research,Genome Wide Association Study Animals,1.0911
ukb,UK Biobank,8,250,General Research,Mice Inbred C57Bl,0.8164
ukb,UK Biobank,9,1312,Genomics & GWAS,Mendelian Randomization Analysis,1.2901
ukb,UK Biobank,9,1312,Genomics & GWAS,Genome Wide Association Study Humans,1.1724
ukb,UK Biobank,9,1312,Genomics & GWAS,Genome Wide Association Study,1.0916
ukb,UK Biobank,9,1312,Genomics & GWAS,Polymorphism Single Nucleotide,0.8321
ukb,UK Biobank,9,1312,Genomics & GWAS,Polymorphism Single Nucleotide Mendelian Randomization Analysis,0.6294
ukb,UK Biobank,10,976,Epidemiology & Risk Factors,Prospective Studies Middle Aged,1.9867
ukb,UK Biobank,10,976,Epidemiology & Risk Factors,Male Prospective Studies,1.9699
ukb,UK Biobank,10,976,Epidemiology & Risk Factors,Prospective Studies,1.5513
ukb,UK Biobank,10,976,Epidemiology & Risk Factors,Incidence Female,0.955
ukb,UK Biobank,10,976,Epidemiology & Risk Factors,Incidence,0.8987
ukb,UK Biobank,11,1763,General Research,Male Middle Aged,1.0783
ukb,UK Biobank,11,1763,General Research,Adult,0.7214
ukb,UK Biobank,11,1763,General Research,Aged,0.713
ukb,UK Biobank,11,1763,General Research,Middle Aged,0.6739
ukb,UK Biobank,11,1763,General Research,Female Adult,0.6304
ukbdc,UK Blood Donor Cohorts,0,5,Infectious Diseases,Vaccination,2.7276
ukbdc,UK Blood Donor Cohorts,0,5,Infectious Diseases,Covid 19 Vaccines,2.2183
ukbdc,UK Blood Donor Cohorts,0,5,Infectious Diseases,Covid 19,1.9118
ukbdc,UK Blood Donor Cohorts,0,5,Infectious Diseases,Research Design,1.6411
ukbdc,UK Blood Donor Cohorts,0,5,Infectious Diseases,Covid 19 Vaccines Male,1.6411
ukbdc,UK Blood Donor Cohorts,1,8,General Research,Child,1.7812
ukbdc,UK Blood Donor Cohorts,1,8,General Research,Child Preschool,1.7047
ukbdc,UK Blood Donor Cohorts,1,8,General Research,Infant,1.5932
ukbdc,UK Blood Donor Cohorts,1,8,General Research,Adolescent,1.125
ukbdc,UK Blood Donor Cohorts,1,8,General Research,India,1.0257
ukbdc,UK Blood Donor Cohorts,2,7,General Research,Cross Sectional Studies,1.2214
ukbdc,UK Blood Donor Cohorts,2,7,General Research,Analysis Of Variance Adult,1.1722
ukbdc,UK Blood Donor Cohorts,2,7,General Research,Aged Cross Sectional Studies,1.1722
ukbdc,UK Blood Donor Cohorts,2,7,General Research,Humans Mass Screening,1.1722
ukbdc,UK Blood Donor Cohorts,2,7,General Research,Adult Female,1.1215
ukbdc,UK Blood Donor Cohorts,3,22,Epidemiology & Risk Factors,Animals,1.5125
ukbdc,UK Blood Donor Cohorts,3,22,Epidemiology & Risk Factors,Reference Values Animals,0.9878
ukbdc,UK Blood Donor Cohorts,3,22,Epidemiology & Risk Factors,Dogs,0.9068
ukbdc,UK Blood Donor Cohorts,3,22,Epidemiology & Risk Factors,Prospective Studies,0.8823
ukbdc,UK Blood Donor Cohorts,3,22,Epidemiology & Risk Factors,Reference Values,0.7983
ukbdc,UK Blood Donor Cohorts,4,15,Genomics & GWAS,Polymorphism Single Nucleotide,1.7534
ukbdc,UK Blood Donor Cohorts,4,15,Genomics & GWAS,Mendelian Randomization Analysis,1.5986
ukbdc,UK Blood Donor Cohorts,4,15,Genomics & GWAS,Polymorphism Single Nucleotide Humans,1.5591
ukbdc,UK Blood Donor Cohorts,4,15,Genomics & GWAS,Genome Wide Association Study,1.5406
ukbdc,UK Blood Donor Cohorts,4,15,Genomics & GWAS,Humans Mendelian Randomization Analysis,1.4487
ukbdc,UK Blood Donor Cohorts,5,9,General Research,Female Adult,2.1567
ukbdc,UK Blood Donor Cohorts,5,9,General Research,Adult Humans,1.7445
ukbdc,UK Blood Donor Cohorts,5,9,General Research,Surveys And Questionnaires,1.1365
ukbdc,UK Blood Donor Cohorts,5,9,General Research,Young Adult,1.1069
ukbdc,UK Blood Donor Cohorts,5,9,General Research,Adult,1.0346
ukbdc,UK Blood Donor Cohorts,6,7,Multi-omics & Biomarkers,Proteome,2.276
ukbdc,UK Blood Donor Cohorts,6,7,Multi-omics & Biomarkers,Biomarkers,1.4612
ukbdc,UK Blood Donor Cohorts,6,7,Multi-omics & Biomarkers,Quantitative Trait Loci,1.4612
ukbdc,UK Blood Donor Cohorts,6,7,Multi-omics & Biomarkers,Quantitative Trait Loci Humans,1.4612
ukbdc,UK Blood Donor Cohorts,6,7,Multi-omics & Biomarkers,Female Quantitative Trait Loci,1.1722
ukbdc,UK Blood Donor Cohorts,7,3,Metabolic & Diabetes,Tertiary Care Centers,3.6972
ukbdc,UK Blood Donor Cohorts,7,3,Metabolic & Diabetes,Tertiary Care Centers Cross Sectional Studies,3.6972
ukbdc,UK Blood Donor Cohorts,7,3,Metabolic & Diabetes,Cross Sectional Studies,2.8499
ukbdc,UK Blood Donor Cohorts,7,3,Metabolic & Diabetes,Diabetes Mellitus Type 2,1.1365
ukbdc,UK Blood Donor Cohorts,7,3,Metabolic & Diabetes,Humans,0.1906
ukbdc,UK Blood Donor Cohorts,8,8,General Research,Reproducibility Of Results,2.7163
ukbdc,UK Blood Donor Cohorts,8,8,General Research,Humans Reproducibility Of Results,2.4936
ukbdc,UK Blood Donor Cohorts,8,8,General Research,Sensitivity And Specificity Male,0.9243
ukbdc,UK Blood Donor Cohorts,8,8,General Research,Sensitivity And Specificity,0.8524
ukbdc,UK Blood Donor Cohorts,8,8,General Research,Blood Chemical Analysis,0.7966
ukbdc,UK Blood Donor Cohorts,9,8,Infectious Diseases,Blood Donors,2.5986
ukbdc,UK Blood Donor Cohorts,9,8,Infectious Diseases,United Kingdom,2.2737
ukbdc,UK Blood Donor Cohorts,9,8,Infectious Diseases,Blood Donors Middle Aged,1.5932
ukbdc,UK Blood Donor Cohorts,9,8,Infectious Diseases,Blood Donors Male,1.3864
ukbdc,UK Blood Donor Cohorts,9,8,Infectious Diseases,Hiv,1.3864
ukbdc,UK Blood Donor Cohorts,10,9,General Research,Humans Male,1.3351
ukbdc,UK Blood Donor Cohorts,10,9,General Research,Adult Humans,1.3084
ukbdc,UK Blood Donor Cohorts,10,9,General Research,Adult,0.9196
ukbdc,UK Blood Donor Cohorts,10,9,General Research,Cross Over Studies,0.8216
ukbdc,UK Blood Donor Cohorts,10,9,General Research,Young Adult,0.7379
ukbdc,UK Blood Donor Cohorts,11,20,General Research,Aged,0.9995
ukbdc,UK Blood Donor Cohorts,11,20,General Research,Female Humans,0.9962
ukbdc,UK Blood Donor Cohorts,11,20,General Research,Middle Aged,0.7528
ukbdc,UK Blood Donor Cohorts,11,20,General Research,Aged 80 And Over,0.748
ukbdc,UK Blood Donor Cohorts,11,20,General Research,Adult Female,0.5888
uklwc,UKCTOCS Longitudinal Women's Cohort,0,27,Cancer & Oncology,Biomarkers Tumor,0.8384
uklwc,UKCTOCS Longitudinal Women's Cohort,0,27,Cancer & Oncology,Adult,0.6785
uklwc,UKCTOCS Longitudinal Women's Cohort,0,27,Cancer & Oncology,Ca 125 Antigen,0.6574
uklwc,UKCTOCS Longitudinal Women's Cohort,0,27,Cancer & Oncology,Algorithms,0.6436
uklwc,UKCTOCS Longitudinal Women's Cohort,0,27,Cancer & Oncology,Case Control Studies,0.6409
uklwc,UKCTOCS Longitudinal Women's Cohort,1,19,Cancer & Oncology,Ovarian Neoplasms Humans,1.169
uklwc,UKCTOCS Longitudinal Women's Cohort,1,19,Cancer & Oncology,Early Detection Of Cancer Ovarian Neoplasms,1.0878
uklwc,UKCTOCS Longitudinal Women's Cohort,1,19,Cancer & Oncology,Female Early Detection Of Cancer,0.8437
uklwc,UKCTOCS Longitudinal Women's Cohort,1,19,Cancer & Oncology,Mass Screening Ovarian Neoplasms,0.814
uklwc,UKCTOCS Longitudinal Women's Cohort,1,19,Cancer & Oncology,Early Detection Of Cancer Mass Screening,0.7263
uklwc,UKCTOCS Longitudinal Women's Cohort,2,33,Cancer & Oncology,Postmenopause,0.7619
uklwc,UKCTOCS Longitudinal Women's Cohort,2,33,Cancer & Oncology,Ultrasonography,0.6275
uklwc,UKCTOCS Longitudinal Women's Cohort,2,33,Cancer & Oncology,Risk Factors,0.6041
uklwc,UKCTOCS Longitudinal Women's Cohort,2,33,Cancer & Oncology,Surveys And Questionnaires,0.5924
uklwc,UKCTOCS Longitudinal Women's Cohort,2,33,Cancer & Oncology,Humans Ovarian Neoplasms,0.5725
vhmpp,VHM&PP,0,5,Cardiovascular Research,Sex Factors,1.2876
vhmpp,VHM&PP,0,5,Cardiovascular Research,Humans Risk Factors,1.2722
vhmpp,VHM&PP,0,5,Cardiovascular Research,Cohort Studies Follow Up Studies,1.0103
vhmpp,VHM&PP,0,5,Cardiovascular Research,Obesity Proportional Hazards Models,1.0103
vhmpp,VHM&PP,0,5,Cardiovascular Research,Cardiovascular Diseases Cohort Studies,1.0103
vhmpp,VHM&PP,1,14,General Research,Aged 80 And Over,0.5748
vhmpp,VHM&PP,1,14,General Research,Aged,0.5605
vhmpp,VHM&PP,1,14,General Research,Follow Up Studies Aged,0.5236
vhmpp,VHM&PP,1,14,General Research,Humans Male,0.4598
vhmpp,VHM&PP,1,14,General Research,Middle Aged Humans,0.4581
vhmpp,VHM&PP,2,6,Environmental Health,Incidence Humans,1.2217
vhmpp,VHM&PP,2,6,Environmental Health,Incidence,1.2217
vhmpp,VHM&PP,2,6,Environmental Health,Humans Middle Aged,1.1893
vhmpp,VHM&PP,2,6,Environmental Health,Austria Biomarkers,0.8419
vhmpp,VHM&PP,2,6,Environmental Health,Environmental Exposure,0.8419
whi,Women's Health Initiative,0,255,Epidemiology & Risk Factors,Prospective Studies,1.777
whi,Women's Health Initiative,0,255,Epidemiology & Risk Factors,Humans Prospective Studies,1.7351
whi,Women's Health Initiative,0,255,Epidemiology & Risk Factors,Prospective Studies Female,1.3608
whi,Women's Health Initiative,0,255,Epidemiology & Risk Factors,Prospective Studies United States,0.7326
whi,Women's Health Initiative,0,255,Epidemiology & Risk Factors,United States,0.5712
whi,Women's Health Initiative,1,203,General Research,Hormone Replacement Therapy,2.3376
whi,Women's Health Initiative,1,203,General Research,Female Hormone Replacement Therapy,1.5782
whi,Women's Health Initiative,1,203,General Research,Hormone Replacement Therapy Aged,1.1845
whi,Women's Health Initiative,1,203,General Research,Humans Female,0.8783
whi,Women's Health Initiative,1,203,General Research,Hormone Replacement Therapy Middle Aged,0.7215
whi,Women's Health Initiative,2,73,General Research,Risk Female,3.3523
whi,Women's Health Initiative,2,73,General Research,Risk,3.1613
whi,Women's Health Initiative,2,73,General Research,Estrogen Replacement Therapy Risk,2.3103
whi,Women's Health Initiative,2,73,General Research,Humans Risk,1.2908
whi,Women's Health Initiative,2,73,General Research,Humans Estrogen Replacement Therapy,0.7874
whi,Women's Health Initiative,3,421,General Research,Humans Estrogen Replacement Therapy,1.4095
whi,Women's Health Initiative,3,421,General Research,Estrogen Replacement Therapy Female,1.339
whi,Women's Health Initiative,3,421,General Research,Estrogen Replacement Therapy,1.2686
whi,Women's Health Initiative,3,421,General Research,Menopause,0.78
whi,Women's Health Initiative,3,421,General Research,Randomized Controlled Trials As Topic,0.7248
whi,Women's Health Initiative,4,159,Multi-omics & Biomarkers,Biomarkers,2.5132
whi,Women's Health Initiative,4,159,Multi-omics & Biomarkers,Biomarkers Female,2.2809
whi,Women's Health Initiative,4,159,Multi-omics & Biomarkers,Case Control Studies,1.1374
whi,Women's Health Initiative,4,159,Multi-omics & Biomarkers,Humans Biomarkers,1.0276
whi,Women's Health Initiative,4,159,Multi-omics & Biomarkers,Aged Case Control Studies,0.8701
whi,Women's Health Initiative,5,147,Genomics & GWAS,Black Or African American,2.3226
whi,Women's Health Initiative,5,147,Genomics & GWAS,Black Or African American Humans,2.25
whi,Women's Health Initiative,5,147,Genomics & GWAS,Hispanic Or Latino,1.6032
whi,Women's Health Initiative,5,147,Genomics & GWAS,White People,1.572
whi,Women's Health Initiative,5,147,Genomics & GWAS,Polymorphism Single Nucleotide,1.5485
whi,Women's Health Initiative,6,603,Nutrition & Diet,Aged 80 And Over,0.537
whi,Women's Health Initiative,6,603,Nutrition & Diet,Humans Female,0.5131
whi,Women's Health Initiative,6,603,Nutrition & Diet,Dietary Supplements,0.3925
whi,Women's Health Initiative,6,603,Nutrition & Diet,Cross Sectional Studies,0.3913
whi,Women's Health Initiative,6,603,Nutrition & Diet,Women S Health,0.3783
whi,Women's Health Initiative,7,310,General Research,Estrogens,1.5218
whi,Women's Health Initiative,7,310,General Research,Progestins,1.1663
whi,Women's Health Initiative,7,310,General Research,Animals,0.9932
whi,Women's Health Initiative,7,310,General Research,Estrogen Replacement Therapy,0.7876
whi,Women's Health Initiative,7,310,General Research,Estrogen Replacement Therapy Female,0.7778
whi,Women's Health Initiative,8,200,Metabolic & Diabetes,Body Mass Index,2.3466
whi,Women's Health Initiative,8,200,Metabolic & Diabetes,Female Body Mass Index,2.2022
whi,Women's Health Initiative,8,200,Metabolic & Diabetes,Obesity,1.451
whi,Women's Health Initiative,8,200,Metabolic & Diabetes,Obesity Risk Factors,0.8265
whi,Women's Health Initiative,8,200,Metabolic & Diabetes,Risk Factors,0.695
whi,Women's Health Initiative,9,355,Epidemiology & Risk Factors,Aged Middle Aged,0.8763
whi,Women's Health Initiative,9,355,Epidemiology & Risk Factors,United States Female,0.6891
whi,Women's Health Initiative,9,355,Epidemiology & Risk Factors,Incidence,0.6636
whi,Women's Health Initiative,9,355,Epidemiology & Risk Factors,United States,0.6196
whi,Women's Health Initiative,9,355,Epidemiology & Risk Factors,Middle Aged Postmenopause,0.6055
whi,Women's Health Initiative,10,107,General Research,Adult,1.9438
whi,Women's Health Initiative,10,107,General Research,Pregnancy,1.7374
whi,Women's Health Initiative,10,107,General Research,Young Adult,1.275
whi,Women's Health Initiative,10,107,General Research,Female Adult,1.0212
whi,Women's Health Initiative,10,107,General Research,Adolescent,0.9914
whi,Women's Health Initiative,11,188,Epidemiology & Risk Factors,Female Proportional Hazards Models,2.6043
whi,Women's Health Initiative,11,188,Epidemiology & Risk Factors,Proportional Hazards Models,2.0653
whi,Women's Health Initiative,11,188,Epidemiology & Risk Factors,Risk Factors,0.7225
whi,Women's Health Initiative,11,188,Epidemiology & Risk Factors,Aged Middle Aged,0.6794
whi,Women's Health Initiative,11,188,Epidemiology & Risk Factors,Proportional Hazards Models Aged,0.6794
